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The ability of the immune system to recognize and respond to pathogenic organisms is 
essential for the body’s ability to control an infection. The broad and prompt innate immune 
response primes the acquired branch eliciting protection against most pathogenic invaders. Cell-
cell communication is critical for rapidly spreading the message of infection and enabling the 
innate immune system to mount a broad response against the pathogen. While cytokines and 
chemokines have been extensively characterized for the roles as messengers in innate immunity, 
exosomes are emerging as key players in this field.  
Exosomes are nanovesicles (~50nm in diameter) that are released extracellularly by all cell 
types. They carry functional cargo in the form of mRNA, microRNA and proteins that reflect the 
host cells molecular composition and can transport this cargo to recipient cells where it  is 
functional and has the ability to affect the phenotype of the cell both transcriptionally and 
biochemically. Their ability to transmit messages between cells at a distance and their rapid 
transport through the body makes them ideal messengers for establishing innate immune 
responses.  
Lymphatic flow is an important component of the circulation and serves to transport of 
antigens, immune cells and large macromolecules from the periphery to the lymph nodes where 
innate and adaptive immune responses are elicited. While exosomes have been seen to modulate 
lymph node function, their ability to use the lymphatics was unknown. Using an in vitro model of 
lymphatic uptake, we have shown that lymphatic endothelial cells actively enhanced lymphatic 
uptake and transport of exosomes to the luminal side of the vessel. Furthermore, we have 
demonstrated a differential distribution of exosomes in the draining lymph nodes that is dependent 
on the lymphatic flow. Lastly, through endpoint analysis of cellular distribution of exosomes in 
the node, we identified macrophages and B-cells as key players in exosome uptake. Together these 
results suggest that exosome transfer by lymphatic flow from the periphery to the lymph node 
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could provide a mechanism for rapid exchange of infection-specific information that precedes the 
arrival of migrating cells, thus priming the node for a more effective immune response. 
Toll-like receptors (TLR’s) are a family of receptors play a central role in the host cell 
defense against disease by detecting highly conserved pathogen associated molecular patterns. 
This results in a localized inflammatory response that results in the production of a broad range of 
molecules including cytokines and chemokines, which are essential for host response to infection 
as well as for the development of an adaptive immune response. However, it is unknown if 
exosomes play a role in propagating the local TLR response to distal cells, aiding in the rapid 
spread of the message of infection as well as the establishment of a pathogen specific response. 
 Here we demonstrate the distal recapitulation of the local toll-like receptor response via 
exosomes. We further delineate the kinetics of the response and show that we can abrogate the 
action-at-a-distance signaling of exosomes by UV irradiation, demonstrating that RNA is crucial 
for their effector function. We also show that exosomes derived from TLR stimulated cells 
epigenetically modify distal cells to be refractory to further LPS stimulation (i.e. undergo 
endotoxin tolerance), thus protecting these distal cells from uncontrolled inflammation. 
 We show a striking increase in total lymphatic transport and nodal retention of pIC 
exosomes within minutes of injection. The data shown here is the first evidence that exosomes 
could directly be involved in modulating flow to the lymph node. We further expand the impact 
of exosome uptake by lymph node macrophages to demonstrate that TLR-exosomes are capable 
of inducing an inflammatory response via Il12 and Nos2 in murine macrophages in vivo. We also 
analyzed the whole lymph node milieu by next generation sequencing to find evidence of 
neutrophil, mast cell and monocyte recruitment in the pIC-exosomes and polarize the node to a 
pro-inflammatory state. 
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CHAPTER 1: BACKGROUND AND LITERATURE REVIEW  
1.1 Immune system 
The immune system is a complex network of cells and organs that protects the organism 
against infectious agents such as bacteria, viruses and other pathogens. This is achieved with a 
combination of the two arms: humoral immunity and adaptive immunity. Innate or humoral 
immunity is an antigen non-specific, evolutionarily conserved system in most multicellular 
organisms that attacks common human pathogens.  Adaptive Immunity on the other hand is 
mediated by lymphocytes and is characterized by specificity and memory(1). 
1.1.1 Adaptive Immunity  
Adaptive immunity relies on the generation of a random and diverse repertoire of antigen 
receptors followed by clonal selection and expansion of receptors with high specificity resulting 
in immunological memory. The main limitation of the adaptive immune system is that specific 
clones need to expand and differentiate into effector cells before they can participate in the host’s 
defense. This process usually takes 4-7 days and the source and biological context of the antigen 
remains undetermined(2). 
1.1.2 Innate immunity 
Innate immunity involves the sentinel cells of the immune system that are initial responders 
upon microbe entry into the body. The host uses innate immunity immediately on exposure to any 
pathogen and is an initial response to prevent infection. It does not recognize every possible antigen 
and relies on a variety of distinct, constitutive and conserved molecules that are characteristic of 
common microbes that infect mammals. These unique microbial molecules can be thought of as 
molecular signatures of microbial invaders and are called Pathogen Associated Molecular Patterns 
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(PAMP’s) or Microbe Associated Molecular Patterns (MAMP’s). They include a large number of 
molecules including lipopolysaccharide (LPS) from Gram negative bacteria, Peptidoglycans from 
Gram positive Bacteria, and unmethylated CpG DNA from bacteria and viruses.  PAMP’s are 
invariant, are essential for microbial survival and are unique to microbes(3).  
Most immune cells such as natural killer cells, phagocytic cells (macrophages, monocytes) 
have a variety of Pattern Recognition Receptors (PRR’s) for common PAMP’s and respond 
immediately against the invading microbe. These receptors are located on the cell surface where 
they interact with extracellular PAMP’s or within phagolysosomes where they interact with 
phagocytosed pathogens. Binding of PAMP’s to the corresponding PRR results in the synthesis 
and secretion of regulatory molecules such as cytokines that are essential for initiating an immune 
response(4). 
A complete list of PAMP’s, their microbial origin, along with the cognate PRR that 
recognizes them is given below in Table 1 
 
Table 1: Recognition of microbial components by PRRs(5) 
Receptor Cellular localization Microbial component(s) Origin(s) 
TLRs       
    
TLR1/TLR2 
Cell surface Triacyl lipopeptides Bacteria 
    
TLR2/TLR6 
Cell surface Diacyl lipopeptides Mycoplasma 
    Lipoteichoic acid Gram-positive bacteria 
    
TLR2 
Cell surface Lipoproteins Various pathogens 
    Peptidoglycan Gram-positive and -negative 
bacteria 
    Lipoarabinomannan Mycobacteria 
    Porins Neisseria 
    Envelope glycoproteins Viruses (e.g., measles virus, 
HSV, cytomegalovirus) 
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Table 1 Continued 
  GPI-mucin Protozoa 
    Phospholipomannan Candida 
    Zymosan Fungi 
    β-Glycan Fungi 





    
TLR4 
Cell surface LPS Gram-negative bacteria 
    Envelope glycoproteins Viruses (e.g., RSV) 
    Glycoinositolphospholipids Protozoa 
    Mannan Candida 
    HSP70 Host 
    
TLR5 
Cell surface Flagellin Flagellated bacteria 
    
TLR7/8 
Endosome ssRNA RNA viruses 
    
TLR9 
Endosome CpG DNA Viruses, bacteria, protozoa 
RLRs       
    
RIG-I 
Cytoplasm dsRNA (short), 5′-
triphosphate RNA 
Viruses (e.g., influenza A 
virus, HCV, RSV) 
    
MDA5 
Cytoplasm dsRNA (long) Viruses (picorna- and 
noroviruses) 
NLRs       
    
NOD1 
Cytoplasm Diaminopimelic acid Gram-negative bacteria 
    
NOD2 
Cytoplasm MDP Gram-positive and -negative 
bacteria 
    
NALP1 
Cytoplasm MDP Gram-positive and -negative 
bacteria 
    
NALP3 
Cytoplasm ATP, uric acid crystals, 
RNA, DNA, MDP 
Viruses, bacteria, and host 
Miscellaneous       
DAI Cytoplasm DNA DNA viruses, intracellular 
bacteria 
    
AIM2 
Cytoplasm DNA DNA viruses 




1.1.2.1 Toll-like receptors 
The Toll-like receptors (TLRs) are an evolutionarily conserved pattern recognition receptor 
family and consist of type-I trans-membrane receptors, which are characterized by an extracellular 
leucine-rich repeat (LRR) domain and an intracellular Toll/IL-1 receptor (TIR) domain. The 
namesake of the family, Toll, is a Drosophila protein with an immune function and responds to 
fungal and gram positive bacterial signals. LRR’s are involved in ligand recognition and signal 
transduction while the TIR region is a conserved protein-protein interaction module(6). 
In mammalian species, there are at least 10 distinct TLR’s and each has a distinct function 
in mammalian immunity (Table 1). Several TLR ligands are known and are diverse in structure 
and origin. However, some common attributes are that TLR ligands are conserved microbial 
products (PAMP’s), TLR’s can recognize several structurally unrelated ligands, and some TLR’s 
need accessory proteins to recognize their ligands(7).   
Activation of signaling pathways by Toll like receptors results in the induction of various 
genes for host defense like cytokines, MHC complex, chemokines, and co-stimulatory molecules. 
Multiple effectors such as antimicrobial peptides and nitric oxide synthase are also induced(8).  
1.1.2.2 LPS signaling pathway 
Human TLR4 was the first characterized mammalian Toll and is expressed predominantly 
in macrophages and DC’s but is found in a variety of cell types(9). It serves as the signal 
transducing receptor for LPS(10). Recognition of LPS by TLR4 is complex and requires several 
accessory proteins such as LPS Binding Protein (LBP), MD-2 and RP105. Once bound by LBP, 
LPS is transferred to CD14 (TLR4 co-receptor), a high affinity LPS receptor(11).  
Post-receptor signal transduction by TLR4 requires the function of several conserved 
proteins since TLR’s don’t have any enzymatic activity. Instead stimuli induced 
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dimerization/oligomerization rearranges the TIR domains such that they act as a scaffold for 
recruiting adaptor proteins. This leads to Myd88 recruitment, a TIR domain protein which interacts 
with IRAK4. This complex (Myd88-IRAK4) activates TRAF6, NIK and TAK1 sequentially and 
this in turn results in MAPK and NF-κB activation.  TNF is an important endpoint of LPS response 
as a result of NF-κB translocation to the nucleus(12).  
Figure 1 shows classical TLR4 signaling mediated by LPS that results in a pro-
inflammatory response resulting in the secretion of TNFA, IL1B and IFNG.  
 
Figure 1: Model of LPS signaling through TLR4 binding in the cell(13) 
1.1.2.3 Regulation of TLR signaling  
The inflammatory cytokines and chemokines produced as a result of TLR engagement, if released 
in excess have the potential to induce serious systemic disorders including chronic inflammation, 
autoimmune disorders(14) and endotoxin shock(15). Thus the tight regulation of toll-like receptor 
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maintains the balance between immune activation in response to microbial pathogens and overt 
systemic inflammation. 
Toll-Interacting protein (TOLLIP) interacts with IRAK and suppresses its activity resulting in the 
blocking of TLR4/LPS signaling(16).NF-κB is a key transcription factor that is held inactive by 
bound Iκ-Bα in the cytoplasm. It is activated in response to a pro-inflammatory signal such as LPS 
or TNFA and translocates to the nucleus where it activates the transcription of several pro-
inflammatory cytokines and chemokines(17). It plays a key role in both TLR 4 and TLR3 response 
to infection. SIRT1, a NAD+ dependent histone deacetylase physically binds to the p65/RelA 
subunit of NF-κB and deacetylates it at a critical Lysine residue (K310) resulting in NF-κB 
inactivation and suppression of the pro-inflammatory response(18). 
1.1.2.4 TLR3 signaling pathway  
TLR3 is expressed predominantly in dendritic cells(19). It functions as a cell surface 
receptor for double stranded RNA (dsRNA) which is a molecular pattern produced by most viruses 
at some point in their life cycle(20). 
Several  synthetic  dsRNAs,  like  PIKA,  Ampligen  [Poly(I:C12U)]  or  polyriboinosinicacid-
polyribocytidylic  acid  – commonly  denoted  as  poly(I:C) efficiently  mimic  viral  dsRNA. This 
results in the activation of TLR3 and an initiation of the host anti-viral response.  
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Figure 2: The TLR3 signaling pathway in dendritic cells (57). 
 
Physiologically, TLR3 encounters dsRNA in the endosome since viruses are taken up by 
the endocytic pathway ( 
Figure 2). CD14 binds to Poly I: C and mediates its cellular uptake where it transfers it to 
TLR3 in intracellular compartments (21). This is followed by phosphorylation of TLR3 resulting 
in initiation of downstream signaling leading to activation of interferon regulatory factor(IRF)-3 
and NF-κB-dependent gene expression via TRIF(22). The outcomes of TLR3 engagement are IL-
12 and Type I IFN induction, both key molecules in antiviral defense and immune activation(23) 
in addition to production of inflammatory chemokines and cytokines. 
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1.1.2.5 Other RNA recognition modules  
TLR3 is mainly expressed endosomally where it recognizes viral RNA (Figure 3a). However, RIG-
1 and MDA-5 are cytoplasmic receptors for the recognition of RNA(24). Both these receptors 
signal to a mitochondrial protein IPS-1 (MAVS), which results in the activation of IRF1 (for an 
antiviral response) and NF-κB (for a pro-inflammatory response)(25). (Figure 3b) 
 
Figure 3: dsRNA recognition pathways in the cell(25) 
 
1.1.3 Local ccellular response to TLR agonist stimulation in vitro 
Response to direct stimulation of cells with TLR agonists is very well studied. Bone marrow 
derived dendritic cells when stimulated with LPS, pIC or PAM (a TLR2 agonist) in vitro ( 
Figure 4) showed distinct expression of distinct gene regulatory networks; pIC induced an antiviral 




Figure 4: Differential response to TLR stimulation in dendritic cells(26) 
 
Macrophages when stimulated with pIC expressed IFN-β in an IRF3  and NF-κB independent 
manner whereas they responded to LPS in a NF-κB dependent manner resulting in the production 
of TNF-α(27). Several other cell types have also been extensively characterized for their responses 
to poly I:C and LPS(11). 
1.1.4 TLR response and innate immune response in vivo 
The TLR response has been studied extensively in vivo in several immune subsets including 
natural killer cells(28), mast cells(29), macrophages(30), dendritic cells(31) and neutrophils(32) 
under physiological(33) and pathological conditions(34). Similar to the observed in vitro 
responses, stimulation of TLR signaling in vivo  results in a tightly controlled and well established 
pro inflammatory pathways and are critical in maintaining host tissue/organism health under 
conditions of infection(35). 
1.1.5 Dual role of TLR signaling in cancer progression and immunotherapy  
TLR signaling is severely deregulated in several cancers since the inflammatory response has a 
strong effect on the survival of tumors at several stages including initiation, metastasis and 
malignancy(36). e.g. LPS stimulation of a mammary adenocarcinoma cell line increased 
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migration, invasion and metastasis(37), TLR stimulation of multiple myeloma cell lines lead to 
increased proliferation and survival(38) and activation of TLR4 signaling on tumor cells promote 
evasion of CTL cells and increased survival in vivo(39). Additionally, constitutive NF-κB due to 
aberrant TLR activation results in chronic inflammation which results in a poor outcome for many 
hematological tumors(40). 
Some TLR agonists are also actively being used in cancer immunotherapy for their ability to 
activate immune cells and promote both innate and adaptive immune responses against cancers. 
Breast and bladder cancer cells when stimulated with TLR3 activated IFN-α resulting in the 
apoptosis of human and mouse cancer cells(41). A summary of the role of poly (I:C) and LPS in 



















Table 2: Summary of the effects of TLR3 and TLR4 Signaling in tumor Cells(41) 
TLR 
Type of 
Cancer  Protumor effects Anti-tumor effects  
TLR3 Breast cancer   Apoptosis, ↑type I IFN 
Colon cancer   Apoptosis 
Cervical 
cancer 
  Apoptosis 
Head and neck 
cancer 
  Apoptosis, necrosis, ↑ICAM-I 
Hepatocellular 
carcinoma 
  Apoptosis 
Melanoma   Decreased proliferation, apoptosis 
Myeloma   Apoptosis, ↑type I IFN 
Lung cancer Proliferation and survival Apoptosis 
Prostate cancer   Inflammation, apoptosis 
TLR4 Breast cancer Viability, immune 
evasion, ↑VEGF, NO, IL-
6, IL-12, MMPs 
  
Colon cancer Inflammation, tumor 
growth, immune evasion, 
↑B7-H2, B7-H2, ↓Fas 
  
Gastric cancer Proliferation   
Hepatocellular 
carcinoma 
Carcinogenesis   
Lung cancer Immunosuppression, 
immune evasion, reduced 
apoptosis, ↑TGF-β, 
VEGF, IL-8 
Decreased lung permeability and 
inflammation 
Melanoma Carcinogenesis   
1.1.6 Organs of the innate immune system 
The effector cells of immunity are all produced within lymphoid organs in the body. The immune 
system is divided into primary and secondary organ systems; the primary lymphoid organs are the 
bone marrow and the thymus where lymphocyte production and maturation occurs. The secondary 
lymphoid organs include lymph nodes, the spleen, the tonsils and other specialized tissues in the 
mucous membranes of the bowel where an immune response is mounted.(42)  
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1.2 Lymphatic System 
The lymphatic system consists of a network of vessels, nodes, and accessory organs that play a 
vital role in the body’s balance of interstitial fluid volume to maintain protein concentration and 
oncotic pressure gradients(43) It operates as an open system that returns excess interstitial fluid 
and proteins to the blood stream via a lymphatic duct in the left subclavian vein(44). Additionally 
the system is essential to a wide variety of physiologic and pathophysiologic processes including 
immune cell trafficking and regulation of immunity(45, 46), lipid transport(47) progression of  
autoimmunity, cancer metastasis (48), and tissue inflammation(49). 
1.2.1 Structure of the lymphatic system 
The lymphatic system is composed of initial collecting lymphatic capillaries which converge intro 
collecting lymphatic vessels which transport fluid via lymph nodes back into circulation (Figure 
5). These initial capillaries collect undrained interstitial fluid, called lymph once it enters the 
lymphatic system; and propel it forward by contraction of the smooth muscle cells embedded in 
the walls of the collecting vessels thereby carrying large proteins and immune cells. They contain 




Figure 5: Structure of the lymphatic system and its components(51).  
 
The lymph nodes are sites where large groups of macrophages, antigen presenting cells and 
leukocytes are present. Lymph enters via the afferent vessel, is filtered through the sub capsular 
sinuses, and around the lymphoid compartment which has high resistance due to the packed cells 
contained within(52). Macrophages and antigen presenting cells present in this compartment 
samples the afferent lymph for antigens and can initiate an immune response if they detect signs 
of infection(53). Most of the lymph exits via the efferent lymphatics without entering the lymphoid 
compartment. Large particles (>70 kDa or with a hydrodynamic radius >4 nm  )cannot cross the 
subcapsular sinus and exit via the efferent lymphatics, whereas small particles can cross the floor 
of the sinus and enter the lymphoid zone(54). While cells can cross the subcapsular sinus by active 
movement, fluid can only enter though small collagen tubules that connect the between sinus lining 
cells and the high endothelial venules (HEV’s) in the lymphoid compartment(54). The fluid in the 
lymphoid compartment can then enter the bloodstream thought the HEV’s. A general structure of 
the lymph node is shown in Figure 6. Mice have 22 identifiable lymph nodes(55)  
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Figure 6:  Structure of a lymph node(56).   
1.2.2 Imaging lymphatics 
Given the central role played by lymphatics in the development of immunity, imaging the transport 
of antigens, and immune cells is essential to monitor health and the development of disease. 
Systemic lymph node imaging was limited to Magnetic resonance imaging (MRI) and 
Computerized tomography (CT) but they are cost prohibitive and lack the required sensitivity to 
image initial and collecting lymphatics(57). Positron emission tomography (PET), has been used 
to image the lymph nodes and although non-invasive suffers from a lack of sensitivity(58) Current 
methods of intra-lymphatic imaging rely on the presence of a contrast agent. Lymphoscintigraphy 
is the gold standard of imaging to investigate lymphatic function but suffers from a lack of 
spatiotemporal resolution(59).   
1.2.2.1 Near Infra-red (NIR) Imaging  
NIR imaging, is an emerging non-invasive imaging technology that collects tissue-scattered light 
to assess conducting and collecting lymphatic vessels at greater penetration depths enabling 
detection of lymph drainage and lymph nodes. NIR light resides in the optimal wavelength, where 
there light absorption and scattering by biological tissue are low, auto fluorescence is minimal and 
offers excellent spatiotemporal resolution(60). NIR imaging with an FDA-approved fluorescent 
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dye, indocyanine green (ICG), has recently emerged as a novel method for quantitative assessment 
of lymphatic function in animals and humans. Upon illumination of tissue surfaces with NIR 
excitation light, contrast agent (typically ICG or Licor IR dyes) fluorescence is collected using 
charge-coupled device (CCD) cameras and can be used to visualize the initial lymphatics, 
collecting and conducting lymphatics, and draining LNs across wide fields of view that can 
encompass entire limbs(61, 62). 
NIR images are collected at high speeds (every millisecond) which allows for real-time 
noninvasive assessment of lymphatic functions(63). It enables quantitative measurements of  
lymphatic pump function such as pumping pressure, packet frequency, packet velocity and total 
lymphatic transport(61, 64, 65) as well as dysfunction as in the case of lymphedema(66). NIR 
imaging has also been successfully used to assess tissue rejection in an animal model of hind limb 
transplantation showing applications in regenerative medicine(67).  
While NIR imaging is ideal for studying superficial lymphatic drainage and lymphatic fluid 
transport in small animals, it lacks the ability to generate strong fluorescent signals through deep 
tissue sections(68). Recent advances in nanotechnology has led to development of small 
semiconductor crystals (5-20nm) called quantum dots (QD’s)  whose emissions can be fine-tuned 
to emit in the NIR range (69). QD’s enable the use of multicolor imaging along with increased 
tissue depth penetration to study multiple lymphatic vessels/components simultaneously(70) 
1.2.3 Role of lymphatics in the establishment of immunity 
The lymphatic system is extremely important in immune surveillance because the collecting 
vessels traffic both antigens and antigen-presenting cells from peripheral tissues to lymph 
nodes(53).  
The continuous circulation of lymph through the lymph nodes allows for enrichment of rare 
antigens and provides more opportunity of antigen-specific lymphocytes to encounter their cognate 
antigen from any part of the body creating an efficient sampling system for foreign pathogens or 
abnormal self-antigens as in the case of cancer. Immune cells and several types of cancer cells 
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secrete the chemokines CCL19 and CCL21(71). Several cancer cells also have the corresponding 
receptor CCR7 to the chemokines which, eventually leads to the cancer cells migrating towards 
the draining lymphatic vessel and are transported to the lymph nodes(72). 
The immune response is initiated when antigen presenting cells and soluble antigens reach the sub-
capsular sinus within the lymph node. Small antigens are able to directly enter the B-cell follicles 
via a system of conduits formed by the stromal cells while larger antigens need to taken up by 
macrophages or dendritic cells and trafficked there(73). Recently, lymphatic endothelial cells and 
stromal cells themselves have been shown to play a role in the transport of antigens and 
communicating with immune cells regulating their functions(74).  
1.3 Exosomes 
 It has been long known that vesicles of various sizes are released form cells. Exosomes were first 
discovered while studying the differentiation of sheep reticulocytes which involved the shedding 
of transferrin receptors on small vesicles of endocytic origin(75). They were initially thought to be 
a method of removing unwanted proteins from cells, and  the term ‘exosomes’ had also been used 
to refer to vesicles from various normal and neoplastic lines that possessed 5’nucleotidase 
activity(76). They were later shown to play an important role in immune regulation, when B-cell 
exosomes were found to contain MHC II molecules that could present antigens to CD4+ T-
cells(77).  
Exosomes are released by diverse cell types including immune cells such as B-cells(77), 
T-cells(78), dendritic cells(79), mast cells(80) and macrophages(81), epithelial cells(82), 
neurons(83), adipocytes(84), tumor cells(85) and stem cells(86).  They are also found in a number 
of bodily fluids such as saliva, urine, breast milk, broncho-alveolar lavage fluid, amniotic fluid, 
synovial fluid, epididymis fluid, serum, and ascites under both physiological and pathological 
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conditions(87). Exosome presence in bodily fluids indicates the potential of exosomes to be used 
as non-invasive diagnostic tool to check for biomarkers of diseased states.  
1.3.1 Exosome Biogenesis 
 Membrane vesicles are classified as spherical structures composed of lipid bilayers 
containing hydrophilic soluble components. In eukaryotic cells, intracellular transfer is mediated 
by carrier vesicles which bud from a donor compartment and fuse with a target compartment, 
thereby delivering luminal material from the donor compartment to target compartments. 
Intercellular trafficking of soluble proteins is accomplished by secretory vesicles which contain 
intraluminal material. Large secreted vesicles (size>100nm) containing cytosol called 
macrovesicles are also released from several cell types and are formed by the budding or shedding 
of the plasma membrane.  
Distinct from other secreted vesicles, exosomes are formed by the invagination of 
endosome membranes to give rise to intraluminal vesicles (ILV’s). ILV’s contain cytosol, are 
enclosed within larger membrane bound intracellular structures called Multi-vesicular bodies 
(MVB’s) and are released from the cell by the fusion of the MVB with the plasma membrane(88).  
MVB’s were well known for their functions as intermediates in protein degradation. They 
carried proteins internalized from the cell surface or from the trans-Golgi network and fused with 
the lysosome initiating degradation(89). Pioneering studies in reticulocytes showed an alternate 
fate for the MVB’s in aiding release of exosomes extracellularly(75).  
In addition to mode of formation, these vesicle types also differ in size, biophysical and 
biochemical properties. Figure 7 below shows the formation and release of exosomes via MVB 





Figure 7: Schematic depicting the formation and release of exosomes from a cell(90). 
1.3.2 Exosome composition 
Exosomes range in size from 30-120 nm and are composed of a lipid bilayer containing 
functional biomolecules like proteins, mRNA and miRNA that can be delivered to a target cell by 
fusion and thus play an important role in cell-cell communication(88). Electron microscopy reveals 
saucer shaped vesicles with a diameter of 50-100nm(91). 
While the molecular composition of exosomes varies depending on cell type of origin, they 
contain a number of biomolecules in common. Proteomic profiling has revealed characteristic 
protein markers on the surface such as tetraspanins (CD63, CD81), components of the ESCRT 
machinery ( Alix, Tsg101), heat shock proteins (Hsc70, Hsp 90), cytoskeletal proteins (Actin, 
tubulin) ,and membrane proteins (Lamp2,  Rab5b, annexin II)(90).  
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Exosomes also contain proteins that are specific to cell type, e.g. exosomes from antigen 
presenting cells carry MHCII molecules(92). Characteristic of their endosomal origin, they do not 
contain any nuclear, mitochondrial or endoplasmic reticulum proteins. 
Figure 8 below shows the proteins present in and on the exosomal membrane. Not all 
cellular proteins found in exosomes suggesting a specific loading mechanism which is as yet 
unknown. Protein sorting requires the machinery of the endosomal sorting complex required for 
transport machinery (ESCRT). Studies in Saccharomyces cerevisiae showed that 
monoubiquitinated proteins are sorted into ILV’s while oligoubiquituination increases chances of 
ILV incorporation(93). Ubiquitination is however only one of the mechanisms of exosomal protein 
inclusion. Additional ubiquitination independent mechanisms such as the ability of tetraspanins to 
partition in lipid rafts and to independently sort into ILV’s(94) or incorporation of Transferrin 
receptor by Alix association(95) also contribute to exosomal sorting. 
 
Figure 8:Typical molecular composition of an exosome (22) 
 
 Exosomal membranes are similar to the plasma membrane and some reports suggest that 
they are enriched in sphingomyelin, cholesterol(96), lyso-bis-phosphatidic-acid (LBPA)(97) and 
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ganglioside GM3, lipids that are typically enriched in detergent-resistant membranes(98). Lipid 
flip flopping is increased in exosomes as compared to plasma membranes and exosomal 
membranes show an increase in rigidity between pH 5 and 7(97). High membrane rigidity has 
implications for exosome stability and prevents its degradation in circulation. 
1.3.3 Functions of exosomes: 
Exosomes are involved in a multitude of biological processes and facilitate intercellular 
communication. Although the initial role of exosomes was attributed to removal of unwanted 
proteins from the cells, they have since expanded to include a wide variety of functions that 
encompass normal physiology, disease pathology, immune modulation and cancer diagnostics and 
therapeutics. A few of their key roles are outlined below 
1.3.3.1 Exosome Functions in physiology 
Exosomes have a number of functions in maintaining homeostasis and normal organism 
physiology(99). They have been discovered in a number of biological fluids including 
cerebrospinal fluid where they play roles in neural development(100), saliva where contributed to 
cell free clotting(101), and amniotic fluid where they play important role in maternal tolerance to 
the fetus(102). Exosomes are also implicated in embryonic development with roles in processes 
like morphogenetic gradients formation, cell migration and the development of cellular 
polarity(103). They are also shown to play important roles in tissue repair and regeneration. E.g., 
mesenchymal stem cell derived exosomes when injected in mice models of myocardial infarction, 
reduced infarct size and helped in tissue repair(104). Overall, the functions of exosomes in 
physiology are diverse and an active area of research with new functions being discovered every 
day.  
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1.3.3.2 Exosomes functions in immunity  
The role of exosomes in immunity are very well characterized and have been shown to 
have both immunostimulatory and immunosuppressive effects.  The immunostimulatory 
properties of exosomes were first discovered in the context of antigen presentation in a landmark 
study which showed that exosomes derived from EBV transformed B-cells were shown to 
stimulate primed CD4+ T-cells in an antigen specific manner. This study also showed the release 
of MHC II on exosomes derived from murine and human T-cells(77). By contrast, exosomes 
cannot activate naïve T-cells and deliver their contents to dendritic cells in the vicinity(105).  
Further evidence for their immunostimulatory effects came from studies in which 
exosomes from mouse dendritic cells pulsed with tumor peptides were shown to be capable of 
priming cytotoxic T-cells and suppress tumor growth in a T-cell dependent manner 
(106).However, T-cell activation by exosomes also depends on the physiological state of the cell 
of origin. Naïve dendritic cell derived exosomes activate T-cells less effectively than those derived 
from mature DC’s(107). Exosomes from pathogen infected cells can such as Cytomegalovirus 
infected endothelial cells allow induction of pathogen specific T-cell responses(108) (Figure 9). 
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Figure 9: The roles of exosomes in innate and adaptive immunity(109) 
The immunosuppressive effects of exosomes are best understood in the context of 
pathogens and intracellular infection. Exosomes from HIV-1 infected macrophages crucial viral 
proteins such as Gag and nef to uninfected cells aiding the rapid spread of HIV to nearby 
cells(110). While several factors impact the activity of exosomes, there have consistent reports of 
bacterial pathogens such as Leishmania spp. and fungal pathogens such as Cryptococcus spp 
secrete immunosuppressive molecules on secreted vesicles to suppress the immune response 
against them resulting in enhanced pathogen survival and poor host prognosis(111, 112) (Figure 
9). 
Exosomes also play important roles in induction of immune tolerance in an antigen specific 
manner in mice(113) which has been further exploited to benefit transplant patients. Exosomes 
from donor bone marrow dendritic cells, when administered prior to transplantation, were shown 
to increase allograft survival in mice after a heart transplant.(114) 
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1.3.3.3 Exosomes function in cancer 
Exosomes have been best characterized in the context of tumor development and immune 
evasion. They transfer antigens from tumor cells to dendritic cells(115), which in turn can induce 
CD8+ T-cell dependent anti-tumor effects and thus play a role in T-cell cross priming. Tumor 
derived exosomes carry tumor specific antigens like MART1 (melanoma) that are delivered to 
dendritic which cross prime cytotoxic T-cells (116).Thus exosomes can aid in antigen presentation, 
boost host immunity and provide us with potential vaccination strategies particularly for targeting 
tumors(Figure 10) 
 
Figure 10: Some functions of exosomes secreted by tumors (32). 
 
Exosomes also play a role in the suppression of immune response, since they carry various 
immunosuppressive molecules such as the Fas-L ligand on melanoma exosomes which can lead 
to T-cell apoptosis(117). Tumor exosomes expressing TGFβ1 and ligands for NKG2D were also 
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able to inhibit Natural Killer (NK) cell proliferation impairing the ability of immune cells to 
recognize and destroy the cancer(118). This results in increased tumor growth, invasiveness and 
metastasis. (Figure 10). 
They are also capable of modifying the transcriptional profile of the target cells by 
delivering functional payloads of biomolecules as demonstrated in exosomes derived from 
colorectal cancer cells, (119) lung(120) and prostate cancer cells(121). Glioblastoma derived 
exosomes carry mRNA and miRNA that are capable of inducing cell migration, proliferation and 
angiogenesis in brain microvascular endothelial cells (122) (Figure 10: Some functions of 
exosomes secreted by tumors (32).Figure 10). This demonstrates a clear role for exosomes as 
important players in cell-cell communication as they carry functional messages between cells with 
pleiotropic effects.  
1.4 Exosome trafficking through the body 
Exosomes travel to distal target cells upon being secreted by the cell of origin via circulation and 
other body fluids. Body fluid-derived exosomes have been found in all biological fluids and are a 
mixture of vesicles originating from different sources such as the cells found in the body fluids 
and/or the cells lining the cavities of extruded body fluids. The two most important body fluids for 
the development of an immune response are blood and lymph, and the exosomes within them are 
described below. 
1.4.1 Exosomes in circulation  
The first report of the existence of EVs in blood was almost 70 years ago and was later described 
as platelet “dust”(123). There have been innumerous reports of exosomes in the circulation since 
where they have been shown to play a number of roles(124-126). Studies with fluorescent 
exosomes have enabled systemic tracking of exosomes in circulation which revealed their organ 
biodistribution and rapid clearance from the body via the liver(125).  Exosome movement through 
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the circulation is well established and current research is focused on understanding the many 
functions of exosomes and the potential to harness exosomes in circulation to deliver therapeutic 
molecules.  
1.4.2 Exosomes in lymphatics 
Exosome trafficking through the lymphatics came to the forefront when research showed the 
strong presence and localization of both tumor derived exosomes and B-cell derived exosomes in 
lymphoid organs such as the spleen and lymph nodes(124, 127). However, the presence of 
exosomes in the lymph or trafficking through the lymphatic system has been undemonstrated.  
1.5 Research Goals 
The overall research goals of this thesis can be divided into two primary objectives: 
1) The role and kinetics of lymphatic transport of exosomes in the establishment of an innate 
immune response both in vitro and in vivo (Chapter 2) 
2) The systemic roles of exosomes in the context of innate immunity, specifically in the 
dissemination of the Toll-like receptor response and the contribution of exosomal cargo to 
this process in vitro and in vivo (Chapter 3). 
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CHAPTER 2: SPECIFIC AIMS AND HYPOTHESES 
 Multicellular organisms rely on cell-cell communication for information exchange in order 
to promote survival, and appropriate development and functioning of tissues. This communication 
occurs either through direct physical contact via nanotubes(128), secreted chemical signals like 
cytokine, chemokines, or small molecule mediators (proteins, nucleic acids), or exchanging 
information via exosomes (129). Exosomes provide the ability to transmit messages between cells 
at a distance and their roles in long distance communication have been well established(130). The 
discovery of functional, transportable mRNA and miRNA within exosomes further increases the 
complexity of cell-to-cell communication. They can fuse with the recipient cells and deliver their 
contents into the cytoplasm of the recipient cell and perturb the recipient cell, especially since 
miRNA can mediate RNA interference (88).They can also bear combinations of ligands to engage 
several cellular receptors at once modulating changes in the recipient cell.  
 Exosomes play a wide variety of roles in the body including immunity and it is critical to 
dissect their contribution to the development of innate immunity. One of the biggest unknowns in 
the field, is the routes of transport utilized by exosomes in the body while transferring immune 
related information systemically. Exosomes have been demonstrated to have functional 
consequences in the lymph node drained by both blood and lymph. While exosomal trafficking in 
circulation is well known, the contribution of lymphatic transport needed to be ascertained. We 
also wanted to understand the effector functions of exosomes in the context of pathogen 
recognition and response by the toll-like receptor pathway. We modeled this response using LPS 
and poly (I:C), agonists that activated the bacterial response via TLR 4 and the viral response via 
TLR 3 respectively. We further characterized the role of exosomes in the dissemination of the TLR 
activation state of the cell of origin distally in a mouse tail lymphatic model and elucidated the 




2.1 Aim 1:  Establishing and characterizing exosome transport through the lymphatics 
in vivo1. 
Hypothesis: Exosomes are taken up and transported by the lymphatics to the lymph node.   
Long distance cell-cell communication is particularly important when cells are exposed to 
infection and helps in mounting a coordinated response against the invading pathogen. Exosomes 
are particularly well suited to transmit messages of infection from exposed cells to distal cells 
which are as yet uninfected(131). The lymphatic system is found in most tissues of the body, and 
plays important roles in maintaining fluid balance, immune cell trafficking from the periphery to 
lymph nodes, and lipid transport from the intestine to the circulation(44). A few salient features 
that make it likely that exosomes utilize the lymphatic system as a route for rapid cell-cell 
communication are: a) The lymphatics can transport large molecules, b) The lymphatics provide 
direct access to lymph nodes which are immune cell hubs. C) Exosomes have a number of 
immunomodulatory effects and d) Exosomes exist in the ideal size-range for lymphatic transport 
Exosomes secreted antigen presenting cells (APC) stimulate T-cells in vitro and in vivo(132). 
However, they cannot activate the T-cells directly; they must be captured by an antigen presenting 
cell proximal to the naïve T-cells for activation. The speculated reason for this alternate route is 
that APC’s in the periphery could use exosomes as a rapid means of priming the downstream 
lymph node instead of directly migrating there themselves since exosomes are in the ideal range 
of lymphatic transport (133). Here we have definitively shown the lymphatic transport of 
exosomes both in vitro and in vivo. Using an in vitro model of lymphatic uptake, we have shown 
that lymphatic endothelial cells actively enhanced lymphatic uptake and transport of exosomes to 
                                                 
 
 
1 Srinivasan, S. et al. Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph 
node. Sci. Rep. 6, 24436; doi: 10.1038/srep24436 (2016). 
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the luminal side of the vessel. Furthermore, we have demonstrated a differential distribution of 
exosomes in the draining lymph nodes that is dependent on the lymphatic flow. Lastly, through 
endpoint analysis of cellular distribution of exosomes in the node, we identified macrophages and 
B-cells as key players in exosome uptake. 
 
2.2 Aim 2 Elucidating effector functions of exosomes under bacterial and viral infection  
states in vitro and in vivo.  
Hypothesis: Exosomes from infected cells have distinct functional effects on downstream cells and 
will differ in their (RNA) contents between control and TLR stimulated cell derived exosomes.  The 
biological functions of the exosome is essentially dependent on the biological state of the parental 
cells that produces it. E.g. Cells under oxidative stress release exosomes that can transmit 
resistance to oxidative stress in recipient cells (134). This protective effect on growth conferred by 
exosomes was annulled by exposing the exosomes to UV implicating exosomal RNA as the causal 
agent. Therefore exosomes released under different conditions have different effects on recipient 
cells due to varied exosomal RNA content. While the responses of cells exposed to LPS and Poly 
I:C are well elucidated in vitro (135)and in vivo(136), these studies don’t take the role of exosomes 
into account. Exosomes have the ability to transmit messages of infection from the location of 
stimulation to a distal location rapidly because of their ability to move through the body rapidly. 
It is as yet unknown if exosomes can transmit differential signals based upon specific TLR 
agonists. This study is the first to explore the importance of exosomes in spreading the message of 
infection to naïve cells and facilitating a rapid response by the innate immune system.   
Here we show that exosomes from TLR stimulated cells can largely recapitulate TLR activation 
in distal cells in vitro. We can abrogate the action-at-a-distance signaling of exosomes by UV 
irradiation, demonstrating that RNA is crucial for their effector function. We are the first to show 
that exosomes derived from poly (I:C) stimulated cells induce in vivo macrophage M1-like 
polarization within murine lymph nodes. These poly (I:C) exosomes demonstrate enhanced 
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trafficking to the node and preferentially recruit neutrophils as compared to control exosomes. This 
work definitively establishes the differential effector function for exosomes in communicating the 
TLR activation state of the cell of origin. 
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CHAPTER 3: LYMPHATIC TRANSPORT OF EXOSOMES FOR RAPID 
INFORMATION DISSEMINATION TO THE LYMPH NODE   
3.1 Abstract  
It is well documented that cells secrete exosomes, which can transfer biomolecules that impact 
recipient cells’ functionality in a variety of physiologic and disease processes. The role of 
lymphatic drainage and transport of exosomes is as yet unknown, although the lymphatics play 
critical roles in immunity and exosomes are in the ideal size-range for lymphatic transport. 
Through in vivo near-infrared (NIR) imaging we have shown that exosomes are rapidly transported 
within minutes from the periphery to the lymph node by lymphatics. Using an in vitro model of 
lymphatic uptake, we have shown that lymphatic endothelial cells actively enhanced lymphatic 
uptake and transport of exosomes to the luminal side of the vessel. Furthermore, we have 
demonstrated a differential distribution of exosomes in the draining lymph nodes that is dependent 
on the lymphatic flow. Lastly, through endpoint analysis of cellular distribution of exosomes in 
the node, we identified macrophages and B-cells as key players in exosome uptake. Together these 
results suggest that exosome transfer by lymphatic flow from the periphery to the lymph node 
could provide a mechanism for rapid exchange of infection-specific information that precedes the 
arrival of migrating cells, thus priming the node for a more effective immune response. 
3.2 Introduction 
Multicellular organisms rely on cell-cell communication for information exchange in order 
to promote survival and appropriate development and functioning of tissues. This communication 
occurs either through direct physical contact via nanotubes(137), secreted chemical signals like 
cytokine, chemokines, or small molecule mediators (proteins, nucleic acids), or exchanging 
information via exosomes(138). Exosomes provide the ability to transmit messages between cells 
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at a distance and their roles in long distance communication have been well established(4). The 
discovery of functional, transportable mRNA and miRNA within exosomes further increases the 
complexity of cell-to-cell communication. They can fuse with the recipient cells and deliver their 
contents into the cytoplasm of the recipient cell and perturb the recipient cell, especially since 
miRNA can mediate RNA interference(88). They can also bear combinations of ligands to engage 
several cellular receptors at once modulating changes in the recipient cell.  
Exosomes are credited with several roles in modulating immune response in vivo :a) dendritic cell 
derived exosomes carried antigens and present them to T-cells(139), b) exosomes from 
macrophages infected with intracellular pathogens induced a pro inflammatory response in 
uninfected macrophages thereby activating the immune response(140) and c) tumor derived 
exosomes carry a variety of immunosuppressive molecules to suppress the immune response to 
the tumor by decreasing proliferation of various immune subsets like natural killer cells, regulatory 
T-cells or myeloid cells(132). 
Lymphatic flow is an important component of circulation as it serves to return interstitial 
fluid from tissue back to the circulation via the lymph nodes(141). Lymphatic drainage from tissue 
results in transport of antigens, immune cells and large macromolecules from the periphery to the 
lymph nodes where innate and adaptive immune responses are elicited. Thus, each lymph node 
obtains region specific antigenic information through the lymphatic capillaries that drain the 
periphery allowing antigen presenting cells (APCs) to initiate an immune response(142).  
Interestingly, the intrinsic physical barriers created by the interstitium and vascular exclusion of 
large proteins, create an “optimal” size range for lymphatic transport of 5-100 nm which is 
primarily the size range of exosomes. Particles smaller than this are easily taken up in the blood 
capillaries and larger particles typically become trapped in the extracellular matrix(143, 144), 
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although more recent evidence suggests that particles as large as 1 micron could be taken up by 
lymphatics(145).  
It is likely that one of the primary advantages of exosome size is that they are small enough 
to convect through the interstitial matrix with interstitial flow, yet large enough to partition their 
uptake into the lymphatic circulation, thus making them an ideal vehicle through which a 
peripheral cell can rapidly signal and transport information to the lymph node. Interestingly, 
melanoma-derived exosomes were able to prime the sentinel lymph node for tumor metastasis by 
initiating a proangiogenic program and remodeling the tissue matrix(24) and CD169+ cells were 
identified as the target cells for B-cell derived exosomes in the lymph nodes and spleen(124) 
implicating the lymphatic system in playing an important role in exosome transport from the 
periphery to lymphoid organs and the nodes. However, experiments involving exosome signaling 
in the node are typically conducted over the course of hours or days and thus it is unclear how 
rapidly exosome trafficking and uptake into cells in the node can occur, a process in which speed 
should be of particular importance if exosomes are utilized to enhance innate immunity. 
 Near-infrared imaging is an emerging technology and has been used to non-invasively 
image and quantify functional lymphatic transport(61) and perform sentinel lymph node 
mapping(146) as it offers maximum tissue penetration with minimal autofluorescence(147). 
Exosomes on the other hand have been imaged by either covalently labeling with a 
fluorophore(148) or with a variety of lipid dyes such as DiL or DiO(24) in the visible range, which 
allows for trafficking of exosomes in cell cultures or endpoint in-vivo biodistribution studies of 
exosomes, but suffers from depth penetration limitations making them ill-suited for in vivo 
imaging. We have successfully labeled exosomes with a near-infrared dye which enables us to 
monitor exosome trafficking in vivo using near-infrared imaging. Thus, we can establish and 
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quantify the kinetics of lymphatic transport of exosomes from the peripheral tissue to the lymph 
node, which is particularly important in the context of innate immunity where rapid antigen 
transport can be crucial to the establishment of host immunity and limiting pathogen spread(149). 
Characterizing exosome trafficking through the lymphatics and the resulting cellular uptake in the 
lymph node provides several key insights into both the role of lymphatic drainage as well as 
paracrine effects of exosomes in the context of immunity.  
3.3 Materials and Methods 
3.3.1 Cell culture 
Fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) was centrifuged for 15 hours at 
120,000g, 4OC to remove exosomes and was used to make exosome free cell culture media. Human 
neonatal dermal lymphatic endothelial cells (LECs) were originally harvested as described 
previously(150). LECs were expanded in flasks coated for 1 h with 50 μg/mL type I rat tail 
collagen (BD Biosciences, Bedford, MA) in 0.1% acetic acid and were cultured in EBM (Lonza, 
Walkersville, MD) supplemented with 20% exosome free FBS, 1% penicillin-streptomycin-
amphotericin, 1% Glutamax (both from Life Technologies, Grand Island, NY), 25 mg/mL cyclic-
AMP, and 1 mg/mL hydrocortisone acetate (both from Sigma, St. Louis, MO). Media was changed 
every 2–3 days and LECs were used for experiments at passages 9 and 10. Human ovarian 
adenocarcinoma cell line, HEY cells (Cedarlane Labs, Ontario, Canada) were cultured in RPMI 
1640 (Mediatech, Manassas, VA) supplemented with 10% exosome free fetal bovine serum, 2 mM 
L-glutamine, 10 mM HEPES buffer (both from Mediatech), penicillin (100 U/ml), and 
streptomycin (100 μg/mL) (Life Technologies) for 48 hours and the culture media was used for 
isolation of exosomes by ultracentrifugation. SV-LECs were cultures as previously described(151) 
and were used as a source of mouse exosomes.  
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3.3.2 Exosome isolation and characterization 
Conditioned media was collected from HEY cells at 90% confluence for exosome isolation. 
Briefly, the culture media was spun at 300g, for 10 min to remove dead cells followed by a spin at 
16,500g, 20 min. The supernatant was then filtered through 0.22µm filters and centrifuged at 
120,000g for 120 min. The pellet containing exosomes was re-suspended in a suitable volume of 
PBS. 
The size homogeneity of vesicles obtained was checked using a Zetasizer Nano ZS90 (Malvern 
Instruments Ltd, Worcestershire, UK) and quantified using Pierce BCA Protein assay kit (Thermo 
Fisher Scientific, Waltham, MA). To analyze the expression of exosomal surface markers, 4 μm 
aldehyde/sulfate latex beads (Life technologies) were coated with Anti-CD9 antibody (BD 
Biosciences, San Diego, CA) overnight and incubated with 30 ug of exosomes. The beads were 
coated with biotin and the streptavidin-coated fluorescent beads were captured and assessed for 
surface marker expression. The exosome-bead complexes were probed with Anti Human CD81-
PE or Anti human CD63-PE (BD Biosciences, San Diego, CA) and data was acquired on a BD 
LSR II Flow cytometer. Data analysis was performed using the FloJo software (FlowJo version 
10, Ashland, OR).  
3.3.3 Scanning electron microscopy 
Exosomes were fixed with 3.7% glutaraldehyde (Sigma–Aldrich GmbH, Taufkirchen, Germany) 
on carbon stubs for 15 min. After washing twice with PBS, the fixed exosomes were dehydrated 
with an ascending sequence of ethanol (40%, 60%, 80%, and 98%). After evaporation of ethanol, 
the samples were left to dry at room temperature for 24 h on a glass substrate and then analyzed 
by Hitachi Cold Field Emission SEM SU8200 (Hitachi High-Tec, Tokyo, Japan).  
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3.3.4 Fluorescent labeling of exosomes 
Exosomes were labeled using PKH67 Green Fluorescent Cell Linker Kit for General Cell 
Membrane Labeling (Sigma-Aldrich) as per the manufacturer’s instructions. Briefly, exosomes in 
PBS were added to 500 µL of Diluent C and 2 μL of PKH67 dye was added to 500 µL of Diluent 
C. The two solutions were mixed and incubated for 5 min at room temperature. 1 ml of 1% BSA 
was added to stop the reaction. The labeled exosomes were centrifuged at 120,000g for 70 min 
and washed twice with PBS to remove excess dye.  
PKH labeled exosomes were labeled with the near-infrared dye using IRDye® 800CW Protein 
labeling kit (Licor, Lincoln, NE) according to the manufacturer’s instructions. Briefly, exosomes 
in PBS were mixed with the IRDye® 800 CW NHS ester and overnight and free dye was removed 
using Zeba desalting spin columns (Pierce).  
3.3.5 Transport assay and data analysis 
Transwell® permeable membrane supports with 3 μm pores (Corning Life Sciences, Corning, NY) 
were coated for 1 h with 100 μg/mL type I rat tail collagen in PBS and LECs were seeded at a 
density of 100,000 cells/cm2 and cultured for 48 h (Figure 12a). A fraction of the transwells were 
not seeded with cells and were used to determine membrane permeability (Peff_cell-free).). Prior to 
transport experiments, cells were incubated for 1 h in serum-free, phenol red-free EBM (Lonza). 
The basal side of the monolayer was incubated with a fluorescent mix containing 20 μg/mL PKH 
labeled exosomes, 20 μg/mL FluoSpheres® Carboxylate-Modified 40nm Microspheres, 5 μg/mL 
3 kDa Cascade Blue dextran (both from Life Technologies) for 1 h. Samples containing 
transported fluorescent exosomes and beads were collected from the apical side.  In a subset of 
experiments, transport time varied from 10 to 30 min instead of 1 h. Fluorescence was measured 
using a Synergy™ H4 Multi-Mode Plate Reader ( Biotek, Winooski, VT) and was used to calculate 
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relative concentration based on a standard curve generated from the fluorescent mix. The effective 
permeability of exosomes, beads and dextran were calculated using the following equation:  
Peff=JsΔC⋅S, where Js is the flux, ∆C is the concentration gradient, and S is the surface area(150). 
Transport is represented as either cellular effective permeability (Peff_cell) which was calculated 
using the equation: 1/Peff_total = 1/Peff_cell +1/Peff_cell-free or as a ratio of cellular transport to cell free 
transport (Peff_total / Peff_cell-free). After samples were removed from the apical side of the transwell 
for fluorescence measurement and the calculation of Peff, membranes containing LECs were rinsed 
twice with PBS, fixed with 4% PFA, stained with DAPI and Alexa Fluor® 647 Phalloidin (Thermo 
Fisher Scientific) and mounted on glass slides for imaging on a Zeiss LSM 700 (Zeiss, Thornwood, 
NY). The fluorescence in the images was quantified using the Image J analysis software (v 1.4.1, 
NIH) 
3.3.6 Optimization of Near-infrared (NIR) imaging of exosomes 
In order to characterize the parameters of exosome imaging in the dermis using NIR, a tissue 
phantom was created as described previously (Figure 43a)(61).  Additionally a node phantom was 
also created with two fixed depth settings; 5mm and 7mm to characterize the imaging setup for 
exosome detection at the node. The node phantom was molded in a standard petri dish using a 
mixture of 97.52% silicone elastomer base (Sylgard 184, Dow Corning), 2.22% Aluminum Oxide 
(Sigma Aldrich), and 0.26% cosmetic powder (Max Factor Crème Puff Deep Beige 42) according 
to previously published methods(152) 
3.3.7 Near-Infrared imaging of mice 
The NIR imaging system was set-up as described previously(61). The camera was connected to a 
computer where the videos were acquired and analyzed by a custom LabView VI (National 
instruments). 
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Lymphatic transport of exosomes was quantified in vivo in the tail of eight-week-old male Balb/C 
mice (Charles River Laboratories, Wilmington, MA) according to procedures approved by the 
Georgia Institute of Technology IACUC Review Board. To minimize light scattering, a depilatory 
lotion was used to remove hair in the region of interest on the tail and back 1 day prior to 
experimentation.  
The mice (n=10) were anesthetized with Isoflurane continuously delivered through a nose cone 
and intradermally injected with 10 ug (10 ul of 1 ug/ul) of exosomes labeled with both PKH67 and 
IRDye 800CW in PBS. Care was taken to position the injection as close to the midline of the tail 
as possible to avoid favoring one collecting vessel over the other. The small volume of fluid 
injection and the use of NIR to enhance tissue penetration ensures that only fluorescence in the 
deeper collecting lymphatics is visible downstream of the injection site. Image acquisition began 
just prior to intradermal injection of the dye and the animals were imaged continuously for 20 min 
post-injection with a frame rate of 1 fps with a camera exposure time of 50 ms. Draining vessels, 
the injection site and the draining lymph nodes were imaged regularly to monitor movement of 
exosomes from the periphery to the nodes. 
To evaluate lymphatic function in each of the mice, two parameters were measured as previously 
described: transport time and the average velocity of the packets traveling through the field of view 
of the recording site(64). An example of fluorescence arrival in the collecting vessel can be seen in 
Supp video 1, and a plot of fluorescence intensity over time during fluorescence arrival can be 
seen in Figure 14a. The number of packets was measured using the plots of fluorescence intensity 
over time generated from two regions of interest (ROIs) in a collecting vessel and was termed the 
packet frequency.  
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3.3.8 Ex vivo node analysis 
Mice were euthanized in 2 groups; group1 (n=5) was monitored and imaged for 2 hours post 
injection before euthanasia and group 2 (n=5) was imaged for 2 hours post injection and again on 
days 1 and 2 before being euthanized. The draining (sacral) lymph nodes, control (axillary) lymph 
nodes were harvested from both the groups of mice after euthanasia. Additionally the liver, spleen, 
pancreas, kidney, heart, lungs, stomach, intestines, thymus and injection site were excised from 
one mouse in each group and was homogenized using 1.4 mm Zirconium Beads Pre-Filled Tubes 
(OPS Diagnostics, Lebanon, NJ) in a FastPrep 24 homogenizer (MP Biomedicals, Santa Ana, 
California). The supernatant was used to measure fluorescence in a Synergy™ H4 Multi-Mode 
Plate Reader (Biotek) to calculate exosome retention by each organ. One set of lymph nodes (both 
sacral and axillary) from both groups were snap-frozen in Tissue-Tek OCT (VWR, Radnor, PA) 
and sectioned at the Winship Cancer Institute’s Pathology Core.  
3.3.9 Fluorescence Confocal microscopy of lymph node sections.  
Frozen sections of excised sacral and axillary nodes were blocked in 10% BSA in PBS and 
incubated with primary antibody overnight, followed by secondary antibody for 2 h. Primary 
antibodies were Anti-mouse CD19, Anti-mouse CD4, Anti-mouse CD8A( all from Life Tech), 
Anti mouse CD14 (Sigma), Anti-mouse CD169 (Thermo Fisher Scientific), Anti-Human CD81 
(BD Biosciences). These sections were detected using secondary antibodies conjugated with Alexa 
Fluor 647 or Alexa 680 (Life Tech) and imaged by confocal microscopy using a Zeiss LSM 700. 
3.3.10  Flow cytometry of nodes 
Harvested lymph nodes from both group 1(n=3)  and group 2 (n=3) were digested with collagenase 
D (Roche Ltd., Mannheim, Germany) and homogenized using 70 μm pore size strainers. Cell 
pellets were washed staining buffer with BSA (BD Pharmingen, San Jose, CA) and centrifuged at 
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300g for 1 min. To quantify exosome retention in the whole node, cells were analyzed for PKH67 
positive populations using a LSR II flow cytometer (BD Biosciences, San Jose, CA). To identify 
cellular subsets responsible for exosome uptake, PKH67 positive cells were sorted on a FACS Aria 
II cytometer (BD Biosciences) and stained with monoclonal antibodies against mouse CD14, Anti-
mouse CD19 and Anti-Human CD81 conjugated with, PE or AF647 for 30 min at 4 °C in the dark. 
Data was acquired in a LSR II flow cytometer (BD Biosciences) with compensation using single-
stained cells. Data analysis was performed using FlowJo software (version 10). 
3.3.11  Statistical analysis 
T-tests were used to compare the expression levels of tetraspanin markers between exosomes and 
beads (unpaired), exosome and bead transport at 370C and 40C (paired), arrival times for dominant 
and non-dominant vessels and nodes (paired). Exosome retention in the node and uptake by 
macrophages and B-cells was analyzed using paired t-tests. All analyses were run in Prism 6 
(GraphPad Software Inc, La Jolla, CA) and significance was defined as p > 0.05 (not significant - 
ns) p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****). All data is presented as 




3.4.1 Characterization of exosomes and beads  
Exosomes from the HEY cell line were isolated and characterized along with size and density 
matched polystyrene beads using dynamic light scattering, scanning electron microscopy and for 
surface marker expression using flow cytometry.   The average size of HEY exosomes was 
78.82±19.17SD nm as compared to the beads which had an average size of 67.34±13.7SD nm 
(Figure 11a).  Exosomes had a spherical shape with a diameter of ~60-75 nm as seen from scanning 
electron microscopy which agreed with previous reports of exosome shape and size reported in 
literature (153)(Figure 11b). The classical tetraspanin surface markers CD63 and CD81, which are 
known to be enriched on exosomal membranes(88),  had an ~80% expression level on HEY 
exosomes (Figure 11c-e). Thus, the HEY exosomes used in this study conformed to known 
exosomal size ranges, expressed the classical tetraspanin markers and were spherical in shape as 




Figure 11:  Characterization of exosomes and beads.  a) Size distribution of HEY exosomes as 
compared to that of beads b) Scanning electron micrograph of exosomes c) Expression of CD63 
and d) CD81 on exosomes and beads. e) Quantitation of CD63 and CD81 on exosomes and beads 
by flow cytometry (p-value <0.01) 
3.4.2 Exosomes are transported rapidly and selectively through the lymphatic endothelium 
in vitro 
To test the hypothesis that transport of exosomes across the lymphatic endothelium is higher than 
size and density matched beads, the effective permeability of cells ( Peff_cell ) to the fluorescently 
labeled exosomes and beads in the basal to apical direction was measured using a transwell system 
as described previously(84) (Figure 12a). Exosomes, beads and dextran were freely transported 
across the membrane in the absence of cells (Figure 12b, dotted lines) and neither exosomes nor 
beads stuck to the membrane (Figure 42d).  
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Figure 12: Exosomes transported rapidly and selectively through the lymphatic endothelium in 
vitro a) Schematic of experiment, b)Transport of exosomes across the lymphatic endothelium 
occurs rapidly (t=5-30mins) and is enhanced in the presence of cells, c) Exosomes are selectively 
transported into the lymphatic endothelium (versus beads), d) Confocal images of LEC’s (nuclei 
stained with DAPI) with PKH67 exosomes and beads at 37OC. Scale= 20 µm   
 
Additionally, the size ranges of the exosomes collected on the apical side were similar to that on 
the basal side, further confirming exosome trafficking from the basal to apical sides of the LECs 
(Figure 42e).  To understand the kinetics of exosome transport by LECs, transport was assessed 
every 5 min. The beads were excluded from this study as their transport was below the detection 
limit at 30 min. Flux was calculated both in the presence and absence of cells to determine the 
extent that LECs enhanced or alternatively provided a barrier to selective transport. Dextran, being 
extremely small (3kDa) freely diffused through the Transwell membrane at the roughly the same 
rate in the presence and absence of LECs and rapidly reached equilibrium at about 15 min. 
Exosomes were rapidly detected across the lymphatic endothelium at 5min and transport in the 
presence of cells was much higher than in the absence of cells (~2 fold) with transport reaching 
equilibrium at ~20 min (Figure 12b, solid lines). In order to quantify this difference, the effective 
permeability of cells was calculated after incubation with exosomes and beads for 75mins so 
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transport could attain equilibrium at 37OC and 4OC. Exosomes were transported across the 
lymphatic endothelium ~10 times more as compared to the fluorescent size matched beads (p-
value < 0.01) at 37OC (Figure 12c). When the cells were fixed and examined using confocal 
microscopy, exosomes were seen within cells at 37OC (Figure 12d, Figure 42c) whereas beads 
were not (Figure 42b). However, exosome uptake was greatly reduced at 4OC (Figure 42a). The 
fluorescence in the images that corresponded to exosomes and beads was quantified at 37OC and 
4OC which showed that exosome transport was reduced by ~80% at 4OC (Figure 12e, p-value< 
0.001). Collectively this data suggests that the lymphatics actively transported exosomes in vitro. 
3.4.3 Exosomes are rapidly transported into lymphatics in vivo 
The tissue phantom was to test the sensitivity of the NIR imaging system for detecting dual labeled 
exosomes. Exosomes were detected at a signal-to-noise ratio >4 at depths of 1-6mm (Figure 43b). 
We tested the limit of detection of exosomes within the vessels by running several dilutions of the 
exosome solution through the tissue phantom and were able to detect 0.1μg/ul of exosomes which 
is 1% of the injected dose (Figure 43c). Lastly the lymph node phantom was able to detect an 
exosome concentration of 0.01μg/μl exosomes, or 1% of the injected dose of 1μg/μl (Figure 43d).  
To track the movement of exosomes real time in vivo, a near-infrared fluorophore was conjugated 
to the N-terminal of exosomal membrane proteins. A second fluorophore was added in the lipid 
bilayer of the exosomes to enable ex-vivo, multi scale analysis of cellular exosome uptake and 
transport (Figure 13a).  Mice were injected intradermally with a 10ug bolus of dual labeled 
exosomes in PBS. The near-infrared excitation source and the field of view of the CCD emission 
detector were centered on the mouse tail 10 cm downstream (toward the base of the tail) from the 
injection site at the tip of tail (Figure 13b). This location ensured that only the downstream 
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collecting lymphatics would be visualized so as to maximize detection sensitivity and avoid image 
saturation form the injection site (Figure 13i).  
 
Figure 13: Exosomes are transported rapidly through the lymphatic endothelium in vivo. a) Dual 
labeling of exosomes, b) injection and visualization scheme in mice. Exosomes are detected in the 
lymphatics rapidly c) vessel at 0 mins, d) vessel at 2 mins, e) vessel at 5 mins, f) vessel at 20 mins 
g) vessel at 2 hours, h) vessel at 2 days, i) lymphatic capillaries seen close to the injection site at 2 
hours, j) injection site at 2 hours, and k) injection site at 2 days. Scale bar =5mm. 
 
Exosomes were seen in the lymphatic collecting vessels within 2 min of injecting the bolus in the 
tip of the tail 10cm downstream of the injection site (Supp Video 1). Exosomes were first detected 
first in the dominant vessel draining the tail, and then in the non-dominant vessel about 2.5 min 
later. Both vessels reaching a steady state value of fluorescence by 20 min after injection (Figure 
13c-f) T. his result agreed with previous findings that reported lymphatic transport in rodent tails 
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and mouse hind limbs where the two collecting vessels had varying functional capacity as 
measured by NIR imaging(64, 154). The collecting vessels maintained these steady state values 
for up to 6 hours post injection however there was no detectable signal that remained in the vessel 
24 hours after injection. Representative images of the collecting vessels are shown at the 2 hour 
and 2 day time points, the end points of our study (Figure 13g and h respectively). The injection 
site continued to retain a fraction of the injected exosomes at 2 hours and 2 days (Figure 13j and k 
respectively).  
3.4.4 Characterization of exosomes transport in vivo 
The fluorescence arrival in the dominant and non-dominant collecting vessels were analyzed and 
quantified from the time of injecting the exosome bolus until steady state fluorescence was 
achieved. The dominant vessel always had significantly higher fluorescence in all trials as 
compared to the non- dominant vessel (Figure 14a; p- value <0.05) and representative line intensity 
profiles are shown for both vessels (Figure 14b). The fluorescence arrival in the draining lymph 
nodes were analyzed and similarly, the dominant node (drained by the dominant collecting vessel) 
was visualized first and was brighter than the non-dominant node which was visualized later and 
was fainter (Figure 14c). Representative line intensity profiles are shown for both the draining 
lymph nodes (Figure 14d). There are two distinct regions in the line intensity graphs that 
corresponding to a) “arrival” where there is a rapid increase in exosome transport and b) “steady 
state” where the exosomal transport is stable. The packet frequency in the dominant vessel was 
significantly higher (p-value <0.05) at arrival as compared to the steady state while the difference 
in non-dominant packet frequency was not significant (Figure 44a, p-value = 0.068).  The packet 
frequency in the lymph nodes followed a similar pattern with a significantly higher frequency in 
the dominant node as compared to the non-dominant node at both the arrival and steady states (p-
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value<0.05, Figure 44b). The transport times of the dominant vessel was significantly lower with 
fluorescence first appearing in the dominant vessel at least 30 seconds ahead of the non-dominant 
vessels [p-value<0.05], and this trend was replicated in the lymph nodes with fluorescence in the 
dominant  node appearing about a 1.5 min before the non-dominant node (Figure 14e).  
.  
Figure 14: Characterization of exosomes transport in vivo a) Steady state fluorescence in the 
lymphatic collecting vessel b) Intensity profile of a specified region of interest of exosome 
transport in a representative vessel over a 10 minute period, c) Steady state fluorescence in the 
draining lymph node, d) Intensity profile of a specified region of interest of exosome transport in 
a representative lymph node over a 10 minute period, e) Arrival time of detectable levels of 
fluorescence for dominant and non-dominant collecting vessels and draining lymph nodes 
 
To verify that the transport characteristics seen with HEY exosomes were features of lymphatic 
transport rather than specific to the cellular source, we injected exosomes from mouse lymphatic 
endothelial cell line (SV-LEC). We were able to recapitulate the collecting vessel and lymph 
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node transport kinetics and characteristics (Figure 45a-d). The arrival time in the collecting 
vessels and draining lymph nodes was comparable (Figure 45e) and the packet frequency (Figure 
45f) is comparable between HEY and SV-LEC exosomes.  
3.4.5 Characterization of exosome retention in vivo 
 The exosome bolus was rapidly seen in the sciatic lymph nodes drained by the collecting 
lymphatics with the fluorescence arriving in both the dominant (Figure 15a) and non-dominant 
node within 5 min (Figure 15b, Supp. Video 2). The nodes reached a steady state of fluorescence 
much like the collecting vessels by 30 min post injection; however unlike the vessels where the 
fluorescence disappeared within 24 hours, the lymph node fluorescence was detectable through 
the skin for at least 2 days after injection (Figure 15c and e respectively). The nodes upon excision 
at 2 hours and 2 days were strongly fluorescent (Figure 15d and f respectively). 
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Figure 15: Characterization of exosome retention in vivo. Exosomes are detected in the node 
rapidly: a) Only dominant node is seen at 5 mins in vivo, b) Both nodes seen at 15 mins in vivo, c) 
Draining lymph nodes visualized at 2h pre-excision (in animal), d) Excised lymph nodes at 2h post 
injection, e) Draining lymph nodes visualized at 2d pre-excision (in animal) f) Excised lymph 
nodes at 2 days post injection, Scale =5 mm. g) Biodistribution of exosomes in mice organs 
analyzed at 2 hours and 2 days post injection and h) quantitation of exosomes and beads retained 
in the lymph node 1 hour post injection as determined by fluorescence  
 
Several organs including the heart, lungs, kidney, spleen, liver, and pancreas were harvested from 
both mice at 2 hours and 2 days post injection and digested. The fluorescence was measured in 
each organ to quantify exosome retention by each organ. Exosomes were predominantly found in 
the injection site, draining lymph nodes, kidney and liver at 2 hours post injection and accumulated 
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in the lymph nodes, spleen, thymus and kidney at 2 days. A significant portion was still present in 
the injection site in the tail (Figure 15g).  
We injected beads and SV-LEC exosomes together in mice to compare lymphatic uptake 
characteristics and quantified the percent of the injected dose in the lymph nodes using 
fluorescence on a plate reader 1 hour after injection. While exosomes were retained to a similar 
degree, the beads were poorly retained with the dominant node contributing to only 2% of the 
uptake. The non-dominant node had very poor (<1%) retention of the beads (Figure 15h).   
3.4.6 Characterization of exosome retention in the draining lymph node 
To investigate the cell populations that were responsible for uptake and retention of the 
exosomes in the draining lymph nodes, the dominant and non-dominant nodes were analyzed 
either by immunostaining or digesting the nodes and quantifying co-localization of the exosome 
signal with immune cells markers using FACS (Figure 16a). The dominant lymph node contained 
a significantly higher proportion of exosomes than the non-dominant node (p-value < 0.05) a 
phenomenon that was observed at both 2 hours and 2 days (Figure 16b and c respectively). 
Although the amount of exosomes retained in the node slightly decreased from 2 hours to 2 days 
post injection in both the dominant and non-dominant nodes, they still contained 10-15% of the 
injected exosomes and contained 1500-fold higher concentration of exosomes than the axillary 
lymph node which served as a control for the study as it did not directly drain the site of local 
exosome injection (Figure 15g, Figure 16d).  Within the draining lymph node, exosomes were 
predominantly present in 2 specific areas: the entire periphery of the node and in small circular 
areas near the periphery that corresponded to the subscapular sinus (SCS) and the follicular regions 
of the lymph node respectively (Figure 16e-g). 
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Figure 16: Characterization of exosome retention in the draining lymph node. a) Schematic of node 
procession post excision from mouse b) Dominant node retains a larger quantity of exosomes at 2 
hours c) Dominant node retains a larger quantity of exosomes at 2 days, d) Quantitation of exosome 
retention by the dominant and non-dominant nodes at 2 hours and 2 days respectively, e) Exosome 
localization within the node; f) Merged image with whole node nuclear staining and exosome 
localization, g) magnified area in the node showing exosome localization (Scale =10um)  
3.4.7 Role of CD11b+ and CD19+ cells in exosome uptake 
To determine the primary in vivo targets of exosomes, we sorted the PKH positive cells and 
quantified the co-localization of the exosome signal with various immune cell subset markers 
including CD11b (Macrophages), CD19 (B-cells) CD4 (Helper T-cells), and CD8 (Killer T- cells). 
CD11b is abundantly expressed on the surface of monocytes and macrophages which are situated 
within the subcapsular sinus of the lymph node(155). Exosomes co-localized with CD11b+ 
macrophages in both the dominant and non-dominant lymph nodes but the dominant node had ~4 
times greater macrophage-exosome co-localization as compared to the non-dominant node at 2 
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hours (Figure 17a, b).   Exosome localization within macrophages was reduced by more than half 
in both the dominant and non-dominant nodes from 2 hours to 2 days (Figure 17c, d, i).  
CD19 is expressed on B-cells and is present in the B-cell follicles underlying the subcapsular sinus 
in the node. Exosomes were not co-localized with CD19+ B-cells at 2 hours (Figure 17e, f) but 
were strongly co-localized at 2 days and the dominant node retained about ~5 times more as 
compared to the non-dominant node (Figure 17g-i). There was no co-localization with either CD4+ 
or CD8+ T-cells at either of the time points (data not shown).  
 
Figure 17: Characterization of exosome uptake by CD11b and CD19 cells in the node by flow 
cytometry. The dominant node was digested and stained for a) CD11b at 2h, c) CD11b at 2 days, 
e) CD19 at 2 hours, g) CD19 at 2 days. The non-dominant node was stained for b) CD11b at 2h, 
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Fig 17 Continued: d) CD11b at 2 days, f) CD19 at 2 hours, h) CD19 at 2 days and i) quantitation 
of exosome uptake by the dominant and non-dominant nodes at 2 hours and 2 days respectively 
Finally, we confirmed the co-localization of exosomes with CD11b macrophages and CD19 B-
cells by immunostaining frozen lymph node sections. We observed a strong co-occurrence of PKH 
(green) signal from the exosomes with CD11b from the macrophages and CD19 from the B-cells 
(Figure 18 a and c respectively). Additionally, we also checked for CD169 co-localization with 
exosomes to confirm macrophage mediated exosome capture (Figure 18b).  In order to ensure that 
the PKH signal is still present on intact exosomes, we checked for CD81 expression and found a 
very high degree of CD81 and PKH co-occurrence indicating that the dye was still associated with 
the exosomal membrane (Figure 18d).   
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Figure 18: Localization of exosomes within the lymph node. Shown are serial lymph node sections 
at 2 days following injection of 10ug of exosomes (green). Immune cells were identified as 
indicated (red) with antibodies against a) CD11b (macrophages), b) CD169 (macrophages), and c) 
CD19 (B-cells), d) CD81 (red) was used as a secondary localization marker to confirm exosome 
retention in the node. White scale bar= 50um while yellow scale bar is 5um.  
 
3.5 Discussion  
The draining lymph nodes are a stable retention site for exosomes with the quantity of exosomes 
retained in the nodes steadily increasing in both the dominant and non-dominant nodes from 2 
hours to 2 days. Exosomes carry functional mRNA and miRNA which cause changes in gene 
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expression in recipient cells(156). They have also been shown to carry antigens when released 
from infected cells resulting in a suppression of inflammatory response in vivo(157). Thus, the 
speed of exosome transport and retention at the node has important implications in innate immune 
responses. Antigen presenting cells can acquire antigens in peripheral tissues such as skin, migrate 
through the lymphatics to the node and activate an immune response(109).  Macrophages can 
release exosomes that carry specific antigens to initiate an immune response at the node: 
M.tuberculosis infected macrophages released exosomes containing mycobacterial lipoproteins 
which were able to stimulate a pro-inflammatory response in mice(140). Our data suggests that 
exosomes can reach the lymph node and be taken up by the Cd11b+ macrophages within 5 min 
and thus offer a faster route for information and antigen transfer from the periphery as compared 
to dermal antigen presenting cell migration to the lymph node which can take hours.  Additionally, 
this process would allow for some APCs to remain around the peripheral site of infection to survey 
for further signs of infection, while at the same time preemptively warning the lymph node of the 
danger with specific information of the nature of the infection encoded within the exosomes. This 
is supported by the observation that DCs continue to crawl around within the interior of the 
lymphatic capillary, often in directions opposite to that of lymph flow, even during 
inflammation(158). Further studies elucidating the time for APC’s to package and secrete pertinent 
antigens and RNA molecules via exosomes are warranted to more fully understand this process. 
Additionally, the quantity of exosomes required to elicit a response is as yet unknown and will 
likely contribute the magnitude of the response developed at the node.  
While both nodes exhibited stable fluorescence from the time of detection and were brightly 
fluorescent upon excision (at 2 hours or 2 days), a majority of exosomal uptake in the node was 
within 10 min post injection. While subtle difference in depths and diameters of the two nodes 
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within the animal can contribute to this phenomenon, we could not observe a visible difference in 
the size of the nodes. 
Exosomes accumulated the most in the liver, followed by the injection site and the kidney, 
with the stomach and intestine showing minor exosomal presence.  Another study of exosomal 
biodistribution showed presence of exosomes in the liver and spleen 30 min post injection in the 
tail vein(159). While we detected a strong signal from the liver, we were unable to detect any 
exosomes in the spleen until the 2 day time point. It is likely that transport via the blood and lymph 
will result in different biodistributions of the exosomes within whole animals and intradermal 
injections result in lymphatic transport with accumulations in the nodes and liver while intravenous 
injections result in transport by blood and accumulation in the spleen and kidneys. This is an 
important finding, as the in vivo release of exosomes from cells in the interstitium will necessarily 
concentrate themselves in the lymph nodes via lymphatic transport. Interestingly, in either case, a 
lymphoid organ is involved in exosome retention along with the liver. This phenomenon is 
corroborated by Saunderson et al(124), where intravenously injected exosomes accumulate in the 
spleen and subcutaneous injections lead to an accumulation in the lymph node 60 min post 
injection.  We believe that the exosomes have not entered the circulation in sufficient quantity at 
2 hours, due their lymphatic targeting and high levels of retention the node, thus explaining the 
appearance of exosomes in both the spleen and thymus only at the two day time point.   
Lymphatic  flow and the resulting immune response are known to be intimately connected(151) 
and in certain cases of inflammation lymph flow itself can be modulated through the recruitment 
of immune cells to the contractility of the afferent vessels draining the node (152). While lymphatic 
transport of exosomes has been implied in several papers(24, 124) they have focused on the 
downstream retention and effects of exosomes at the lymph node and the role of lymphatic 
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drainage has been overlooked.  Our results suggest that lymphatic flow can transfer exosomes from 
the periphery to the draining lymph nodes and that the transport capacity of the afferent vessels 
draining to the lymph node contributes to the distribution of exosomes between the nodes with the 
dominating collecting vessel transporting a higher payload of exosomes to the dominant node even 
though both nodes appear to drain the same tissue space. This distribution remains consistent even 
for up to two days, and is the first study to our knowledge, that shows that the quantity of antigen 
in the node is correlated to the lymphatic flow in that node. Additionally, the lymphatic uptake 
kinetics are similar for both human and mouse cell line derived exosomes, which implies that 
lymphatic transport is a common mode for exosome transport from the periphery to the draining 
lymph nodes rather than a selective route that depends on the biological state of the cellular source 
at early time points. Future studies that characterize the lymphatic retention and biodistribution of 
exosomes from different cell types could help understand the role of the cell of origin in the fate 
of exosomes in vivo. 
HEY cells are an ovarian cancer cell line and the strong retention of HEY exosomes in the lymph 
node is comparable to the retention of melanoma exosomes in the node(127). Given that ovarian 
cancer has one of the poorest outcomes(160), spreads through the retroperitoneal lymphatics 
during metastasis(161), and the numerous reports of tumor exosomes modulating immune 
responses at the node(132, 162), understanding the lymphatic transport of these exosomes will 
further help in understanding the role of lymphatic transport during cancer progression.  
Rapid uptake of exosomes into the node also appears to be facilitated by active transport 
mechanisms in the initial lymphatic endothelial cells that are selective for exosomes, as the 
presence of LEC in vitro specifically enhanced the transport of exosomes across a permeable 
membrane, but not size-matched nanoparticles or lower molecular weight dextran. In fact exosome 
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transport was 10 times higher than that of size-matched beads at 37OC.  Reduction of exosome 
transport at 4OC by 80% reduction implies active cellular transport. This concurs with previous 
data that indicates that exosome uptake is actin dependent(148) and active(163).  The molecular 
mechanisms that underlie exosome uptake is not well characterized and is a matter of debate. 
Several mechanisms including clathrin mediated endocytosis(164), pinocytosis, plasma and 
membrane fusions and phagocytosis(165) have been proposed without much consensus. Once a 
clearer understanding of uptake mechanisms is achieved, specific inhibitors can tease out the 
contributions of these pathways in exosome uptake by the lymphatic endothelial cells. Additional 
work to characterize the intracellular compartments as well as surface receptors that participate in 
exosomal shuttling will reveal potential transport mechanisms that enable selective uptake and 
transport. Rapid and active transport of other particles have recently been reported in lymphatic 
endothelial cells including lipoproteins, antigens, and albumin bound free-fatty acid, suggesting 
that active lymphatic trafficking, while selective, is not restricted solely to exosomes(150, 166-
168) 
In vivo, the initial lymphatics have unique button junctions that when combined with anchoring 
filaments enable fluid uptake and transport from the interstitium into the initial lymphatics(169). 
Additionally, elevated transmural flow has been shown to alter expression of cell-cell junction 
proteins in LEC to increase uptake(170). Thus, the injection of an exosome bolus would increase 
interstitial fluid pressure, lymphatic flow, and thus uptake of exosomes either directly or indirectly 
through active rearrangement of junctions to alter lymphatic permeability. It is likely that this 
passive drainage works in concert with active transcytosis to further enhance exosome clearance 
from the interstitial space.  
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Lymphatic endothelial cells (LECs) were recently shown to play an active role in scavenging 
antigens and presenting them to the cognate T-cells(171). Collecting lymphatic permeability was 
also shown to enhance the sampling of lymphatic antigens by antigen presenting cells within the 
surrounding adipose tissue(49). Thus, the selective transport of exosomes by LEC’s is a further 
demonstration of their active role in the establishment of immunity as they aid the exposure of the 
exosomes to immune cells.  
The dominant and non-dominant nodes widely differ in exosome uptake by macrophages and B-
cells. While this difference could be partially caused by the differing amounts of exosomes 
received by each node, may not be sufficient to explain the differences observed. Macrophages in 
the subcapsular sinus can capture and retain antigen from the lymphatics for up to 72 hours and 
then present them intact to B-cells(172, 173). Additionally, T-cells transferred exosomes to APC’s 
at the immunological synapse through cognate interactions(174). A similar mechanism could be 
potentially operating in exosome transfer although further studies need to be conducted to 
understand the kinetics of exosome movement within the node. It will be interesting to further 
understand the time and location of RNA and protein release from the exosomes at the node and 
the modulation of the immune cell subsets by this mechanism. Further studies need to be conducted 
to see if these differences in co-localization could impact the immune response development at 
each of these nodes in the presence of antigen which could reveal important information about the 
development of an innate immune response at the lymph node. 
3.6 Conclusions 
Collectively, our findings highlight the importance of lymphatic permeability and drainage in the 
transport of exosomes from the periphery to the lymph nodes. It also sheds light on the immune 
cell subsets involved in exosome retention at the node which was hitherto unknown and can 
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potentially be exploited in targeting the lymph node. The differential distribution of exosomes 
between the two draining nodes while unexpected has opened up new questions in distribution of 
antigens during an immune response and vaccine response suggesting subtle differences between 
the immune cell niche between the dominant and non-dominant nodes. The combination of rapid 
lymphatic delivery to the node and the functional consequences of exosomes on downstream cells 
could be a powerful combination in drug delivery but will need a great deal of further work to 
unlock the full spectrum of possibilities.  
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CHAPTER 4: EXOSOMES DERIVED FROM TLR ACTIVATED CELLS 
SHOW DISTINCT EFFECTOR FUNCTIONS 
4.1 Abstract  
The innate immune system is vital to rapidly responding to pathogens and Toll-like receptors 
(TLRs) are a critical component of this response. Nanovesicular exosomes play a role in immunity, 
but to date their exact contribution to the dissemination of the TLR response is unknown. Here we 
show that exosomes from TLR stimulated cells (TLR-exosomes) can largely recapitulate TLR 
activation in distal cells in vitro. We can abrogate the action-at-a-distance signaling of exosomes 
by UV irradiation, demonstrating that RNA is crucial for their effector function. We are the first 
to show that exosomes derived from poly (I:C) stimulated cells induce in vivo macrophage M1-
like polarization within murine lymph nodes. These TLR-exosomes demonstrate enhanced 
trafficking to the node and preferentially recruit neutrophils as compared to control-exosomes. 
This work definitively establishes the differential effector function for TLR-exosomes in 
communicating the activation state of the cell of origin. 
4.2  Introduction  
Detecting microbial pathogens rapidly and containing their spread is a critical function of the 
innate immune system1. Toll-like receptors (TLRs) are an essential arm of innate immunity as they 
detect highly conserved pathogen associated molecular patterns (PAMPs) and play an important 
role in host cell defense2. The direct response of cells stimulated with TLR agonists locally is well 
characterized3,4. Dendritic cells exposed to the TLR4 agonist lipopolysaccharide (LPS) show a 
distinct gene expression response as compared with cells exposed to the TLR3 agonist poly I:C 
(pIC), and these gene expression profiles are known to be pathogen specific5. TLR stimulation 
induces production of a broad range of molecules including cytokines and chemokines6, which are 
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essential for host response to infection as well as for the development of an adaptive immune 
response7. 
While cytokines and chemokines are well studied for their roles in mediating cell-cell 
communication to establish immunity8, recently more complex messengers such as extracellular 
vesicles have been discovered9. Exosomes are nanovesicles (30-150 nm in diameter) released by 
the fusion of large multivesicular endosomes with the host cell membrane10. They are produced 
by most known cell types, and ubiquitously found in biological fluids11 and carry functional cargo 
in the form of mRNA, miRNA and proteins to distal recipient cells where the contents can 
modulate the recipient cell phenotype12. 
Exosomes have many distinct roles in physiology and immunity13-15 and have known to play dual 
roles in both immune system activation16 and immune suppression17. Furthermore, we recently 
showed that exosomes are rapidly trafficked from peripheral tissues by the lymphatics, and 
retained in the draining lymph node by macrophages in a murine model18. 
While local cellular response to TLR stimulation is well studied both in vitro and in vivo19-21, the 
role of exosomes in the distal dissemination of the TLR response is less well understood. We 
speculated that exosomes from TLR stimulated cells could potentially transmit information to 
distal unexposed cells in vitro. Moreover, we wanted to understand the impact of stable lymphatic 
retention of exosomes by macrophages in the development of an immune response in vivo. 
Here we delineate the differential effector function of TLR-exosomes based on the innate immune 
activation state (control-, LPS-, pIC-stimulation) of the cell of origin in both in vitro and in vivo 
experiments. pIC derived exosomes are rapidly transported to the lymph node and polarize distal 
macrophages to an M1-like state and recruit neutrophils. We show that exosomes are 
62 
reprogrammed to carry a TLR-specific message to distal cells and more work is warranted to 
understand the implications of this in immunity to pathogens and cancer. 
4.3  Materials and Methods 
4.3.1 Cell culture and TLR stimulation  
Fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) was centrifuged for 15 hours at 
120,000 g, 4OC to remove exosomes and was used to make exosome free cell culture media. HEY 
cells (Cedarlane Labs, Ontario, Canada) were cultured in RPMI 1640 (Mediatech, Manassas, VA) 
supplemented with 10% exosome free fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES 
buffer (both from Mediatech), penicillin (100 U/ml), and streptomycin (100 μg/mL) (Thermo 
Fisher Scientific, Waltham, MA) for 48 hours and the culture media was used for isolation of 
exosomes by ultracentrifugation. Ultra-pure E.coli K12 LPS and poly(I:C) ( Invivogen, San Diego, 
CA) were used to treat cells at concentrations of 100 ng/mL and 10 µg/mL  respectively for most 
experiments. Fluorescent LPS- Alexa Fluor 594 (Thermo Fisher Scientific) and poly(I:C) 
Rhodamine (Invivogen) were used at the same concentration to determine exosome mediated 
carryover.  
4.3.2 Exosome isolation and characterization  
Conditioned media was collected from HEY cells (with or without TLR agonist treatment) at 90% 
confluence for exosome isolation. Briefly, the culture media was spun at 300 g, for 10 minutes to 
remove dead cells followed by a spin at 16,500 g, 20 min. The supernatant was then filtered 
through 0.22 µm filters and centrifuged at 120,000 g for 120 min. The pellet containing exosomes 
was re-suspended in a suitable volume of PBS. The size homogeneity of vesicles obtained was 
checked using a Zetasizer Nano ZS90 (Malvern Instruments Ltd, Worcestershire, UK) and 
quantified using Pierce BCA Protein assay kit (Thermo Fisher Scientific). 
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4.3.2.1 Flow Cytometry:  
To analyze the expression of exosomal surface markers, 4 μm aldehyde/sulfate latex beads 
(Thermo Fisher Scientific) were coated with anti-CD9 antibody (BD Biosciences, San Diego, CA; 
Cat: 555370) overnight and incubated with 30 μg of exosomes. The exosome-beads complexes 
were probed with human anti-CD81-PE (BD Biosciences; Cat: 555676) or human anti-CD63-PE 
(BD Biosciences; Cat: 557305) and data was acquired on a LSR II Flow cytometer (BD 
Biosciences). Data analysis was performed using the FloJo software (FlowJo version 10, Ashland, 
OR).  
4.3.2.2 Confocal microscopy 
The exosomes were labeled using PKH67 Green Fluorescent Cell Linker Kit for General Cell 
Membrane Labeling (Sigma-Aldrich, St. Louis, MO) as per the manufacturer’s instructions. 
Briefly, exosomes in PBS were added to 500 µL of Diluent C and 2 μl of PKH67 dye was added 
to 500 µL of Diluent C. The two solutions were mixed and incubated for 5 min at room 
temperature. 1 ml of 1% BSA was added to stop the reaction. The labeled exosomes were 
centrifuged at 120,000 g for 70 min to remove excess dye. Labeled exosomes were added to 5*105 
cell suspension, mixed gently for 2-3 min and seeded in 6-well plates. The cells were imaged after 
24 and 48 hours using a Zeiss LSM 700 Image processing and data analysis were performed using 
the ZEN imaging software (Zeiss, Germany). 
4.3.2.3 Scanning electron microscopy 
Exosomes were fixed with 3.7% glutaraldehyde (Sigma–Aldrich) on carbon stubs for 15 min. After 
washing twice with PBS, the fixed exosomes were dehydrated with an ascending sequence of 
ethanol (40%, 60%, 80%, 96–98%). After evaporation of ethanol, the samples were left to dry at 
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room temperature for 24 h on a glass substrate, and then analyzed by Hitachi Cold Field Emission 
SEM SU8200 (Hitachi High-Tec, Tokyo, Japan).  
4.3.2.4 UV treatment of exosomes:  
Exosomes from control, and TLR agonist stimulated cells were re-suspended in PBS were then 
subjected to UV-light (254 nm) for 30 mins at 4°C to neutralize RNA carried within similar to 
previous studies27.  
4.3.2.5 Nucleic acid extraction from exosomes 
Exosomal RNA was extracted from exosome samples using the QIAamp viral RNA mini kit 
(Qiagen), and RNA was eluted with 40 µL buffer AVE, according to the manufacturer's 
instructions. RNA quality and quantity was analyzed using Nanodrop and Agilent Bioanalyzer 
chips 
4.3.2.6 Western blot 
The total protein was extracted from cells and exosomes using modified RIPA buffer (Thermo 
Fisher Scientific) and cell debris was removed by centrifugation. Equal amounts of protein (15–
20 µg) were then separated on polyacrylamide gels, transferred onto PVDF membranes (Bio-Rad, 
Hercules, CA, USA) and blotted using mouse anti-human CD81 Antibody (BD Biosciences; Cat: 
555676).  Membranes were developed using SuperSignal™ West Dura Extended Duration 
Substrate (Thermo Fisher Scientific).  
4.3.3 Microarray procedure and data analysis  
Total RNA was isolated from control and TLR stimulated parental and recipient cells (grown with 
exosomes) after 48 hours using RNeasy mini RNA isolation kit (QIAGEN, Valencia, CA). The 
integrity of the RNA was verified using the Agilent 2100 Bioanalyzer (Agilent Technologies, 
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Santa Clara, CA). mRNA’s were converted to double stranded DNA and amplified using the 
Applause 3’-Amp System (NuGen, San Carlos, CA). This cDNA was fragmented and biotin 
labeled using the Encode Biotin Module (NuGen), hybridized to Affymetrix HG U133 Plus 2.0  
oligonucleotide arrays and analyzed with a Gene Chip Scanner 3000 (Affymetrix, Santa Clara, 
CA). Raw data in the form of CEL files were produced by the Affymetrix GeneChip Operating 
System (GCOS) software. 
mRNA microarray data were analyzed using the Expression Console software (Affymetrix) and 
Bioconductor tools44 written in the R statistical programming language (www.rproject.org). Pre-
processing of raw signal intensities and normalization was performed using GCRMA (R). Linear 
modelling of the transformed data was determined by using Limma45 in R with the Benjamini and 
Hochberg correction. Differentially expressed probesets were identified using a threshold 5% FDR 
correction and a fold change ≥ 1.4 was applied. The microarray data is publicly accessible in GEO 
under the accession number GSE81248.  
4.3.4 Real-time quantitative PCR (qRT-PCR)  
Parental HEY cells were grown with or without LPS or poly(I:C) stimulation and total RNA from 
the cells was collected at 2h, 6h, 12h , 24h or 48 hours.  Similarly, control, LPS or poly(I:C) 
exosomes were added to recipient cells and total RNA was collected from cells grown with 
exosomes at 2h, 6h, 12h, 24h and 48 hours respectively. Total RNA from macrophages as well as 
parental and recipient cells was extracted using an RNeasy plus kit (QIAGEN), and cDNA was 
generated with SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Analysis was 
done on a Strategene Mx3005P System (Agilent Technologies) with SYBR Green PCR master 
Mix (Thermo Fisher Scientific). The (intron spanning) primers were used for quantitative real-
time PCR are shown Table 3 and Table 4.  The fold change was calculated using the ΔΔCt method. 
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All analyses were run in Prism 6 (GraphPad Software Inc, La Jolla, CA) and all data is presented 
as mean ± standard deviation. 
4.3.5 Proximity Ligation Assay(PLA) 
HEY cells were cultured on 12-mm glass cell culture coverslips (Thermo Fisher Scientific).  Cells 
were washed three times with phosphate-buffered saline (PBS) and then fixed for 15 min in PBS 
with 4% paraformaldehyde. After washing with gentle shaking, cells were permeabilized for 5 min 
with methanol and washed. The proximal-ligation assay to detect the interaction of p50 with p65, 
anti- NF-κB p50 (Santa Cruz Biotech, Dallas, TX; Cat: sc-8414) and anti-NF-κB p65 (Santa Cruz; 
Cat: sc-372) and for p65- SIRT1 interaction, anti-NF-κB p65(Santa Cruz Biotech; Cat: sc-8008) 
and anti-SIRT1 (Santa Cruz; Cat: sc-15404) were used with a Duolink PLA assay kit (Sigma 
Aldrich). Images were acquired Zeiss LSM 700 (Zeiss). 
4.3.6 Animal study and handling 
Exosomes from unstimulated (Control) and poly I:C stimulated HEY cells were dual labeled with 
PKH67 and near infrared dye using IRDye® 800CW Protein labeling kit (Licor, Lincoln, NE). 
Control or Poly I:C exosomes (total quantity=10 μg) were injected intradermally into the tail of 
eight-week-old male Balb/C mice (Charles River Laboratories, Wilmington, MA) as described 
previously18 and euthanized on day two( t=48 hours). PBS was mixed with PEGylated IRdye 
800CW (Licor) and injected similarly as the experimental control. The LAL Chromogenic 
Endotoxin Quantitation Kit (Thermo Fisher Scientific) was used per the manufacturer’s instruction 
to measure LPS concentration on all injected exosomes to ensure no endotoxin crossover. All 
procedures in this study have been approved by the Georgia Institute of Technology IACUC 
Review Board (Protocol #A15051).  
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4.3.7 Lymph node extraction and macrophage isolation 
The draining (sacral) lymph nodes, and control (axillary) lymph nodes were harvested from 
Control exosomes [Group 1; n=10], poly I:C exosomes[Group 2; n=10] and PBS control [Group 
3; n=8]. Harvested lymph nodes from all groups were digested with collagenase D (Roche Ltd., 
Mannhein, Germany) and homogenized using 70 μm pore size strainers as previously described46. 
Cells were centrifuged at 300 g, 4OC, 5 mins and the pellet was resuspended in HBSS and used for 
either whole node sequencing or macrophage isolation. CD11b positive macrophages were pulled 
down with Anti-mouse CD11b magnetic particles (BD Biosciences; Cat: 558013) according to the 
manufacturer’s protocol. The isolated macrophages were resuspended in Trizol (Thermo Fisher 
Scientific) and stored at -80oC till further analysis. 
4.3.8 Immunohistochemistry of frozen lymph node sections 
One set of lymph nodes (both sacral and axillary) from both groups were snap-frozen in Tissue-
Tek OCT (VWR, Radnor, PA) and sectioned at the Winship Cancer Institute’s Pathology Core. 
Frozen sections of excised sacral and axillary nodes were blocked in 10% BSA in PBS and 
incubated with primary antibody overnight, and then secondary antibody for 2 h. Primary 
antibodies were anti-CD86 (Cat: MA1-10299), anti-iNOS(Cat: PA3-030A),  anti-MHCII (Cat: 
MA5-16913) [all 3 from Thermo Fisher Scientific] and anti-IL12A (Acris Antibodies, San Diego, 
CA; Cat: AM32704AF-N). These sections were detected using secondary antibodies conjugated 
with Alexa Fluor 647 or Alexa 680 (Thermo Fisher Scientific) and imaged by confocal microscopy 
using a Zeiss LSM 700. 
4.3.9 RNA Seq: Macrophage and whole node RNA isolation and library prep 
RNA was isolated from macrophages or digested whole nodes stored in Trizol (ThermoFisher 
Scientific) per the manufacturer’s instructions. Briefly, macrophages from control exosomes 
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(n=2), pIC exosomes (n=2) and PBS dye (n=2) were homogenized for 20–30 sec with a rotor-
stator homogenizer (Kimble Chase, Vineland, NJ). The sample lysates were then transferred to 
2.0 ml Phase Lock Gels – Heavy (Eppendorf, Hamburg, Germany). Choloroform was added to 
each sample and centrifuged at 12,000 rcf for 10 min, and the upper aqueous layer was transferred 
to a new tube. The RNA was precipitated in isopropanol and washed in 75% ethanol according to 
the standard TRIzol protocol. The RNA pellet was then re-suspended in RNase-free water 
(Ambion, Austin, TX) according to the manufacturer's instructions. RNA quantity and integrity 
were assessed by examining the relative intensity of 18s and 28s rRNA bands using an Agilent 
2100 Bioanalyzer and RNA6000 Pico LabChip Kit (Agilent Technologies).  
10 ng of Macrophage RNA was used as input to a Clontech Smart Seq v4 kit (Clontech labs, 
Mountain View, CA) to generate double stranded cDNA per the manufacturer’s instructions. The 
cDNA was quantified using the Qubit HS DNA kit (Thermo Fisher Scientific) and 1 ng was used 
to prepare libraries using a Nextera XT DNA library preparation kit (Illumina, San Diego, CA) per 
the manufacturer’s instructions.  
250 ng of whole node RNA was used as input in a TruSeq Stranded mRNA library prep kit 
(Illumina) to generate cDNA libraries. Both libraries were quantified using a Qubit Fluorimeter 
(Thermo Fisher Scientific) and multiplexed samples were run on a HiSeq 2500 instrument 
(Illumina). Using 101 bp paired end sequencing we allocated ~40 million reads per library index. 
4.3.10  Data analysis 
RNA seq analysis for the three conditions, each with two replicates, was performed using raw 
reads (101bp, paired end) from an Illumina HiSeq 2000 machine. The reads were first aligned to 
the mouse reference genome (mm10, UCSC), using TopHat with default parameters. The 
transcripts were assembled from the aligned reads using Cufflinks, and the transcript abundance 
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was calculated in terms of FPKM (fragments per kilobase of exon per million fragments 
mapped)47. To compare the expression profile of the different samples, we used Cuffdiff, a 
differential expression analysis tool provided with the Cufflinks package. The results from Cuffdiff 
were used to plot the gene expression distribution graphs using a custom R script  
The pathway analysis was performed using the GAGE RNA Seq workflow for pathway 
enrichment analysis48. The –Log10(P-value) of the pathways of interest was plotted in R.  Details 
of the analysis and the custom R scripts used to generate the figures are publicly available at the 
Github web site https://github.com/shashidhar22/macrophageRnaSeq. The data is publicly 
accessible in Sequence read archive (SRA) under the accession numbers: SRP074717 and 
SRP074576.All graphs were generated on Prism 6 (GraphPad Software Inc, La Jolla, CA) and data 
is presented as mean ± standard deviation. 
4.4 Results  
4.4.1 Characterization of exosomes 
To understand the effect of stimulation of local cell and the effect of exosomal cargo on distal cell 
expression, we collected exosomes from local ovarian adenocarcinoma (HEY) cells that were 
unstimulated (control exosomes), or stimulated with poly I:C (pIC exosomes), or 
lipopolysaccharide (LPS exosomes) for 48 hours. The three groups of exosomes were added to 
naïve (distal) cells and the changes in gene expression profiles were compared between local TLR 
stimulation (for 6 hours) and distal stimulation mediated by exosomes (for 48 hours) on a 
microarray (Figure 19).  
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Figure 19: Schematic of experiment to elucidate transmission of TLR response to naïve distal cells. 
 
Surface CD81 protein expression by western blot revealed similar expression (Figure 20c, Figure 
37a) and flow cytometry showed comparable levels of expression of CD81 and CD63 on control, 
pIC and LPS exosomes (Figure 20a, Figure 37 b-c).  The size distribution profiles were similar for 
the three groups (Figure 20b) and the overall shape of control, pIC and LPS exosomes was 
spherical, as revealed by scanning electron micrographs (Figure 20 d-f respectively). The uptake 
of control, pIC and LPS exosomes by distal cells was comparable (Figure 20 g-i). Therefore, the 




Figure 20: Characterization of exosomes used in the study. (a) Expression of CD81 and CD63 on 
the surface of Control, pIC and LPS exosomes as quantified by flow cytometry (b) Size distribution 
profiles of control, pIC and LPS exosomes quantified on a Zetasizer. (c) Western blot of CD81 
protein expression on control, pIC and LPS exosomes (d) Scanning electron micrographs of (e) 
Control exosomes, (f) pIC exosomes and (g) LPS exosomes showing characteristic spherical.        
shape. Scale bar, 500nm. Confocal images of distal cells showing uptake of pkh67 labeled 
(h)Control exosomes, (i) pIC exosomes and (j) LPS exosomes. Scale bar, 10µm.  
 
4.4.2 Effect of LPS on local and distal cells 
Microarray data was analyzed for genes that were upregulated in both local and distal cells with 
respect to unstimulated cells. Differentially expressed genes that are involved in initiation of an 
inflammatory response were compared between local and distal cells. Both local and distal cells 
stimulated with LPS or LPS exosomes respectively showed an enhanced expression of 
inflammatory genes (Figure 21a). The classical response to LPS occurs via binding to membrane 
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bound TLR4 which results in activation of an inflammatory response with the release of molecules 
such as TNFA, CCL3 and IL1B.  The cell then enters a refractory where it is resistant to any further 
stimulation with LPS and is characterized by increased expression of TOLLIP accompanied by 
NF-κB inactivation(175) (Figure 21b).  
 
Figure 21: Microarray analysis to compare local and distal LPS response. (a) Heat map of gene 
expression profiles (b) LPS response pathway showing the key genes and inhibitors that establish 
the initial inflammatory phase and the subsequent refractory phase (c) Pathways enriched in distal 
cells stimulated with LPS exosomes. 
 
We examined the pathways enriched in distal cells with LPS exosomes and saw an increase in 
chemokine signaling as well as TLR pathway activation (Figure 21c). To examine the temporal 
response of local and distal cells to LPS and LPS exosomes respectively, we evaluated changes in 
gene expression in local and distal LPS cells with respect to control cells using real-time PCR. We 
looked at CCL3, TNFA, TIRAP, IL1B, TRAF6 and TOLLIP expression over 48 hours and observed 
that local cells responded strongly to LPS stimulation at 6 hours with TOLLIP expression peaking 
at 12 hours. Conversely, distal cells responded to LPS exosome stimulation strongly at 24 hours. 
Interestingly, both local and distal cell expression changes were comparable with a shift of ~18h 
in temporal expression (Figure 22a).  
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To determine the contribution of exosomal nucleic acid contents to the distal cells gene expression, 
we exposed exosomes to UV, and the RNA within exosomes was completely degraded upon 
exposure to UV.  (Figure 38 a-c). This UV treatment did not completely abrogate protein 
expression or inhibit uptake by cells (Figure 39). Interestingly, distal gene expression after 
exposure to UV treated LPS exosomes was comparable to distal cells treated with control 
exosomes for all genes except TNFA, indicating that the nucleic acid contents of the exosomes 




Figure 22: Temporal changes in gene expression in local and distal cells post LPS stimulation. a) 
Time course of gene expression comparing local cell response to poly I: C (solid lines) against 
distal cell response to poly I: C exosomes (dotted lines) for the genes shown. (b) Distal cell gene 
expression after exposure to either LPS exosomes or LPS exosomes after UV treatment (24 hours 
post exosome addition) (c) Scatter plots showing the correlation between the fold changes detected 
via qtr. when compared to microarrays 
 
There was very limited carryover of LPS to distal cells (~4%) by exosomes (Figure 23 a-b). The 
effect of 4% LPS on local cells at various time points (6h, 12h and 24h) was fairly low (Figure 
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23c) and doesn’t contribute significantly to the effect of LPS exosome stimulation on distal cells 
but might explain TNFA levels after addition of UV treated exosomes(Figure 23 d). 
 
Figure 23: Estimating the carryover of  LPS from local cells to distal cells by exosomes. Confocal 
images showing (a) LPS-AF594 uptake by local cells and (b) exosomes from local cells treated 
with LPS-AF594 added to distal cells to show 4% LPS carryover. Scale bars, 50 μm. (c) Time 
course of gene expression in local cells after stimulation with 4% LPS and (d) Comparison of gene 
expression at 24 hours between local cells stimulated with 4% LPS and distal cells stimulated with 
LPS exosomes. 
 
A proximity ligation assay (PLA) was used to determine the co-localization of the p50 and p65 
subunits of NF-κB to indicate activation. NF-κB activation in local and distal cells exposed to LPS 
or LPS exosomes respectively was assessed by PLA (Figure 40a). Distal cells treated with LPS 
exosomes showed co-localization of p50 and p65 subunits indicating that the NF-κB complex was 
active (Figure 24a).  
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Endotoxin tolerance is a protective mechanism to prevent overt inflammation in response to LPS 
and results in a transient unresponsive cellular state, characterized by the epigenetic inactivation 
of the p65 subunit of NF- κB by SIRT1, a histone deacetylase(176),  Local and distal cell response 
to restimulation with LPS and resulting impact on NF-κB activation and silencing state was 
analyzed by PLA (Figure 40 b). Distal cells exposed to LPS exosomes when re-stimulated with 
LPS enter a refractory state similar to endotoxin tolerance accompanied by NF-κB inactivation 
and p65-SIRT1 co-localization (Figure 24b). Additionally, both NF-κB activation and SIRT1 
mediated inactivation was lost upon pre-incubation of exosomes in UV prior to addition to distal 
cells (Figure 24c).  
 
Figure 24: Activation state of NF-κB in local and distal cells with LPS, LPS exosomes or 
secondary stimulation. (a) NF-κβ activation state in distal cells with LPS exosome stimulation, (b) 
SIRT1 mediated inactivation of NF-κB after restimulating distal cells with LPS and (c) inactivation 




4.4.3 Effect of pIC on local and distal cells 
Microarray data was analyzed for genes that were upregulated in both local and distal cells with 
respect to unstimulated cells and distal cells with control exosomes. Differentially expressed genes 
that are involved in antiviral activity were compared between local and distal cells (Figure 25a).  
The classical pIC response occurs via endosomally bound TLR3 which results in NF-κB and 
interferon activation.  A cytoplasmic pathway of recognition utilizes MDA5 and mitochondrial 
protein MAVS to activate interferon production(177)(Figure 25b).  
 
Figure 25: Microarray analysis to compare local and distal pIC response. (a) Heat map of top 
changed genes between local and distal cells. (b) Pathways of cellular response to pIC. (c) 
Pathways enriched in distal cells stimulated with pIC exosomes. 
 
We examined the pathways enriched in distal cells with pIC exosomes and saw an increase in both 
the cytoplasmic RIG-1 like pathways as well as TLR pathway activation (Figure 25c). To examine 
the temporal response of local and distal cells to pIC and pIC exosomes respectively, we evaluated 
changes in gene expression in local and distal pIC cells with respect to control cells using 
quantitative PCR (Figure 26a). We looked at IRF1, MAVS, IFN, STAT1 and TRAF6 expression 
over 48 hours and observed that local cells responded strongly to pIC stimulation between 6-12 
hours. Conversely, distal cells responded to pIC exosome stimulation strongly between 12-24 
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hours. Interestingly, both local and distal cell expression changes were comparable with a shift of 
~12-18 h in temporal expression. Additionally, the correlation between local and distal cell gene 
expression as determined by microarrays and validation by PCR was high (Figure 22c).  
 
Figure 26: Temporal changes in gene expression in local and distal cells post pIC stimulation. (a) 
Time course of gene expression comparing local cell response to pIC (solid lines) against distal 
cell response to pIC exosomes (dotted lines) for the genes shown. (b ) Distal cell gene expression 
after exposure to either pIC exosomes or pIC exosomes + UV treatment (24 hours post exosome 
addition) 
Distal gene expression after exposure to UV treated pIC exosomes showed a complete abrogation 
of changes in gene expression indicating that the nucleic acid contents of the exosomes were 
crucial in transmitting the effector functions to distal cells (Figure 26). There was no carryover of 
pIC to distal cells by exosomes (Figure 27a-b). 
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Figure 27: Activation state of NF-κB in local and distal cells with pIC or pIC exosomes. (a) 
Confirmation of pIC stimulation of local cells using fluorescent pIC, (b) estimation of pIC 
carryover by exosomes to distal cells. NF-κB activation in (c) local cells with pIC, (d) distal cells 
with pIC exosomes or (e) distal cells with UV treated pIC exosomes confirming the colocalization 
of P50-P65 subunits using a proximity ligation assay. Scale bars, 50 µm 
 
The NF-κB activation state in local and distal cells was verified using a proximity ligation assay. 
Both local and distal cells exposed to pIC or pIC exosomes showed NF-κB activation (Figure 27 
c, d respectively). Additionally, this activation was lost upon pre-incubation of UV treated 
exosomes prior to addition to distal cells (Figure 27e).  
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4.4.4 Effect of exosome uptake on macrophages 
We verified the uptake of both control and pIC exosomes by macrophages ( 
Figure 28 a, b). To understand the impact of exosome uptake on macrophage function in vivo, mice 
were injected with either PBS or control or pIC exosomes. The lymph nodes were extracted at 48 
hours post injection; CD11b macrophages were pulled down analyzed by RNA-Seq.  Whole lymph 




Figure 28: Macrophages retain both control and pIC exosomes. (a) CD11b+ macrophages and (b) 
CD169+ macrophages retain  control and pIC exosomes. (c) Schematic showing mouse study  
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Figure 28 continued: with injection of either PBS or exosomes (control or pIC) locally followed 
by excision of distal draining lymph nodes, isolation of macrophages and analysis of gene 
expression by next generation sequencing. 
 
The relative gene expression of macrophages with PBS, control and pIC exosomes is depicted for 
selected genes. Control exosomes show an intermediate phenotype with an increased expression 
of most M1 genes while pIC exosomes strongly polarize the macrophages to an ‘M1 like’ state 
with a significant shift in gene expression. The housekeeping gene expression is the same across 
the samples (Figure 29a).  The pathways enriched in macrophages with pIC exosomes are all pro-
inflammatory and show the activation of the TLR response in vivo (Figure 29b). A complete list 
of genes enriched in pIC exosomes with respect to PBS and control exosomes is provided (Table 




Figure 29: Impact of pIC and control exosome uptake by CD11b+ macrophages in mice at the 
RNA level. (a) Relative expression of key M1 and housekeeping genes in macrophages after 
exposure to PBS, control or pIC exosomes. (b) Pathways enriched in distal macrophages with pIC 
exosomes as compared to PBS. (c) Scatter plots showing the correlation between the fold change 
detected via qPCR when compared to RNA-Seq.  (d)Validation of key M1 genes in macrophages 
with control or pIC exosomes as compared to PBS by qPCR. 
 
The expression of M1 markers was validated in both control and pIC exosomes with respect to 
PBS macrophages by qPCR. pIC exosomes had a higher expression of all the selected M1 markers 
when compared to control exosomes (Figure 29d). The correlation between macrophage gene 
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expression with PBS, control or pIC exosomes determined by RNA-Seq and validation by 
quantitative PCR was high (Figure 29c).  Whole lymph node sections with pIC exosomes showed 
high expression of Il12, Nos2, Cd86, and MhcII (Figure 31), while sections with control exosomes 
showed low to no expression of the same markers (Figure 32). 
 
 
Figure 30: Validation of key M1 markers in whole lymph node sections with pIC exosomes. 





Figure 31: Validation of key M1 markers in whole lymph node sections with control exosomes. 
Immunohistochemistry of sections showing little to no expression of Nos2, Il12, Mhc-II and Cd86 
 
4.4.5 Impact of lymphatic trafficking of exosomes on draining lymph node retention 
To investigate differences in lymphatic transport of control and pIC exosomes, mice tails were 
imaged using the NIR system described previously(178). We observed that the kinetics of transport 
of pIC exosomes in both the dominant and non-dominant vessel was considerably higher than that 
of control exosomes in either lymphatic vessel (Figure 32 a-i). Similarly, pIC exosomes were 
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retained to a much higher extent in the draining lymph nodes as compared to control exosomes 
(Figure 33a-e). We showed that the transport times of the control and pIC exosomes were not 
significantly different in the vessels or lymph nodes (Figure 32j).  The packet frequency of control 
and pIC exosomes at the collecting vessels and nodes are shown in (Figure 33g) 
 
Figure 32: Lymphatic transport and retention of exosomes. pIC exosomes are seen in the lymphatic 
collecting vessels at (a) 0 mins, (b) 1.5 mins, (c) 3 mins, (d) 5mins , (e) 15 mins and (f) 2 days. 
The injection site is shown at (g) 20 mins and (h) 2 days.(i) Kinetics of lymphatic vessel transport 
showing control and pIC exosome trafficking in the dominant and non-dominant vessels (j) Arrival 
time of detectable levels of fluorescence for pIC and control exosomes in collecting lymphatic 
vessels and draining lymph nodes 
 
The total packet transport is significantly higher for pIC exosomes than control exosomes (Figure 
33f) Taken together, this data suggests that initial lymphatic uptake between the exosome 
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populations is similar, but that mechanisms involved in exosome capture and retention at the lymph 
node are significantly enhanced in exosomes released from pIC stimulated cells.  
 
Figure 33: Lymphatic retention of exosomes. pIC exosomes are detected in the draining lymph 
node at (a) 0 mins, (b) 2mins, (c) 5 mins and (d) 15 mins. (e) Kinetics of draining lymph node 
retention of control and pIC exosomes in dominant and non-dominant nodes. (f) Lymphatic packet 
transport of control and pIC exosomes (g) Packet frequency of control and pIC exosomes in the 
collecting lymphatic vessels and nodes. 
 
To understand the impact of exosome retention on the lymph node in vivo, the lymph nodes were 
extracted at 48 hours post exosome injection and analyzed by RNA-Seq (Figure 34a). We extracted 
the gene expression of the 546 genes utilized to estimate the abundance of 22 immune subsets 
based on the CIBERSORT algorithm, extending the algorithm to utilize our RNA-Seq data24. 
Using this analysis we found evidence of neutrophil, mast cell and monocyte recruitment in the 
pIC-exosomes group as compared to the PBS and control-exosome groups (Figure 41). The 
relative gene expression of whole nodes with PBS, control and pIC exosomes for selected 
neutrophil markers shows that control and pIC exosomes increase neutrophil recruitment and 
activation markers with pIC exosomes having a stronger effect (Figure 34b). The pathways 
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enriched in whole nodes with pIC exosomes with respect to PBS is shown in Figure 34c. A 
complete list of genes enriched in whole nodes with pIC exosomes with respect to control 
exosomes in given in Table 7. The expression of pro-inflammatory genes and neutrophil 
recruitment markers were validated in whole node with control or pIC exosomes with respect to 
PBS nodes by qPCR.  pIC exosomes had a higher expression of all the selected genes when 
compared to control (Figure 34d) 
 
Figure 34: Impact of exosomes retention on  whole lymph nodes. (a) Schematic of experiment 
showing PBS, control or pIC exosomes in mouse tail, followed by lymph node extraction at 48 
hours and RNA-Seq. (b) Relative expression of key neutrophil markers in whole lymph nodes after 
exposure to PBS, control or pIC exosomes and (c) Pathway analysis showing pathways enriched 
in pIC exosomes in whole nodes with respect to PBS. d) Validation of expression level key 
transcripts identified in RNA-Seq by qRT-PCR. 
 
Neutrophil recruitment to the node was also verified by imaging markers GR1 and Ly6g in the 
whole nodes. pIC exosomes induced a stronger presence of neutrophils in the whole node as 
compared to control exosomes (Figure 35) 
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Figure 35: Validation of key neutrophil recruitment markers in whole lymph node sections with 
control and pIC exosomes. Immunohistochemistry of sections showing little to no expression of 
GR1 and Ly6G  in control sections but high expression in pIC sections. 
 
Finally, our model for exosome mediated cell-cell communication in the dissemination of the TLR 
response is shown. We have shown that both LPS and pIC exosomes elicit a pro-inflammatory or 
antiviral gene response in vitro that is characterized by the activation and localization of NF-κB in 
the nucleus. Furthermore, exosomes are taken up by macrophages and polarized to a ‘M1-like’ 
90 
pro-inflammatory state characterized by the increased expression of Il12 and Nos2 while the node 
is reprogrammed to recruit neutrophils and shows increased inflammation (Figure 36).  
 
Figure 36: Model of exosome action showing transmittance of local cell TLR activation to distal 
cells resulting in a pro-inflammatory response both in vitro and in vivo 
 
4.5 Discussion 
The ability of the immune system to recognize and respond to foreign organisms is essential 
to survival and TLR’s play a central role in this response(179). While the local response of cells 
directly exposed to pathogens via Toll-like receptor activation is well characterized(15, 135, 180), 
the transmission of this response to distal cells is understudied.  
Exosomes have many distinct roles that vary depending on their cell of origin, from modulating 
the immune response(181), to cancer progression and immune evasion(182). Here, for the first 
time we can compare the responses at distal target cells to the local cell response in the context of 
TLR response and understand the transmittance of information from the cell of origin. Our findings 
91 
show that distal cells are primed to respond to imminent pathogen attack via TLR mediated NF-
κB activation and the resulting secretion of pro-inflammatory cytokines.  
Our experiments demonstrate reproducible perturbations of distal cells without little to no 
agonist carryover demonstrating the importance of immune state of the cell of origin. pIC 
exosomes induced the activation of both the cytoplasmic and endosomal RNA recognition 
pathways to produce an antiviral response while LPS exosomes show activation of the TLR4 
response resulting in an inflammatory response in distal cells. We observed that no pIC and very 
low quantities of LPS (<5%) were carried in exosomes, indicating that the distal response was not 
due to agonist carryover. Nevertheless, the expression of TIRAP in distal LPS cells and TRAF6 
and MAVS in distal pIC cells indicates that most, if not all, of the components downstream of TLR 
activation are being activated.  
We delineated the temporal kinetics of exosome impact on distal cell phenotype to discover 
~12-18 hours shift in distal cell response which we believe is required for sufficient exosome 
uptake, unpacking and release of contained biomolecules for the response in distal cells, similar to 
luciferase mRNA delivery by glioblastoma derived vesicles(122). Both exosomal RNA contents 
and the distal cell response are completely abrogated by UV treatment (Supp fig 3) and we believe 
that the RNA is the key contributor to the effects observed.  
We also show an epigenetic reprogramming of distal cells to be resistant to any subsequent 
LPS stimulation, a well characterized outcome of endotoxin tolerance(183); absence of the ability 
to enter endotoxin tolerance would lead to an uncontrolled cytokine storm and inflammation(184). 
While the TLR response and endotoxin tolerance is well characterized in immune cells, it is less 
understood in non-immune cells(185). This is the first study to demonstrate that exosomes from 
non-immune cells prime distal cells for both epigenetic change and for increased defense against 
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pathogens without the distal cells ever being exposed to the antigens responsible for the change. 
Further studies are needed to understand the contribution of exosomes from non-immune cells to 
the innate and adaptive immune response.  
Human selection at the TLR1 locus on 4p14 has been reported, with a functional non-
synonymous variant in the transmembrane domain associated with susceptibility to 
Mycobacterium leprae infection(186). A nonsynonymous mutation in TLR5 led to altered NF-κB 
signaling in response to stimulation with bacterial flagellin(187). Additionally, families with fully 
penetrant mutations within key TLR genes are susceptible to a wide variety of pathogens(188), 
demonstrating the global importance of TLR signaling in immunity. 
SCS macrophages were shown to play roles in suppressing the spread of melanoma thus 
enhancing immunity(189). We have previously shown that SCS macrophages played an important 
role in exosomes retention(178) which we expand to demonstrate that ovarian cancer-derived 
exosomes are capable of inducing an inflammatory response via Il12 and Nos2 in macrophages in 
vivo. Nos2 results in nitric oxide (NO) production by macrophages aids in cytotoxic activity against 
viruses and bacteria(190), reduced lymphatic contractions(46) and inhibits ovarian cancer 
growth(191). Future work will elucidate the impact of macrophage uptake pIC exosomes and the 
subsequent immune response. 
 The biological importance of exosomes in the cancer – immune cell crosstalk is a growing 
area of research. Ovarian cancer is associated with one of the highest mortalities(192) and survival 
statistics have not improved significantly over the past three decades(193), highlighting the need 
for better understanding the tumor microenvironment. Inflammation in the tumor 
microenvironment results in cancer survival, proliferation and migration(194) and increases 
lymphatic permeability(48).  Given that TLR activation of immune cells negatively impacts tumor 
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outomes(195-197), and actively contributes to inflammation, tumor derived exosomes play a vital 
role in cancer fate. Administration of poly I:C in mouse models of melanoma, lung cancer and 
colon cancer elicited robust anti-tumor immune responses(198). Future work in understanding 
both the mechanism of anti-tumor response by pIC and the role of exosomes in this process will 
provide key insights in the use of TLR agonists for cancer immunotherapy. 
We expand upon the impact of lymphatic transport and macrophage mediated retention of 
exosomes(178) to demonstrate that ovarian cancer-derived exosomes are capable of inducing an 
inflammatory response in macrophages in vivo. Interestingly, pIC exosomes had a much stronger 
impact on the macrophage response resulting in their polarization to a ‘M1-like’ state, as 
characterized by production of Il1b, Il12, Nos2 and Cxcl2(199). Nos2 results in nitric oxide (NO) 
production by macrophages and helps in cytotoxic activity against viruses and bacteria(190) and 
also results in reduced lymphatic contractions(46).  
Conversely, trafficking of pIC exosomes by the lymphatic system was enhanced within the 
first 20 mins post intradermal exosome injection. The ability of pIC exosomes to rapidly modulate 
lymphatic function to increase transport and nodal retention coupled with NO secretion 48 hours 
later makes the kinetics of pIC exosome movement in the lymphatics very interesting. Given the 
reliance of exosomes and immune cell trafficking on lymphatic transport, the impact of NO 
secretion by macrophages on the subsequent immune response should be studied.  
The pathways enriched in macrophages with pIC exosomes are all indicative of a TLR 
response resulting in the production of a pro-inflammatory state demonstrating the ability of 
exosomes to functionally transmit the TLR activation state of the cell of origin in vivo. Future 
studies wherein the injection of control or pIC exosomes is followed with a microbial challenge 
will help us elucidate the contribution of exosomes in establishing an immune response in vivo. 
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We saw an enrichment of neutrophil recruitment signals including FPR1 and CXCR2(200) in 
the whole node accompanied with an increase in pro-inflammatory cytokines, such as IL1B. 
Neutrophils release cytokines and chemokines to coordinate the innate and adaptive immune 
responses and play active roles in antigen presentation(201). Thus, the lymph node 
microenvironment is being reprogrammed by exosomes to respond to the signals sent by the parent 
cells 
The ability of exosomes to carry siRNA, drugs, proteins and other molecules makes them ideal 
therapeutic vehicles(202). This is the first study to show that UV irradiation ‘resets’ the exosomes 
effect on distal cells, and this approach can be used to neutralize exosomal cargo prior to loading 
of the therapeutic molecules. Furthermore, our in vitro model may be appropriate to verify the 
intended effects of exosomes prior to therapeutic use and eliminate any TLR agonist response 
thereby overcoming technical challenges to maximize the clinical potential to provide viable 
therapeutic options.  
  This study demonstrates that exosomes play a key role in informing the immune system of 
the presence of foreign organisms initiating a pro-inflammatory response both in vitro and in vivo. 
Furthermore, based on the differences in distal cell response with LPS and pIC exosomes, we show 
that the function and contents of exosomes vary with the biological state of the cell of origin and 
the result in reprogramming the target (distal) cells to elicit an inflammatory response. 
4.6  Conclusions  
We demonstrate that exosomes from cells stimulated with TLR ligands locally are able to transmit 
an antiviral and inflammatory response in distal cells which is specific to the biological state of 
the cell of origin in vitro. We were also able to reset the distal response by UV irradiating the 
exosomes prior to distal cell exposure. Additionally, we showed that exosomes from pIC 
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stimulated cells polarize distal macrophages in the draining lymph node towards a pro-
inflammatory “M1-like” phenotype accompanied by saw enhanced lymphatic transport and 
retention of pIC exosomes which was hitherto unknown. Furthermore, we characterize the lymph 
node milieu by showing a pro-inflammatory remodeling and neutrophil recruitment at the node. 
This study helps dissect the role of exosomes in cell-cell communication and expand upon current 
knowledge of their role in modulating the gene expression profile of distal cells in the context of 
Toll-like receptor biology. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS  
In this thesis, I have established a role for exosomes as rapid and complex messenger that aid and 
modulate the innate immune system. Specifically, I have demonstrated the ability of exosomes to 
use the lymphatic system to rapidly travel from the periphery with information related to biological 
state of the cell of origin and transport it to the draining lymph node, a hub for information 
processing and immune response initiation. Using the tools developed in the Dixon lab for 
quantifying lymphatic transport, I have definitively shown, for the first time that lymphatics play 
a crucial role in the transport of exosomes both in vitro and in vivo. Further drawing on the 
expertise of the Vannberg lab in the genomics of infectious diseases, I have shown that the TLR 
activation state of the cell of origin is largely recapitulated by exosomes in distal cells both in vitro 
and in vivo.  
I have detailed my main findings and future work that will help further the paradigm of exosome 
mediated activation of innate immunity below: 
a) I have developed a transwell model to show that lymphatic endothelial cells actively and 
selectively transport exosomes in vitro by transcytosis. This in vitro model can be further used 
to test compounds for their efficacy in either increasing or suppressing cellular transport of 
exosomes which can help uncover the mechanisms underlying exosome uptake and secretion. 
b) I have successfully labeled exosomes with two labels: a near infrared fluorophore conjugated 
to the N-terminal of exosomal membrane proteins and a second fluorophore was in the lipid 
bilayer of the exosomes to enable ex-vivo, multi scale analysis of cellular exosome uptake and 
transport. This can be further expanded in the future by using NIR fluorophores with different 
spectra and imaging exosomes from different sources simultaneously. While I have data to 
show that pIC exosomes are transported and retained in the lymphatics to a higher extent than 
control exosomes, this will enable parallel tracking of control and pIC exosomes to understand 
the transport kinetics further.  
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c) While the differential transport of exosomes by collecting vessels has been previously 
demonstrated, the surprising finding of differential exosome retention in the lymph nodes was 
novel. Future studies need to be conducted to see if these differences in co-localization could 
impact the immune response at each of these nodes in the presence of antigen which could 
reveal important information about the development of an innate immune response at the 
lymph node. 
d) I determined the primary immune subsets within the lymph nodes that were responsible for 
exosomes uptake and retention. Cd11b+ macrophages were a stable target for exosomes within 
the lymph node and were found to contain exosomes at very early time points (2 hours) as well 
as 2 days.  I also showed that B-cells were found to contain exosomes at 2 days but not 2 hours, 
implying that the macrophages played a role in exosome processing and transfer to B-cells. 
Future work using confocal and multiphoton microscopy will be useful to understand the 
intraorgan capture and kinetics of exosome transfer within the node.  
e) Since innate immunity is fast acting, the time points in my in vitro and in vivo work have been 
limited to 2 days and has been focused at the uptake and retention of exosomes at the cellular 
level. The functional consequences of exosomes are as a result of the complex biomolecular 
cargo contained within them, future work on the release of exosomal RNA and protein within 
the target cells both in vitro and in vivo will help elucidate the principal mechanisms of innate 
immune modulation by exosomes that result in pro-inflammatory responses in the target cell. 
f) I have used confocal microscopy to demonstrate uptake of extraneously labeled exosomes by 
cells in vitro.  Future work using genetically marked exosomes (such as CD63-RFP) will 
enable us to monitor in real time the kinetics of exosome uptake and release by cells.  
g) I have shown the ability of exosomes from TLR stimulated cells to largely recapitulate the 
TLR activation state in the cell of origin. While many studies have demonstrated that exosomes 
are capable of modifying the phenotype of the distal cells, the phenotype of the cell of origin 
has never been compared to the exosome induced phenotype distally. This unique study design 
enables us to compare and contrast the ability to exosomes to activate the various facets of 
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TLR activation and response in distal cells in the context of local cells. Future work can be 
done on further characterizing other TLR agonists to verify that the dissemination of the TLR 
response is not limited to some TLR’s.  
h) This study points to a crucial role for exosomal RNA in the dissemination of the TLR response 
as UV irradiation of exosomes prior to distal cells results in complete abrogation of the distal 
cell response. While other studies in the field have used UV light to abrogate exosome effects, 
such extensive characterization enables us to depict the importance of exosomal cargo in its 
functionality. Future studies in understanding the uptake and impact of UV treated exosomes 
will further delineate the role of exosomal RNA. Comparing the in vivo trafficking of UV 
exosomes in the lymphatic rodent tail model with control and pIC exosomes will allow us to 
further dissect the difference in lymphatic transport and retention of exosomes. Additionally, 
the contribution of exosomal proteins to the distal response can be studied using proteomics 
which may explain the differences in expression of exosomal surface proteins that might 
contribute to differential exosome trafficking. 
i) The kinetics of exosome mediated changes in distal cell gene expression has been clearly 
characterized with respect to local cell response and helps understand the temporal kinetics 
involved in exosome uptake, cargo release and transcriptional modulation. This will be useful 
to design future studies using exosomes to deliver therapeutic RNA molecules.  
j) This is the first study to show that exosomes can prime distal target cells for epigenetic 
modification. Further work with SIRT1 knock out cells can help define the contribution of 
other epigenetic players in the TLR activation by exosomes.  Since we used a cancer cell model 
for the demonstration of exosome effector function, comparing the methylation status of the 
target cells before and after exosome exposure would reveal the impact of tumor derived 
exosomes in distal cell remodeling. 
k) The data shown here is the first evidence that exosomes could directly be involved in 
modulating flow to the lymph node. This is a significant finding since enhanced lymphatic 
function also leads to enhanced uptake of the exosomes within the cells of the draining lymph 
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node. Given the reliance of exosomes and immune cell trafficking on lymphatic transport, the 
impact of exosome-mediated flow modulation, either through NO secretion by macrophages 
or some other unidentified mechanism, on the subsequent immune response warrants further 
study. Furthermore, the total lymphatic pump flow is significantly higher for pIC-exosomes 
than control exosomes implying the ability of pIC exosomes enhance lymphatic flow. Future 
work with isolated collecting vessels can help quantify the modulation of lymphatic flow by 
exosomes. 
l) The expression of Nos2 by macrophages with pIC exosomes is very interesting since NO 
signaling results in the reduction of lymphatic trafficking. Future work where the injection of 
PIC exosomes is followed by the injection of a NIR tracer will help us quantitate the change 
in lymphatic trafficking as modulated by exosomes.  
m) I have shown that the lymph node shows markers of neutrophil recruitment and activation 
which implies the initiation of the innate immune response in the node. Future work with a 
challenge model where the mouse is exposed to exosomes followed by a pathogen will help 
outline the ability of exosomes to prepare the organism for imminent pathogen attack 
n) This work comprehensively dissects the impact of exosome uptake and retention by the 
draining lymph node. I expanded on the exosome mediated macrophage reprogramming to 
show that macrophages undergo M1 polarization via Il12 and Nos2 in vivo.  I have also profiled 
the impact of the whole lymph node after exosome uptake to show remodeling of the node 
milieu to a pro-inflammatory state through the expression of Il1b. Future work in 
understanding the impact of lymph node reprogramming will help understand the physiological 
roles played by exosomes in the development of the innate immune response  
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APPENDIX 
A.1. Supplementary information for Aim 1 
A.1.1. Supplementary figures 
Supplementary figure: Characterization of exosomes used in the study 
 
Figure 37: Characterization of exosomes used in the study. (a) Complete western blot of CD81 
with control, pIC and LPS exosomes. Flow cytometry showing (b) CD63 and (c) CD81 levels on 
the exosomes.  
 
 
Figure 38:  Effect of UV on nucleic acid content of exosomes. RNA size distribution profiles 
obtained on a Bioanalyzer pico RNA chip of (a) Control exosomes , (b) pIC exosomes,  and (c) 




Figure 39: Impact of UV on protein expression and cellular uptake. A) Changes in tetraspanin 
expression on exosome surface before and after exposure to UV light, and B) UV treated exosomes 




Figure 40: The LPS response in local and distal cells. Proximity ligation assay showing (a) the 




Figure 41: Relative gene expression of PBS, control exosomes and pIC exosomes depicted in a) 
natural killer cells, b) plasma cells c)activated dendritic cells, d) monocytes, e) activated mast 
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Figure 41 continued cells.  F) Relative fraction of PBS, control exosomes and pIC exosomes gene 
expression in the 10 main immune subsets 
A.1.2. Supplementary Tables 














mRNA NCBI Accession  Forward Primer (5'-3') Reverse Primer (5'-3') 
IRF1 NM_002198.2 CTCTGAAGCTACAACAGATGAG  GTAGACTCAGCCCAATATCCC 
MAVS NM_001206491.1 CAGGAGCAGGACACAGAAC AGGAGACAGATGGAGACACAG 
TRAF6 NM_004620.3  GAGTCGTGCGGTTGGTG   GCTGGATCCACAGCTGTTTT 
IFNA1 NM_024013.2 GAGTGTGGAGACCATCAAGGA  GTATTGCTTTGCGTTGGACA  
STAT1 NM_007315.3 TTCAGGAAGACCCAATCCAG TGCTCTGAATATTCCCCGAC  
TNF NM_000594.3 GAGGCCAAGCCCTGGTATG CGGGCCGATTGATCTCAGC 
CCL3 NM_002983.2 TGCAACCAGTTCTCTGCATC  TGGCTGCTCGTCTCAAAGTA 
IL1B NM_000576.2 AGCTGATGGCCCTAAACAGA CCTGAAGCCCTTGCTGTAGT  
TOLLIP NM_019009.3 CATGTCTGGTGTTTGTGGTTC TGTGGGCATTCTCTTTCTGTC 
TIRAP NM_001039661.1 TTAAGGCTGAAAGAGTGTCCG CTGTTCTCTGCTCCACCTG 
Reference Gene   
GAPDH NM_001256799.2 ACATCGCTCAGACACCATG TGTAGTTGAGGTCAATGAAGGG 
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Accession  Forward Primer (5'-3') Reverse Primer (5'-3') 
Cxcl2 NM_009140.2 CCAACCACCAGGCTACAGG GCGTCACACTCAAGCTCTG 
IL12a NM_001159424.2 CAATCACGCTACCTCCTCTTTT AGCAGTGCAGGAATAATGTTTC 
IL23a NM_031252.2 AACAACAGCTCGGATTTGGTAT ATGACCAGGACATTCAGCAGT 
Nos2 NM_001313922 GTTCTCAGCCCAACAATACAAGA GTGGACGGGTCGATGTCAC 
Irak3 NM_028679.3 GTTCTACTCCTGTTCCGTCACC GTCCCGTTGCTCATATAGGGATA 
Myd88 NM_010851.2  GACCGTGAGGATATACTGAAGGA GGCCACCTGTAAAGGCTTCTC 
CCL3 NM_011337.2 TGTACCATGACACTCTGCAAC CAACGATGAATTGGCGTGGAA 
IL1B NM_008361.4 GAAATGCCACCTTTTGACAGTG TGGATGCTCTCATCAGGACAG 
NLRP3 NM_145827.3 ATTACCCGCCCGAGAAAGG CATGAGTGTGGCTAGATCCAAG 
Reference Gene 
ActB 
NM_007393.5 GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
 
Table 5: Genes enriched in pIC macrophages w.r.t PBS macrophages 
Gene Locus Value PBS Value pIC  
log2(fold_c
hange) p-value q-value 
8030451O07Rik 
chr16:72226382-
72234327 42.9639 0 -inf 5.00E-05 0.0534667 
Vmn1r228 
chr17:20776058-
20777501 39.518 0 -inf? 5.00E-05 0.0534667 
Kcna4 
chr2:107290588-
107298504 19.3042 0 -inf? 5.00E-05 0.0534667 
Icmt 
chr4:152297213-
152318625 0 20.9953 inf 5.00E-05 0.0534667 
Saa3 
chr7:46711997-
46715676 0 602.841 inf 5.00E-05 0.0534667 
Suv39h1 
chrX:8061170-
8074760 0 19.632 inf 5.00E-05 0.0534667 
Rfk 
chr19:17394042-
17401349 27.3396 0 -inf? 0.0001 0.06416 
Atg13 
chr2:91674611-
91710592 0 26.4579 inf 0.0001 0.06416 
Neurog3 
chr10:62133089-
62134763 57.8144 0 -inf? 0.00015 0.06416 
4921533I20Rik 
chr18:17234482-
17235482 88.7925 0 -inf? 0.00015 0.06416 
Npl 
chr1:153503015-
153549714 42.6803 0 -inf? 0.0002 0.06416 
Olfr1356 
chr10:78846950-
78847913 40.8647 0 -inf? 0.0002 0.06416 
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Wimp chr13:32802029-
32822610 0 63.451 inf 0.0002 0.06416 
1700037C18Rik chr16:3905797-
3908689 0 56.9555 inf 0.0002 0.06416 
Olfr167 
chr16:19514695-
19515634 0 37.286 inf 0.0002 0.06416 
Tas2r134 
chr2:51627510-
51628407 0 52.0894 inf 0.0002 0.06416 
Olfr1264 
chr2:90021137-
90022064 0 48.2576 inf 0.0002 0.06416 
Agap3 
chr5:24452176-
24502047 0 27.5255 inf 0.0002 0.06416 
Inmt 
chr6:55170626-
55174990 54.0105 0 -inf? 0.0002 0.06416 
Art4 
chr6:136848450-
136857600 0 19.5346 inf 0.0002 0.06416 
Htr5b 
chr1:121509772-
121528465 36.8468 0 -inf? 0.00025 0.06416 
Cbr2 
chr11:120729484-
120732021 74.9733 0 -inf? 0.00025 0.06416 
Nrn1 
chr13:36725621-
36734477 45.8621 0 -inf? 0.00025 0.06416 
Rsrp1 
chr4:134923624-
134927370 80.7523 0 -inf? 0.00025 0.06416 
Themis2 
chr4:132782356-
132796364 0 25.6782 inf 0.00025 0.06416 
Mvk 
chr5:114444268-
114460590 0 54.993 inf 0.0003 0.0712889 
Cirh1a 
chr8:106893639-
106923094 0 29.4662 inf 0.0003 0.0712889 
Olfr827 
chr10:130210159-
130211128 45.6499 0 -inf? 0.00035 0.0802 
Gpbar1 
chr1:74278599-
74279589 0 76.9662 inf 0.0004 0.0802 
Vmn1r202 
chr13:22501336-
22502245 0 56.2155 inf 0.0004 0.0802 
Sec61a2 chr2:5870986-5895353 0 24.2966 inf 0.0004 0.0802 
Tspan7 
chrX:10485115-
10596604 0 24.7349 inf 0.0004 0.0802 
Teddm1a 
chr1:153891645-
153893060 0 30.9105 inf 0.00045 0.0824914 
Rab11fip4os1 
chr11:79591211-
79694012 0 23.9915 inf 0.00045 0.0824914 
Socs3 
chr11:117966086-
117969366 0 35.0248 inf 0.00045 0.0824914 
Cited2 
chr10:17723227-
17725674 0 42.4857 inf 0.0005 0.083687 
Appbp2 
chr11:85191309-
85235120 20.2115 0 -inf? 0.00055 0.083687 
Olfr1445 
chr19:12883882-
12884827 0 35.2985 inf 0.00055 0.083687 
Ifnb1 
chr4:88522024-
88522794 0 72.7145 inf 0.00055 0.083687 
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Mgst1 
chr6:138140536-
138156752 64.4402 0 -inf? 0.00055 0.083687 
Klrb1b 
chr6:128813705-
128826315 0 33.7584 inf 0.00055 0.083687 
Ntpcr 
chr8:125734202-
125748235 54.633 0 -inf? 0.00055 0.083687 
Spryd3 
chr15:102116527-
102136215 0 23.229 inf 0.0006 0.083687 
Olfr1087 
chr2:86690031-
86690973 0 41.9582 inf 0.0006 0.083687 
Svop 
chr5:114026912-
114091380 0 20.7093 inf 0.0006 0.083687 
Cldn34b4 
chrX:76393349-
76397979 0 40.1605 inf 0.0006 0.083687 
Camk1 
chr6:113326975-
113343922 34.6672 0 -inf? 0.00065 0.0887319 
Olfr741 
chr14:50473056-
50486395 0 45.0443 inf 0.0007 0.089824 
Chmp2b 
chr16:65539132-
65562697 34.072 0 -inf? 0.0007 0.089824 
Stard7 
chr2:127270228-
127298934 19.2474 0 -inf? 0.0007 0.089824 
Pold2 
chr11:5861865-
5878256 0 35.1219 inf 0.0008 0.0991564 
Ginm1 
chr10:7767946-
7780917 41.3771 0 -inf? 0.00085 0.0991564 
Ptgs1 
chr2:36230425-
36252271 20.0208 0 -inf? 0.00085 0.0991564 
Vmn1r15 
chr6:57258148-
57259048 53.9254 0 -inf? 0.00085 0.0991564 
Elovl4 
chr9:83778691-
83806305 19.5133 0 -inf? 0.00085 0.0991564 
Slc25a22 
chr7:141429748-
141437874 0 19.066 inf 0.00105 0.1203 
P4ha2 
chr11:54100923-
54131667 0 20.0854 inf 0.0011 0.121683 
Mrpl55 
chr11:59202485-
59206135 0 61.4094 inf 0.0011 0.121683 
Insl3,Jak3 
chr8:71676382-
71690577 0 22.4754 inf 0.00195 0.212054 
Cd1d2 
chr3:86986585-
86989532 0 40.8373 inf 0.0025 0.267333 
Elovl1 
chr4:118428092-
118437343 19.6743 0 -inf? 0.00295 0.310282 
Tssc4 
chr7:143069367-
143071087 22.825 0 -inf? 0.004 0.323885 
Ppt2 
chr17:34616661-
34628279 0 19.4096 inf 0.0042 0.323885 
Spata3 
chr1:86021941-
86029958 22.7755 0 -inf? 0.0049 0.323885 
Susd3 
chr13:49230830-
49248706 29.1898 0 -inf? 0.0052 0.323885 
Slc50a1 
chr3:89268245-
89270570 50.0845 0 -inf? 0.0053 0.323885 
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Ift22 
chr5:136908149-
136913244 76.9089 0 -inf? 0.0053 0.323885 
C1qtnf7 
chr5:43515568-
43616586 19.1167 0 -inf? 0.0054 0.323885 
Ybx3 
chr6:131364857-
131388450 34.7044 0 -inf? 0.00565 0.323885 
Dhrs11 
chr11:84820727-
84829003 0 31.138 inf 0.0057 0.323885 
Mptx2 
chr1:173274460-
173277756 0 65.5094 inf 0.00585 0.323885 
Vmn1r200 
chr13:22395028-
22395967 0 40.6515 inf 0.00585 0.323885 
Ppm1g 
chr5:31202667-
31220545 0 23.3792 inf 0.00585 0.323885 
Olfr224 
chr11:58566398-
58567343 0 33.7066 inf 0.00625 0.323885 
2810032G03Rik 
chr12:5376501-
5416132 0 28.8057 inf 0.00625 0.323885 
Angptl4 
chr17:33774899-
33781575 0 25.8577 inf 0.00625 0.323885 
Olfr1341 
chr4:118709408-
118710347 0 29.2462 inf 0.00625 0.323885 
Olfr483 
chr7:108103310-
108104258 0 37.5952 inf 0.00625 0.323885 
Olfr862 
chr9:19883382-
19884303 0 29.7759 inf 0.00625 0.323885 
4933412E12Rik 
chr10:116950561-
116963279 21.3103 0 -inf? 0.0065 0.323885 
Tspan17 
chr13:54789404-
54796775 0 30.9838 inf 0.0066 0.323885 
Olfr1272 
chr2:90281646-
90282573 0 38.1952 inf 0.0066 0.323885 
Mmp23 
chr4:155650654-
155653384 0 37.5151 inf 0.0066 0.323885 
Wdr91 
chr6:34880425-
34910831 0 18.8525 inf 0.0066 0.323885 
Asna1 
chr8:85017930-
85025278 0 42.6107 inf 0.0066 0.323885 
Ear6,Ear7 
chr14:51853767-
51854642 38.0098 0 -inf? 0.00665 0.323885 
4930579F01Rik 
chr3:138164134-
138186713 24.7816 0 -inf? 0.00675 0.323885 
Slc25a33 
chr4:149744035-
149774267 0 20.6883 inf 0.0068 0.323885 
Olfr237-ps1 
chr6:43153306-
43154239 0 24.7116 inf 0.0068 0.323885 
R3hcc1 
chr14:69697303-
69714809 23.5724 0 -inf? 0.0069 0.323885 
Ccnb1ip1 
chr14:50789248-
50795728 0 22.8899 inf 0.007 0.323885 
Ccdc134 
chr15:82127921-
82142202 0 18.8391 inf 0.007 0.323885 
Actl10 
chr2:154544404-
154558853 0 28.282 inf 0.00705 0.323885 
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Cdkn2c 
chr4:109660875-
109666756 25.8656 0 -inf? 0.00705 0.323885 
Ccl20 
chr1:83116765-
83119167 0 29.6737 inf 0.00725 0.323885 
Spaca1 
chr4:34024871-
34050067 30.0177 0 -inf? 0.00725 0.323885 
Kdf1 
chr4:133518962-
133530790 0 25.3996 inf 0.0073 0.323885 
Tac2 
chr10:127724477-
127731768 54.988 0 -inf? 0.0074 0.323885 
Taar1 
chr10:23920405-
23921404 0 30.7256 inf 0.00745 0.323885 
Gm5111 
chr6:48589444-
48590584 0 42.7986 inf 0.00745 0.323885 
Fah 
chr7:84585158-
84605942 0 23.2363 inf 0.00745 0.323885 
Nrbf2 
chr10:67266688-
67285281 24.0699 0 -inf? 0.0076 0.323885 
Wdr46 
chr17:33940722-
33949695 22.1773 0 -inf? 0.0076 0.323885 
Rrp36 
chr17:46667452-
46674255 46.9523 0 -inf? 0.0076 0.323885 
Aldh3b1 
chr19:3913490-
3929716 23.1654 0 -inf? 0.0076 0.323885 
Msrb2 
chr2:19371635-
19394971 33.3518 0 -inf? 0.0076 0.323885 
Olfr1305 
chr2:111872914-
111873853 28.9292 0 -inf? 0.0076 0.323885 
Wnt10a 
chr1:74792018-
74804175 0 20.5375 inf 0.00775 0.323885 
Gstt4 
chr10:75814943-
75822543 0 32.5337 inf 0.00775 0.323885 
Hddc3 
chr7:80343136-
80346097 0 37.3227 inf 0.00775 0.323885 
Exosc6 
chr8:111056338-
111057664 0 46.0969 inf 0.00775 0.323885 
9930111H07Rik 
chr1:85775270-
85784694 0 21.2558 inf 0.0078 0.323885 
Ntmt1 
chr2:30807976-
30823014 0 28.7616 inf 0.0078 0.323885 
Ggh 
chr4:20042051-
20066111 0 20.8744 inf 0.0078 0.323885 
Vmn1r25 
chr6:57978393-
57979302 0 26.9174 inf 0.0078 0.323885 
Cml1 
chr6:85910153-
85915677 0 30.3489 inf 0.0078 0.323885 
Fgf3 
chr7:144838611-
144843348 0 38.6524 inf 0.0078 0.323885 
Sprr3 
chr3:92456501-
92458720 22.6371 0 -inf? 0.0079 0.323885 
Tnfrsf18 
chr4:156026341-
156028891 22.4939 0 -inf? 0.0082 0.323885 
Olfr785 
chr10:129409367-
129410306 20.4505 0 -inf? 0.00825 0.323885 
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B230217C12Rik 
chr11:97840779-
97843043 20.1123 0 -inf? 0.00825 0.323885 
Fam195b 
chr11:120542887-
120549727 25.9445 0 -inf? 0.00825 0.323885 
Tmem14c 
chr13:41016249-
41022582 32.0683 0 -inf? 0.00825 0.323885 
Cbr1 
chr16:93607836-
93610349 43.6206 0 -inf? 0.00825 0.323885 
Ctsw 
chr19:5465239-
5468498 26.2031 0 -inf? 0.00825 0.323885 
Tm2d1 
chr4:98355369-
98383265 26.309 0 -inf? 0.00825 0.323885 
Urod 
chr4:116990216-
116994375 27.3033 0 -inf? 0.00825 0.323885 
Ier2 
chr8:84661330-
84662852 35.3164 0 -inf? 0.00825 0.323885 
Rrad 
chr8:104628065-
104631321 25.2089 0 -inf? 0.00825 0.323885 
Gm6936 
chr16:49980459-
49997475 19.8891 0 -inf? 0.0084 0.323885 
Ivd 
chr2:118861999-
118881357 20.4369 0 -inf? 0.0084 0.323885 
Glmp 
chr3:88325022-
88328631 28.0218 0 -inf? 0.0084 0.323885 
Olfr512 
chr7:108713354-
108714335 27.2798 0 -inf? 0.0084 0.323885 
Olfr807 
chr10:129754512-
129755448 0 23.3018 inf 0.0085 0.323885 
Jmjd6 
chr11:116837431-
116843449 0 20.1006 inf 0.0085 0.323885 
Dynlt1b 
chr17:6430111-
6436295 0 38.7014 inf 0.0085 0.323885 
Olfr1234 
chr2:89362482-
89363427 0 23.5992 inf 0.0085 0.323885 
1700009N14Rik 
chr4:39450292-
39451778 0 21.383 inf 0.0085 0.323885 
Snhg5 
chr9:88521052-
88522897 0 26.0158 inf 0.0085 0.323885 
Ifi27l2b 
chr12:103450897-
103457223 0 28.0971 inf 0.0086 0.323885 
E330017A01Rik 
chr16:58635261-
58638403 0 42.2717 inf 0.0086 0.323885 
Snrnp35 
chr5:124483154-
124491122 0 26.1556 inf 0.0086 0.323885 
4632427E13Rik 
chr7:92740705-
92741459 0 51.7959 inf 0.0086 0.323885 
Olfr49 
chr14:54281895-
54282925 22.0851 0 -inf? 0.00865 0.323885 
Cma1 
chr14:55941450-
55944661 25.9075 0 -inf? 0.00865 0.323885 
Vmn1r224 
chr17:20419162-
20420059 20.3149 0 -inf? 0.00865 0.323885 
Nubp2 
chr17:24882610-
24886350 20.5085 0 -inf? 0.00865 0.323885 
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Olfr1145 
chr2:87809821-
87810799 23.3217 0 -inf? 0.00865 0.323885 
Svs2 
chr2:164235928-
164238341 20.0852 0 -inf? 0.00865 0.323885 
Fam213b 
chr4:154896429-
154899043 53.3879 0 -inf? 0.00865 0.323885 
Vmn1r60 chr7:5544196-5545099 24.8937 0 -inf? 0.00865 0.323885 
1700026D08Rik 
chr7:83775616-
83794839 23.893 0 -inf? 0.00865 0.323885 
Bst2 
chr8:71534261-
71537437 60.0248 0 -inf? 0.00865 0.323885 
Olfr980 
chr9:40005993-
40007029 18.9121 0 -inf? 0.00865 0.323885 
Clec4d 
chr6:123262106-
123275268 0 19.4164 inf 0.00875 0.323885 
5430425K12Rik 
chr13:80940402-
80948597 20.0775 0 -inf? 0.00895 0.323885 
1110007C09Rik 
chr13:49202950-
49216026 54.1188 0 -inf? 0.00895 0.323885 
Amdhd2 
chr17:24155832-
24163733 26.0834 0 -inf? 0.00895 0.323885 
Olfr1448 
chr19:12919362-
12920307 23.2755 0 -inf? 0.00895 0.323885 
Olfr1024 
chr2:85904068-
85905052 23.8723 0 -inf? 0.00895 0.323885 
Pithd1 
chr4:135975601-
135987244 31.7372 0 -inf? 0.00895 0.323885 
4930513D17Rik 
chr5:39461748-
39603574 30.172 0 -inf? 0.00895 0.323885 
Tas2r118 
chr6:23969160-
23970060 28.0034 0 -inf? 0.00895 0.323885 
Vmn1r123 
chr7:21162184-
21163108 25.181 0 -inf? 0.00895 0.323885 
Olfr944 
chr9:39217358-
39218294 22.1162 0 -inf? 0.00895 0.323885 
Mrgprb1 
chr7:48444112-
48456342 8.69978 56.4743 2.69854 0.0092 0.323885 
Uck2 
chr1:167226083-
167285127 0 45.9198 inf 0.00925 0.323885 
Hist1h3f 
chr13:23544051-
23544954 0 63.0315 inf 0.00925 0.323885 
Vmn1r210 
chr13:22827193-
22828114 0 22.5534 inf 0.00925 0.323885 
Tacstd2 
chr6:67534058-
67535822 0 31.3957 inf 0.00925 0.323885 
Mrpl44 
chr1:79776017-
79781445 22.668 0 -inf? 0.00985 0.323885 
Dcxr 
chr11:120725372-
120727281 30.438 0 -inf? 0.00985 0.323885 
Tubb2a-ps2 
chr12:11882195-
11882899 20.6329 0 -inf? 0.00985 0.323885 
Tpsb2 
chr17:25366332-
25368092 19.7134 0 -inf? 0.00985 0.323885 
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Ptgds 
chr2:25466711-
25469749 26.0146 0 -inf? 0.00985 0.323885 
Cdkn2b 
chr4:89306288-
89311032 25.8236 0 -inf? 0.00985 0.323885 
Pop5 
chr5:115235850-
115240970 44.762 0 -inf? 0.00985 0.323885 
Ptov1 
chr7:44863067-
44869788 20.5055 0 -inf? 0.00985 0.323885 
Ruvbl2 
chr7:45421897-
45434464 20.6705 0 -inf? 0.00985 0.323885 
Upf3a 
chr8:13785614-
13798537 29.2402 0 -inf? 0.00985 0.323885 
Cdr1 
chrX:61183245-
61185558 19.6273 0 -inf? 0.00985 0.323885 
Prdx4 
chrX:155323919-
155338454 26.5092 0 -inf? 0.00985 0.323885 
Ddt 
chr10:75771232-
75773374 0 63.5472 inf 0.01 0.323885 
Hist3h2a 
chr11:58954684-
58955192 0 98.6378 inf 0.01 0.323885 
Olfr750 
chr14:51070310-
51071442 0 19.9333 inf 0.01 0.323885 
Nudt22 
chr19:6993018-
6996037 0 23.3294 inf 0.01 0.323885 
Xpa 
chr4:46175221-
46196311 0 30.771 inf 0.01 0.323885 
Icam2 
chr11:106377655-
106382641 19.5837 0 -inf? 0.01025 0.323885 
Cd7 
chr11:121036748-
121039478 22.625 0 -inf? 0.01025 0.323885 
Rpl10l 
chr12:66283378-
66284401 27.2673 0 -inf? 0.01025 0.323885 
Gm10823 
chr16:27849929-
27926128 25.8352 0 -inf? 0.01025 0.323885 
Bex6 
chr16:32179799-
32186944 26.4758 0 -inf? 0.01025 0.323885 
Psmg1 
chr16:95979934-
95990903 19.5249 0 -inf? 0.01025 0.323885 
Mad2l1bp 
chr17:46147384-
46153551 19.3716 0 -inf? 0.01025 0.323885 
Mydgf 
chr17:56176540-
56183920 23.2706 0 -inf? 0.01025 0.323885 
1700030N03Rik 
chr19:3153798-
3197703 79.6032 0 -inf? 0.01025 0.323885 
Gm826 
chr2:160311400-
160327494 23.1694 0 -inf? 0.01025 0.323885 
Wfdc3 
chr2:164731225-
164743267 26.9721 0 -inf? 0.01025 0.323885 
Psmg3 
chr5:139823593-
139826843 36.7331 0 -inf? 0.01025 0.323885 
Timm50 
chr7:28305825-
28312046 21.3216 0 -inf? 0.01025 0.323885 
5830454E08Rik 
chr9:120577330-
120578073 40.7484 0 -inf? 0.01025 0.323885 
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A930006K02Rik 
chr16:91465103-
91470123 0 43.618 inf 0.0105 0.323885 
Grxcr2 
chr18:41986200-
41999049 0 29.5598 inf 0.0105 0.323885 
Dfnb59 
chr2:76650272-
76658554 0 25.0701 inf 0.0105 0.323885 
Penk chr4:4133535-4138445 0 26.6919 inf 0.0105 0.323885 
Olfr68 
chr7:103777395-
103778343 0 20.9962 inf 0.0105 0.323885 
Arv1 
chr8:124722138-
124734123 0 23.1182 inf 0.0105 0.323885 
Camta2,Spag7 
chr11:70663768-
70688105 57.3321 2.50407 -4.517 0.011 0.337684 
Nt5dc2 
chr14:31134852-
31168641 21.0978 0 -inf? 0.01355 0.413985 
Ccl19 
chr4:42754524-
42756518 130.83 1096.71 3.06741 0.01465 0.445471 
Fam60a 
chr6:148921058-
148946432 149.931 33.6692 -2.1548 0.01565 0.473634 
Pde6g 
chr11:120447606-
120453500 23.3889 0 -inf? 0.01625 0.489484 
Pnrc2 
chr4:135870925-
135873846 17.4832 125.979 2.84915 0.01745 0.523174 
Msr1 
chr8:39467447-
40227787 14.1845 72.1555 2.34679 0.0179 0.534169 
Chchd7 chr4:3938887-3951382 139.618 6.43323 -4.4398 0.01815 0.539122 
Acy3 
chr19:3986569-
3990005 0 18.9047 inf 0.01835 0.542551 
Prr27 
chr5:87825696-
87846386 0 19.2469 inf 0.0187 0.550363 
Gucy1a2 chr9:3532348-3905787 4.88846 21.0582 2.10693 0.0188 0.55078 
Capza1 
chr3:104822784-
104864505 23.954 95.9779 2.00243 0.02025 0.590564 
Cox18 
chr5:90214724-
90223996 0 20.408 inf 0.0228 0.661922 
Pgap1 
chr1:54472999-
54557684 12.6214 39.5624 1.64826 0.02415 0.697957 
Zap70 
chr1:36761797-
36782820 21.8591 0 -inf? 0.02545 0.73223 
Sox11 
chr12:27334267-
27342718 70.0018 17.981 -1.96092 0.02595 0.739543 
A730020M07Rik 
chr3:121634935-
121646453 19.6322 0 -inf? 0.02595 0.739543 
Cxcl13 
chr5:95956938-
95961068 372.854 1100.85 1.56193 0.02605 0.739543 
Myl1 
chr1:66924295-
66945056 27.9507 0 -inf? 0.04945 0.862506 
Tbx1 
chr16:18581703-
18590671 0 19.628 inf 0.02635 0.744765 
Casc5 
chr2:119047118-
119104121 6.7173 41.4277 2.62464 0.0271 0.762604 
BC037032 
chr15:4020110-
4155344 12.6229 65.5151 2.37579 0.0284 0.795696 
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Btbd18 
chr2:84659078-
84668781 11.7068 64.8968 2.4708 0.02875 0.798528 
Tktl2 
chr8:66511739-
66519199 13.1168 48.9789 1.90075 0.02875 0.798528 
Cyhr1 
chr15:76643394-
76660208 6.46585 81.1985 3.65054 0.0294 0.807484 
Myo9a 
chr9:59751173-
59928866 9.49742 32.0823 1.75617 0.0294 0.807484 
Sdcbp chr4:6365679-6396122 39.9372 134.138 1.74792 0.02945 0.807484 
Ttc14 
chr3:33800182-
33844310 11.4942 43.675 1.9259 0.0307 0.838175 
Prlr 
chr15:10177237-
10349180 21.2528 61.3362 1.52908 0.0317 0.86181 
Cacnb4 
chr2:52428319-
52676609 7.96714 32.9625 2.04869 0.03185 0.862235 
Rfx7 
chr9:72532239-
72622949 6.41744 37.7751 2.55737 0.0327 0.862506 
Cnot7 
chr8:40492537-
40634792 17.9681 84.2284 2.22887 0.0328 0.862506 
Gm13546 
chr2:58163973-
58177063 33.6367 0 -inf? 0.03295 0.862506 
Cfb 
chr17:34856373-
34862514 59.1975 219.062 1.88773 0.0333 0.862506 
Gm13157 
chr4:147753973-
147809788 60.0194 199.302 1.73146 0.03345 0.862506 
1500011B03Rik 
chr5:114808195-
114813976 69.772 0 -inf? 0.03355 0.862506 
Ccr6 
chr17:8236042-
8257129 96.1231 18.006 -2.4164 0.03365 0.862506 
Rc3h2 
chr2:37370070-
37422903 30.2586 83.7996 1.4696 0.03445 0.862506 
Itgal 
chr7:127296259-
127335137 3.74952 31.8574 3.08685 0.03645 0.862506 
S100a6 
chr3:90612893-
90614414 657.262 127.69 -2.36383 0.0368 0.862506 
Trim30b 
chr7:104355397-
104358646 6.06866 61.1817 3.33365 0.03685 0.862506 
Unc5d 
chr8:28646716-
29219636 38.3182 10.8762 -1.81685 0.0371 0.862506 
Gpcpd1 
chr2:132529081-
132578248 7.20012 39.9156 2.47086 0.03725 0.862506 
Cml2 
chr6:85865421-
85869137 3.24936 32.2051 3.30906 0.038 0.862506 
1700025M24Rik 
chr5:73268579-
73284184 31.6883 0 -inf? 0.0381 0.862506 
Jazf1 
chr6:52768067-
53068624 49.7855 5.2142 -3.25521 0.03815 0.862506 
Bod1l 
chr5:41787539-
41844315 11.7008 40.1507 1.77882 0.0382 0.862506 
Usp49 
chr17:47630689-
47684067 2.68761 25.9879 3.27344 0.03825 0.862506 
1810026B05Rik,Chd2 
chr7:73426651-
73558395 28.7033 89.8281 1.64595 0.0384 0.862506 
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1600020E01Rik 
chr6:86527329-
86564449 31.1869 0 -inf? 0.03865 0.862506 
Rbm25 
chr12:83632233-
83683123 22.3807 75.5445 1.75507 0.0389 0.862506 
Fut8 
chr12:77238103-
77475996 595.664 241.652 -1.30156 0.04015 0.862506 
Cpne1,Rbm12 
chr2:156071840-
156111965 8.06345 57.0215 2.82204 0.0403 0.862506 
Bgn 
chrX:73483634-
73495936 15.3881 77.4481 2.33142 0.0403 0.862506 
9430037G07Rik 
chr9:88595324-
88599243 41.3365 4.61762 -3.16219 0.0405 0.862506 
Il33 
chr19:29925113-
29960715 27.3317 107.872 1.98068 0.0422 0.862506 
Tia1 
chr6:86404218-
86433405 34.067 5.10782 -2.7376 0.0424 0.862506 
Crebzf 
chr7:90442780-
90448043 20.8962 3.24773 -2.68574 0.04265 0.862506 
Mdc1 
chr17:35841497-
35859670 86.5403 31.2146 -1.47115 0.04305 0.862506 
Zfp81 
chr17:33333727-
33358878 131.596 39.749 -1.72713 0.04315 0.862506 
L2hgdh 
chr12:69690435-
69724874 26.4937 2.95839 -3.16277 0.0432 0.862506 
Garem 
chr18:21127341-
21300139 32.3837 3.66879 -3.14189 0.0433 0.862506 
Foxa1 
chr12:57540631-
57546121 6.09907 52.6068 3.10859 0.04335 0.862506 
Mkrn1 
chr6:39397820-
39420369 49.9685 5.6803 -3.13698 0.0434 0.862506 
Zfp945 
chr17:22846696-
22867134 2.31459 20.8215 3.16924 0.0436 0.862506 
Vmn2r113 
chr17:22943183-
22958814 5.64039 49.1333 3.12283 0.044 0.862506 
Eif4h 
chr5:134619875-
134639328 11.8327 104.486 3.14246 0.04405 0.862506 
Cd79a 
chr7:24897510-
24902197 100.165 12.003 -3.06091 0.045 0.862506 
Tsr3 
chr17:25240169-
25256364 27.2416 0 -inf? 0.04545 0.862506 
Fxyd5 
chr7:31032722-
31042331 305.512 37.4639 -3.02766 0.0458 0.862506 
Il15ra 
chr2:11705292-
11733985 8.75868 76.654 3.12958 0.0459 0.862506 
Kctd4 
chr14:75896936-
76010865 185.96 60.5274 -1.61933 0.04595 0.862506 
Lxn 
chr3:67430114-
67475068 35.5344 226.991 2.67534 0.046 0.862506 
Ube2d3 
chr3:135438758-
135467178 46.6531 5.7338 -3.02441 0.0464 0.862506 
Ero1l 
chr14:45283086-
45318572 52.9749 13.7084 -1.95025 0.04675 0.862506 
Dcn 
chr10:97479499-
97518162 52.4608 198.39 1.91903 0.04745 0.862506 
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Serpina3f, 3g 
chr12:104214543-
104241934 39.9176 142.501 1.83587 0.0475 0.862506 
Tiparp 
chr3:65527484-
65555518 16.9349 64.5231 1.92982 0.0478 0.862506 
Pxylp1 
chr9:96823342-
96889474 13.7749 59.3614 2.10748 0.04825 0.862506 
Car3 
chr3:14863537-
14872373 190.934 22.5028 -3.0849 0.04835 0.862506 
Cep57 
chr9:13807787-
13827107 6.94431 58.624 3.07759 0.0485 0.862506 
Serpini1 
chr3:75557532-
75642523 4.77499 41.5677 3.1219 0.04875 0.862506 
Mir7678,Slpi 
chr2:164354069-
164356507 0 18.8406 inf 0.0493 0.862506 
Rmnd5a 
chr6:71388633-
71440637 14.5115 46.2264 1.67153 0.04935 0.862506 
 





Control Value pIC log2(fold_change) p_value q_value 
Serp2 
chr14:76532811-
76556889 17.6265 0 -inf 0.0002 0.969383 
Gbp9 
chr5:105078393-
105110292 8.87728 90.6153 3.35157 0.0003 0.969383 
Defb48 
chr14:62977523-
62984510 19.3185 0 -inf 0.00075 0.969383 
Hist1h1a 
chr13:23763667-
23764412 17.6532 0 -inf 0.00105 0.969383 
Saa3 
chr7:46711997-
46715676 249.744 1760.41 2.81739 0.00115 0.969383 
Pmp22 
chr11:62951192-
63386069 8.55896 87.6998 3.35706 0.0015 0.969383 
Pik3ap1 
chr19:41274217-
41385070 8.68499 64.4607 2.89182 0.0022 0.969383 
Bst1 
chr5:43818892-
43843468 4.22605 27.643 2.70953 0.003 0.969383 
Gm15056 
chr8:20900605-
20901973 124.877 1229.32 3.29928 0.0032 0.969383 
Mrgpra2b 
chr7:47463806-
47489582 6.13454 82.8145 3.75486 0.00365 0.969383 
Serping1 
chr2:84765359-
84775429 20.8867 111.605 2.41775 0.004 0.969383 
Abce1 
chr8:79683441-
79711740 3.8509 21.3887 2.47358 0.00495 0.969383 
Tlr13 
chrX:106143274-
106160493 2.68866 28.2885 3.39525 0.00565 0.969383 
Alpk1 
chr3:127670309-
127780527 3.84433 31.1979 3.02064 0.00595 0.969383 
Nlrp3 
chr11:59542685-
59566956 1.95406 18.3023 3.22748 0.007 0.969383 
117 
Table 6 continued 
Il33 
chr19:29925113-
29960715 11.1252 58.6499 2.3983 0.00835 0.969383 
1810053B23Rik 
chr16:93343715-
93359543 58.8752 8.46191 -2.7986 0.0095 0.969383 
Gm20098 
chr17:51882726-
51965257 15.4046 3.82278 -2.01066 0.00955 0.969383 
Ccl19 
chr4:42754524-
42756518 193.965 805.785 2.0546 0.00965 0.969383 
Bgn 
chrX:73483634-
73495936 2.25069 37.0296 4.04024 0.01025 0.969383 
Tmbim7 
chr5:3657003-
3679544 14.4757 1.93174 -2.90566 0.01055 0.969383 
Dnajb9 
chr12:44205896-
44210068 2.76637 24.2897 3.13428 0.01165 0.969383 
Pstpip2 
chr18:77794549-
77882879 6.38511 30.772 2.26884 0.01305 0.969383 
Rab8b 
chr9:66843663-
66919705 22.7716 98.2803 2.10967 0.0134 0.969383 
Gpr141 
chr13:19749681-
19824257 3.81407 21.6848 2.50728 0.01375 0.969383 
Themis2 
chr4:132782356-
132796364 17.8501 78.2911 2.13292 0.0154 0.969383 
Stx12 
chr4:132854063-
132884458 6.06862 23.3462 1.94375 0.01545 0.969383 
Gstm2 
chr3:107981701-
107986436 21.3883 90.57 2.08221 0.01555 0.969383 
Pfkfb4 
chr9:108991901-
109032225 4.15233 18.1514 2.12809 0.0158 0.969383 
Il18 
chr9:50565367-
50581837 25.3719 110.691 2.12523 0.0161 0.969383 
Olfr695 
chr7:106713731-
106716345 26.3833 5.09584 -2.37224 0.01645 0.969383 
Olfr138 
chr17:38274772-
38275711 36.0129 7.99548 -2.17126 0.017 0.969383 
B230323A14Rik 
chr9:69761145-
69830199 25.7765 6.02477 -2.09708 0.017 0.969383 
Usp8 
chr2:126707327-
126759314 6.21788 27.0666 2.12202 0.01715 0.969383 
Olfr530 
chr7:140372684-
140373608 24.2926 3.72725 -2.70433 0.0176 0.969383 
LOC100504703 
chr10:127070480
-127071101 18.6478 0 -inf 0.0182 0.969383 
Rap2c 
chrX:51003913-
51018018 3.39226 25.3182 2.89986 0.01855 0.969383 
Ggh 
chr4:20042051-
20066111 6.92689 54.5174 2.97644 0.0189 0.969383 
Dcn 
chr10:97479499-
97518162 31.3259 164.207 2.39009 0.01965 0.969383 
Odf2 
chr2:29889719-
29931746 4.51633 21.6132 2.25869 0.0198 0.969383 
Cfb 
chr17:34856373-
34862514 55.4999 265.978 2.26075 0.02015 0.969383 
Cul1 
chr6:47454323-
47526139 11.6158 41.2845 1.82952 0.02075 0.969383 
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Gna12 
chr5:140759943-
140830431 7.27527 34.4999 2.24552 0.0208 0.969383 
Col3a1 
chr1:45311537-
45349706 4.05122 16.9559 2.06536 0.021 0.969383 
Ccr1 
chr9:123962125-
123968692 29.4293 111.494 1.92164 0.0216 0.969383 
Capn7 
chr14:31336723-
31371983 3.92507 13.8964 1.82392 0.02185 0.969383 
Lcp2 
chr11:34047200-
34092280 29.6742 114.009 1.94187 0.02205 0.969383 
Ier3 
chr17:35821712-
35822911 30.7313 157.412 2.35677 0.02325 0.969383 
Rassf3 
chr10:121410350
-121476250 15.1804 52.3153 1.78503 0.02335 0.969383 
Ap3b1 
chr13:94358959-
94566316 10.0849 35.4552 1.8138 0.0237 0.969383 
Gm7168 
chr17:13948372-
13950678 20.3774 4.73129 -2.10667 0.02375 0.969383 
Olfr1199 
chr2:88755740-
88756673 42.7385 11.6768 -1.87189 0.02405 0.969383 
Sorl1 
chr9:41968488-
42124289 4.72918 14.1702 1.58319 0.02455 0.969383 
Gm5416 
chr16:36210402-
36217788 0 65.9932 inf 0.0249 0.969383 
Nploc4 
chr11:120379797
-120437700 4.68015 16.0672 1.77949 0.0252 0.969383 
Grk6 
chr13:55445071-
55460927 11.7563 39.1847 1.73685 0.0258 0.969383 
Trip13 
chr13:73912461-
73937767 2.95142 15.0055 2.34601 0.02605 0.969383 
Cnn3 
chr3:121426540-
121458205 19.6022 78.302 1.99803 0.02665 0.969383 
Otx2 
chr14:48657676-
48667644 19.0547 4.89226 -1.96158 0.02685 0.969383 
Ripk1 
chr13:34002873-
34035170 3.16639 19.8561 2.64867 0.0269 0.969383 
Tfg 
chr16:56690328-
56717450 13.3403 48.5655 1.86414 0.02745 0.969383 
Il13ra1 
chrX:36112107-
36171261 8.07564 50.871 2.65519 0.0278 0.969383 
Sucnr1 
chr3:60081868-
60087566 14.0674 1.58376 -3.15092 0.02845 0.969383 
Olfr1453 
chr19:13027403-
13028327 29.1004 7.11782 -2.03153 0.0285 0.969383 
Susd6 
chr12:80790531-
80880833 6.40361 25.5734 1.99769 0.02865 0.969383 
Lrrc25 
chr8:70616843-
70620850 6.79908 83.7823 3.62323 0.0292 0.969383 
Dgat2 
chr7:99153662-
99182713 8.49625 40.4722 2.25203 0.0296 0.969383 
Dync1i2 
chr2:71211705-
71263302 5.98245 22.6304 1.91946 0.0297 0.969383 
Tgtp1 
chr11:48985328-
48992246 3.51893 22.339 2.66636 0.03015 0.969383 
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Bcl2l11 
chr2:128126037-
128162547 7.5487 28.4769 1.91549 0.0305 0.969383 
Zc3h7a 
chr16:11136593-
11176393 7.25499 38.4446 2.40573 0.0313 0.969383 
Tmed7 
chr18:46585927-
46597535 6.84337 21.2619 1.63549 0.03185 0.969383 
Ssr3 
chr3:65379656-
65392553 9.2873 31.5132 1.76262 0.03195 0.969383 
Il18bp 
chr7:102015076-
102018155 12.3129 65.4335 2.40986 0.03205 0.969383 
Il12a 
chr3:68690643-
68698550 5.66534 27.4637 2.27729 0.0321 0.969383 
Wfikkn1 
chr17:25877627-
25880858 15.164 3.91737 -1.9527 0.03225 0.969383 
Gfpt2 
chr11:49794154-
49838620 3.40338 14.233 2.0642 0.03245 0.969383 
Pomgnt1 
chr4:116150517-
116159844 4.45256 20.1317 2.17676 0.0326 0.969383 
Spg21 
chr9:65460936-
65488470 15.5932 50.2179 1.68728 0.0328 0.969383 
Mmp3 
chr9:7445821-
7455974 10.5736 40.4484 1.93562 0.03305 0.969383 
Pdha1 
chrX:159988432-
160138336 8.34522 30.6502 1.87687 0.0331 0.969383 
1110038B12Rik 
chr17:34950235-
34952471 39.2008 6.78782 -2.52986 0.03315 0.969383 
Dclre1a 
chr19:56529160-
56548222 3.74849 14.3543 1.9371 0.0337 0.969383 
Taf9b 
chrX:106206873-
106221158 4.22182 15.8915 1.91232 0.0344 0.969383 
Iigp1 
chr18:60376028-
60392629 11.4405 39.4112 1.78445 0.03445 0.969383 
Garem 
chr18:21127341-
21300139 14.9744 4.29596 -1.80145 0.03515 0.969383 
Ctsl 
chr13:64363213-
64370306 13.3655 56.6817 2.08437 0.03525 0.969383 
Panx3 
chr9:37659901-
37669222 19.5486 5.92478 -1.72223 0.03545 0.969383 
S100a16 
chr3:90541222-
90543151 2.53632 26.0895 3.36266 0.0357 0.969383 
Gm6815 
chr16:36194479-
36197886 24.9113 8.43998 -1.56149 0.0362 0.969383 
B3gnt2 
chr11:22834738-
22860336 7.95788 26.5961 1.74076 0.0363 0.969383 
Clec4a2 
chr6:123122689-
123143999 10.0645 34.1235 1.7615 0.0365 0.969383 
Olfr972 
chr9:39873276-
39874221 25.1732 6.11923 -2.04047 0.0373 0.969383 
Adrb2 
chr18:62177712-
62179981 10.7379 52.897 2.30047 0.03745 0.969383 
Nod1 
chr6:54923941-
54972612 11.0242 38.0176 1.78599 0.03775 0.969383 
Ccne1 
chr7:38097983-
38107490 1.34643 20.1578 3.90413 0.0378 0.969383 
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Stfa2l1 
chr16:36156810-
36161948 14.4151 247.498 4.10177 0.038 0.969383 
Il10ra 
chr9:45253838-
45269146 10.3221 45.3276 2.13465 0.0385 0.969383 
Mrgpra2a 
chr7:47426328-
47452139 4.55683 33.7555 2.88902 0.03855 0.969383 
Rasa3 
chr8:13567217-
13677587 8.6855 26.5971 1.61459 0.0386 0.969383 
Mptx2 
chr1:173274460-
173277756 6.61052 31.0838 2.23333 0.0392 0.969383 
Xpo6 
chr7:126101718-
126200408 5.32846 17.0367 1.67686 0.0392 0.969383 
Igbp1b 
chr6:138657091-
138658444 25.3977 5.63629 -2.17188 0.04005 0.969383 
Smpdl3b 
chr4:132732965-
132757171 7.4168 34.7624 2.22866 0.04045 0.969383 
Ergic1 
chr17:26561511-
26656933 6.1747 25.9574 2.0717 0.0409 0.969383 
Fabp3 
chr4:130308777-
130315463 157.49 47.103 -1.74136 0.04155 0.969383 
St3gal6 
chr16:58470540-




96243642 2.02573 20.8035 3.36031 0.04185 0.969383 
Pgm1 
chr5:64092949-
64128158 3.39193 19.537 2.52603 0.04245 0.969383 
Peg12 
chr7:62461870-
62464510 23.1475 6.68513 -1.79183 0.0426 0.969383 
Slc40a1 
chr1:45908069-
45925594 6.40735 25.1718 1.97401 0.04295 0.969383 
Olfr1352 
chr10:78981049-
78984721 14.7438 4.10328 -1.84526 0.0431 0.969383 
Plekho2 
chr9:65552576-
65580087 9.25148 41.9962 2.1825 0.04315 0.969383 
Tmem106a 
chr11:101582241
-101591785 15.149 45.1067 1.57412 0.0432 0.969383 
Ctnnb1 
chr9:120933399-
120960507 14.3199 50.1776 1.80903 0.04325 0.969383 
Ngp 
chr9:110419807-
110423012 15.6557 2.24798 -2.79999 0.0433 0.969383 
Mad2l1bp 
chr17:46147384-
46153551 3.90298 21.6959 2.47478 0.0435 0.969383 
Vmn1r64 
chr7:5883579-
5884542 19.7987 2.61821 -2.91875 0.0437 0.969383 
Antxr2 
chr5:97884687-
98030962 5.37033 24.3591 2.18138 0.04455 0.969383 
Micu2 
chr14:57916279-
57999262 13.0973 40.7597 1.63787 0.04475 0.969383 
Marcks 
chr10:37133242-
37138926 70.029 235.873 1.75198 0.04495 0.969383 
Wdr91 
chr6:34880425-
34910831 2.87002 17.7808 2.63119 0.04545 0.969383 
Zmat4 
chr8:23669660-
24063116 24.9034 8.46755 -1.55633 0.04555 0.969383 
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Plscr1 
chr9:92250193-
92272561 12.0372 54.291 2.17322 0.0457 0.969383 
Riok1 
chr13:38036988-
38061433 8.22511 22.9243 1.47877 0.046 0.969383 
Fpr-rs6 
chr17:20182077-
20183097 17.6381 2.91847 -2.59542 0.046 0.969383 
3110062M04Rik 
chr6:34863145-
34878065 3.65715 17.9972 2.29898 0.04665 0.969383 
Hdhd1a 
chr18:50567655-
50568699 16.527 3.76865 -2.13271 0.04705 0.969383 
Ifitm1 
chr7:140967428-
140969827 123.178 837.384 2.76514 0.0473 0.969383 
Ubd 
chr17:37193891-
37196101 13.4089 45.77 1.77121 0.0474 0.969383 
Tgm2 
chr2:158116404-
158146392 16.575 60.5639 1.86945 0.0474 0.969383 
Ndufs3 
chr2:90894635-
90904721 35.9538 111.418 1.63177 0.0477 0.969383 
Gm10696 
chr3:94174411-
94178193 28.7039 9.76069 -1.55619 0.04825 0.969383 
Alkbh3 
chr2:93980033-
94010730 7.72873 42.1056 2.44571 0.04845 0.969383 
1700037C18Rik 
chr16:3905797-
3908689 5.99782 31.8476 2.40868 0.04855 0.969383 
Tas2r139 
chr6:42140935-
42141895 19.7514 4.14162 -2.25369 0.04855 0.969383 
Gm5483 
chr16:36184211-
36188110 19.759 243.888 3.62564 0.04905 0.969383 
Hspa9 
chr18:34937414-
34954351 14.3436 48.5239 1.75828 0.04905 0.969383 
Adora2b 
chr11:62248983-
62266452 4.84157 20.2761 2.06623 0.0491 0.969383 
Gbp7 
chr3:142530335-
142550151 11.2838 52.4492 2.21667 0.04915 0.969383 
Tdrd7 
chr4:45965334-
46034765 8.23057 27.4524 1.73787 0.0492 0.969383 
Acly 
chr11:100476351
-100528000 6.00419 26.0092 2.11498 0.0496 0.969383 
Arid5a 
chr1:36307732-
36324029 4.98337 25.2747 2.3425 0.0497 0.969383 
Olfr1170 
chr2:88224079-















nge) p_value q_value 
Ankrd23 chr1:36530533-36535729 29.4488 2.37552 -3.6319 5.00E-05 0.098713 
Eno3 
chr11:70657175-
70662513 235.397 24.2773 -3.27742 5.00E-05 0.098713 
Ostn 
chr16:27307640-
27351209 5.16117 0 -inf 5.00E-05 0.098713 
S100a9 chr3:90692629-90695721 107.816 417.682 1.95384 5.00E-05 0.098713 
Cxcl2 chr5:90903898-90905938 6.58271 98.3162 3.90068 5.00E-05 0.098713 
Mylpf 
chr7:127211607-
127214287 1147.89 6.98374 -7.36077 5.00E-05 0.098713 
Tnni2 
chr7:142442467-
142444405 781.582 9.72325 -6.32882 5.00E-05 0.098713 
Cd209b chr8:3917654-3926841 152.165 33.9096 -2.16588 5.00E-05 0.098713 
Ryr1 chr7:29003339-29125151 4.49056 
0.28564
4 -3.9746 0.0001 0.175489 
Gzmb 
chr14:56258857-
56262260 32.9068 104.551 1.66775 0.0002 0.287164 
Mmp3 chr9:7445821-7455974 24.8705 79.572 1.67783 0.0002 0.287164 
Des chr1:75360291-75375015 48.0906 14.1908 -1.7608 0.0004 0.451257 
Slfn4 
chr11:83175185-
83190216 7.14325 31.1404 2.12414 0.0004 0.451257 
Hp 
chr8:109575127-
109579172 14.7777 64.7729 2.13197 0.0004 0.451257 





5 -5.78996 0.00105 0.999803 
Ampd1 
chr3:103074013-
103099720 21.6483 2.46273 -3.13593 0.0012 0.999803 
Lilrb4a 
chr10:51490897-
51496611 30.0346 85.211 1.50441 0.0013 0.999803 
Fpr1 
chr17:17876470-
17883939 4.20963 35.4804 3.07526 0.00135 0.999803 
Ttn chr2:76703983-76982547 3.73804 
0.76029
3 -2.29765 0.00145 0.999803 
Il1b 
chr2:129364579-
129375733 69.4498 343.866 2.30781 0.0015 0.999803 
Tpm2 chr4:43513725-43523554 32.1027 6.47248 -2.31031 0.0016 0.999803 
Saa3 chr7:46711997-46715676 352.848 1457.15 2.04603 0.0016 0.999803 
Timd4 
chr11:46810798-
46844333 61.6385 24.103 -1.35462 0.00185 0.999803 
Slpi 
chr2:164354069-
164356507 33.5373 159.756 2.25203 0.0019 0.999803 
Fpr2 
chr17:17887823-
17893952 19.7425 83.0948 2.07345 0.0021 0.999803 
Il1rn chr2:24336859-24351491 17.9351 54.5878 1.6058 0.0023 0.999803 
Lcn2 chr2:32384636-32387739 12.512 155.6 3.63645 0.00275 0.999803 
Cd14 
chr18:36725063-
36726815 21.0166 71.4616 1.76564 0.0028 0.999803 
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Cxcl10 chr5:92331840-92414627 30.5607 104.488 1.77359 0.003 0.999803 
Neb chr2:52136646-52338798 5.50376 0.43294 -3.66818 0.00305 0.999803 
Clec4e 
chr6:123281788-
123289871 13.1437 39.1196 1.57352 0.00305 0.999803 
Adssl1 
chr12:112620046-
112641355 27.5228 7.00345 -1.97449 0.00345 0.999803 
Wfdc17 
chr11:83704055-
83706269 115.753 289.719 1.3236 0.004 0.999803 
Ccrl2 
chr9:111054833-





2 -2.45715 0.00525 0.999803 
Cmya5 
chr13:93040714-
93144724 6.80668 1.03786 -2.71335 0.0061 0.999803 
S100a8 chr3:90669070-90670034 113.347 380.594 1.74751 0.00625 0.999803 
Ndrg2 
chr14:51905270-
51913488 24.1288 5.69835 -2.08214 0.00645 0.999803 
Fabp5 chr3:10012584-10016610 107.207 222.109 1.05087 0.0065 0.999803 
Hba-a2 
chr11:32283674-
32284493 158.546 49.9862 -1.6653 0.00665 0.999803 
Gm15056 chr8:20900605-20901973 145.143 466.358 1.68396 0.00665 0.999803 
Gpd1 
chr15:99717592-
99725007 10.0203 1.97938 -2.33981 0.0077 0.999803 
Irg1 
chr14:103047011-
103056573 3.91781 37.2071 3.24746 0.0082 0.999803 
Ms4a6d 
chr19:11586605-
11604804 66.4276 132.309 0.994054 0.00885 0.999803 
Ank1 chr8:22974835-23150497 1.6122 
0.13986
2 -3.52695 0.0099 0.999803 
Xirp2 chr2:67446001-67526606 5.14729 
0.60005
7 -3.10064 0.01215 0.999803 
Pde4dip chr3:97689828-97888707 18.3557 8.01331 -1.19576 0.0122 0.999803 
Ccl3 
chr11:83647842-
83649378 12.8508 72.8743 2.50355 0.0134 0.999803 
Sod2 
chr17:13007838-
13018119 19.5943 36.4829 0.896784 0.01465 0.999803 
Clec4a3 
chr6:122952514-





6 -2.24267 0.0156 0.999803 
Fcgr4 
chr1:171018925-
171029761 11.1161 34.6176 1.63886 0.0156 0.999803 
Agl 
chr3:116739998-
116808166 7.68035 3.4872 -1.1391 0.01665 0.999803 
Tnfaip2 
chr12:111442660-












98984565 3.33114 0 -inf 0.01945 0.999803 
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25143241 1.46238 0 -inf 0.01945 0.999803 
C1ql4 
chr15:99084753-
99087728 1.64093 0 -inf 0.01945 0.999803 
Krtap22-2 
chr16:89010379-
89010759 5.39221 0 -inf 0.01945 0.999803 
Dcpp2 
chr17:23898721-
23900787 2.11965 0 -inf 0.01945 0.999803 
Defb23 
chr2:152459054-
152464620 2.04676 0 -inf 0.01945 0.999803 
Defb45 
chr2:152593190-
152596485 5.13912 0 -inf 0.01945 0.999803 
Sprr2b chr3:92316704-92318085 1.70662 0 -inf 0.01945 0.999803 
Lce6a chr3:92620084-92621660 1.41635 0 -inf 0.01945 0.999803 
Lce1k chr3:92806290-92807891 1.85484 0 -inf 0.01945 0.999803 
Ifna5 chr4:88835524-88836094 2.38652 0 -inf 0.01945 0.999803 
A930016O22R
ik chr7:19411093-19421583 39.3451 1.13871 -5.11071 0.01945 0.999803 
4932443I19Ri
k chr8:13705888-13743066 1.44307 0 -inf 0.01945 0.999803 
Gm2837 chrX:33056285-33057063 1.45128 0 -inf 0.01945 0.999803 
Rhox2b chrX:37412104-37416806 1.49963 0 -inf 0.01945 0.999803 
Cd274 
chr19:29367437-
29388094 24.1427 44.3672 0.877909 0.02035 0.999803 
Fcer1g 
chr1:171229571-
171234349 181.342 343.517 0.921666 0.02065 0.999803 
Pfkm 
chr15:98038743-
98132447 49.1548 3.74335 -3.71493 0.02095 0.999803 
Fcgr2b 
chr1:170960558-




71556133 1.502 0 -inf 0.0221 0.999803 
Hbb-bs 
chr7:103826522-




76156086 0 2.01623 inf 0.02245 0.999803 
S100a2 chr3:90590246-90591508 0 5.34607 inf 0.02245 0.999803 
Klrb1 
chr6:128706507-
128723046 0 1.3904 inf 0.02245 0.999803 
Gm17252 chr9:35685078-35687371 0 3.35151 inf 0.02245 0.999803 
Gm10823 
chr16:27849929-
27926128 0 1.32746 inf 0.0225 0.999803 
Krtap21-1 
chr16:89403026-








120930802 0 2.19614 inf 0.02255 0.999803 
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Olfr768 
chr10:129093033-
129093972 1.66741 0 -inf 0.02295 0.999803 
Olfr777 
chr10:129268385-
129269321 1.67472 0 -inf 0.02295 0.999803 
Olfr314 
chr11:58786138-




49480862 2.50971 0 -inf 0.02295 0.999803 
Vmn1r197 
chr13:22327910-
22328807 1.77584 0 -inf 0.02295 0.999803 
Vmn1r215 
chr13:23075791-
23076694 1.7595 0 -inf 0.02295 0.999803 
Olfr1466 
chr19:13341759-
13342692 1.68208 0 -inf 0.02295 0.999803 
Olfr1265 chr2:90036920-90037850 1.68952 0 -inf 0.02295 0.999803 
Olfr1179 chr2:88402008-88402932 1.70458 0 -inf 0.02295 0.999803 
Olfr1225 chr2:89170218-89171245 1.47829 0 -inf 0.02295 0.999803 
1700012A03Ri
k chr6:32050287-32058915 1.72769 0 -inf 0.02295 0.999803 
Vmn1r47 chr6:90021887-90022820 1.68208 0 -inf 0.02295 0.999803 
Vmn1r168 chr7:23540719-23541649 1.68952 0 -inf 0.02295 0.999803 
Klk1b24 chr7:44188262-44192451 1.92486 0 -inf 0.02295 0.999803 
Olfr53 
chr7:140646451-
140652919 1.25919 0 -inf 0.02295 0.999803 
Vmn1r117 chr7:20883197-20884121 1.70458 0 -inf 0.02295 0.999803 
Olfr667 
chr7:104916313-
104917294 1.57146 0 -inf 0.02295 0.999803 
Olfr250 chr9:38367547-38368543 1.53981 0 -inf 0.02295 0.999803 
1110036E04Ri
k chr9:64049828-64054100 2.18106 0 -inf 0.02295 0.999803 
Cldn34b1 
chrX:154886802-




58638403 0 1.74503 inf 0.02325 0.999803 
Agr3 
chr12:35925620-
35949730 1.39877 0 -inf 0.02355 0.999803 
Hcar2 
chr5:123863569-
123865516 8.67602 28.469 1.71429 0.0237 0.999803 
Gtsf1l 
chr2:163087030-
163089601 0 1.49668 inf 0.02405 0.999803 
Olfr29-ps1 chr4:43781364-43782327 0 1.33019 inf 0.02405 0.999803 
Reg1 chr6:78425982-78428666 0 1.79756 inf 0.02405 0.999803 
Vmn1r52 chr6:90178715-90179645 0 1.39174 inf 0.02405 0.999803 
Olfr213 
chr6:116540454-
116541438 0 1.29377 inf 0.02405 0.999803 
Vmn1r178 chr7:23893528-23894443 0 1.42164 inf 0.02405 0.999803 
Olfr628 
chr7:103731927-
103732878 0 1.35193 inf 0.02405 0.999803 
Tcf21 
chr10:22817274-
22820128 0 1.17905 inf 0.026 0.999803 
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Rfpl4b 
chr10:38820540-
38821779 0 1.42271 inf 0.026 0.999803 
Vmn1r222 
chr13:23232114-
23233041 0 1.67715 inf 0.026 0.999803 
Olfr1163 chr2:88070364-88071407 0 1.44165 inf 0.026 0.999803 
Olfr1230 chr2:89296350-89297268 0 1.69867 inf 0.026 0.999803 
4930519H02Ri
k chr5:15863927-15883766 0 1.5856 inf 0.026 0.999803 
Vmn1r174 chr7:23753910-23754852 0 1.64245 inf 0.026 0.999803 
Mybpc2 chr7:44501698-44524669 61.4543 1.09595 -5.80926 0.026 0.999803 
1700057G04Ri
k chr9:92309376-92357876 0 1.42612 inf 0.026 0.999803 
Cldn34c4 
chrX:127721175-
127736554 0 1.97468 inf 0.026 0.999803 
Ifitm2 
chr7:140954838-
140955961 231.253 417.29 0.851577 0.02745 0.999803 
Mir466k chr3:85467376-85467498 96.9582 0 -inf 0.0278 0.999803 
Klk1b7-ps chr7:43945011-43945927 1.88132 0 -inf 0.0278 0.999803 
Vmn2r-ps60 chr7:42430104-42430369 7.07224 0 -inf 0.0278 0.999803 
Defa-ps12 chr8:19210461-19212760 32.1317 0 -inf 0.0278 0.999803 
1700072B07Ri
k chr9:58370503-58374183 1.90752 0 -inf 0.0278 0.999803 








66124064 0 2.88793 inf 0.02855 0.999803 
Gm10104 chr8:21065037-21066001 0 2.08044 inf 0.02855 0.999803 
Csf3r 
chr4:126024658-
126044975 7.61702 18.3529 1.26871 0.0287 0.999803 
Igfbp5 chr1:72858064-72874865 14.743 7.082 -1.0578 0.029 0.999803 
Prss40 chr1:34552330-34560943 0 1.28166 inf 0.0296 0.999803 
Taar7a 
chr10:23992404-
23993481 0 1.61544 inf 0.0296 0.999803 
Olfr736 
chr14:50392757-




61305334 0 2.39101 inf 0.0296 0.999803 
Gm4719 
chr17:89379240-
89384993 0 2.37873 inf 0.0296 0.999803 
Scp2d1 
chr2:144823665-
144824415 0 2.60625 inf 0.0296 0.999803 
Olfr1213 chr2:88972953-88980267 0 1.28641 inf 0.0296 0.999803 
Olfr1245 chr2:89574711-89575773 0 1.64411 inf 0.0296 0.999803 
Olfr8 
chr10:78955206-
78956139 2.24278 0 -inf 0.03005 0.999803 
Vmn1r216 
chr13:23099148-
23100045 2.36779 0 -inf 0.03005 0.999803 
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Gm904 
chr13:50643227-
50645838 3.83907 0 -inf 0.03005 0.999803 
Olfr186 
chr16:59026975-
59027905 2.25269 0 -inf 0.03005 0.999803 
Olfr117 
chr17:37659377-
37660331 2.17577 0 -inf 0.03005 0.999803 
Olfr1445 
chr19:12883882-
12884827 2.20399 0 -inf 0.03005 0.999803 
Olfr1448 
chr19:12919362-
12920307 2.20399 0 -inf 0.03005 0.999803 
Olfr1013 chr2:85769802-85770720 2.29323 0 -inf 0.03005 0.999803 
Olfr1161 chr2:88024701-88025713 2.00991 0 -inf 0.03005 0.999803 
Cabs1 chr5:87979450-87981541 1.23441 0 -inf 0.03005 0.999803 
Olfr535 
chr7:140492639-
140493578 2.22322 0 -inf 0.03005 0.999803 
Olfr480 
chr7:108065767-
108066796 1.96599 0 -inf 0.03005 0.999803 
Spata45 
chr1:191036821-
191042941 0 1.89715 inf 0.0303 0.999803 
Fcgr3 
chr1:171051168-
171059403 31.122 60.1566 0.950789 0.0303 0.999803 
Smco2 
chr6:146850109-
146871404 1.51336 0 -inf 0.03035 0.999803 
Pdlim7 
chr13:55497486-
55513446 27.6814 9.26722 -1.57871 0.0308 0.999803 
Olfr455 chr6:42538066-42539020 0 2.15429 inf 0.03275 0.999803 
Olfr556 
chr7:102669900-
102670923 0 1.96989 inf 0.03275 0.999803 
Vmn1r124 chr7:21259693-21260617 0 2.24568 inf 0.03275 0.999803 
Trdn 
chr10:33083482-
33476709 16.4301 1.21485 -3.75749 0.0331 0.999803 
Fscn1 
chr5:142960354-
142973189 70.1763 40.0091 -0.81066 0.0337 0.999803 
Clec4a2 
chr6:123122689-
123143999 8.30379 20.4947 1.30341 0.0341 0.999803 
S100a5 chr3:90608521-90611780 2.1456 0 -inf 0.0342 0.999803 
Pgm2 chr4:99929450-99987294 41.1049 20.3484 -1.01439 0.0344 0.999803 
Pla2g7 
chr17:43568450-
43612201 46.1659 86.1717 0.900386 0.03455 0.999803 
Cacng6 chr7:3424661-3434940 1.23926 0 -inf 0.0353 0.999803 
Ak1 chr2:32621757-32635058 26.3035 2.79966 -3.23193 0.03585 0.999803 
Tnnt3 
chr7:142460811-
142516009 1100.06 3.71488 -8.21006 0.0365 0.999803 
Gpx3 
chr11:54902853-
54910382 34.9339 14.8877 -1.23051 0.0375 0.999803 
Olfr728 
chr14:50139701-
50140637 2.79119 0 -inf 0.03905 0.999803 
Gm1587 
chr14:77793944-
77798968 1.73329 0 -inf 0.03905 0.999803 
Olfr92 
chr17:37111041-
37111980 2.77902 0 -inf 0.03905 0.999803 
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Olfr1031 chr2:85991818-85992829 2.5157 0 -inf 0.03905 0.999803 
Skint8 
chr4:111919554-
111950356 1.86158 0 -inf 0.03905 0.999803 
Pramef17 
chr4:143991126-
143994369 1.27962 0 -inf 0.03905 0.999803 
Btg1-ps1 chrX:38013907-38018815 3.33108 0 -inf 0.03905 0.999803 
Cacna2d1 chr5:15934690-16374511 2.36864 
0.69317
1 -1.77278 0.0398 0.999803 
Myl1 chr1:66924295-66945056 845.073 2.04866 -8.68825 0.0404 0.999803 
Atp1a2 
chr1:172271708-
172298064 5.38849 1.35472 -1.99189 0.0405 0.999803 
Ccr1 
chr9:123962125-
123968692 5.88944 16.3089 1.46946 0.0405 0.999803 
Ctsc chr7:88278092-88310875 83.2511 143.418 0.784688 0.04115 0.999803 
4933415F23Ri
k chr1:23100473-23102253 1.25786 0 -inf 0.0415 0.999803 
Clec4a1 
chr6:122921847-
122934619 11.834 26.2801 1.15103 0.04205 0.999803 
Atp6v1e2 
chr17:86944108-
86947887 0 2.5186 inf 0.043 0.999803 
Vmn1r77 chr7:12041298-12042219 0 2.81906 inf 0.043 0.999803 
H2-M2 
chr17:37480850-
37483529 38.9588 19.0987 -1.02848 0.0446 0.999803 
Fas 
chr19:34290658-
34327770 22.9617 44.0506 0.939931 0.0452 0.999803 
Nexn 
chr3:152236983-
152266320 6.47478 1.8935 -1.77378 0.0453 0.999803 
Il18bp 
chr7:102015076-
102018155 24.7498 47.4827 0.939982 0.04555 0.999803 
Slc25a4 chr8:46207340-46211009 287.314 159.866 -0.84576 0.04645 0.999803 
Ifltd1 
chr6:145397234-
145434925 0 1.4075 inf 0.04665 0.999803 
Ifnlr1 
chr4:135686456-
135708180 3.65885 1.08761 -1.75023 0.047 0.999803 
Il1a 
chr2:129297369-
129309972 4.48178 29.4672 2.71697 0.0478 0.999803 
Gzma 
chr13:113093826-
113100981 134.726 230.205 0.772892 0.04835 0.999803 
Rrm2 
chr12:24708253-
24714146 27.8907 47.1693 0.758063 0.04905 0.999803 
Olfr1000 chr2:85607963-85608908 0 2.99876 inf 0.0492 0.999803 
1700028B04Ri





2 -6.45791 0.04935 0.999803 




A.1.3. Supplementary videos 
 
Supplementary Video 1: Example video of pIC exosome arrival in the collecting vessels of a 
mouse 10 cm downstream from the site of intradermal injection. The dominant vessel is seen below 
and the non-dominant vessel is seen above. Video is played at 10X speed  
Supplemental Video 2: Example video of pIC exosome arrival in the draining (sciatic) lymph 
nodes of a mouse within minutes of intradermal exosome injection at the tip of the tail. The 
dominant node is seen below and the non-dominant vessel is seen above. Video is played at 10X 
speed 
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A.2. Supplementary information for Chapter 5 
A.2.1. Supplementary figures 
 
Figure 42: Transport of exosomes and beads across the lymphatic endothelium in vitro Confocal 
images showing a: exosomes and beads are not taken up the lymphatic endothelial cells at 4oC, b:  
exosomes but not beads are taken up at 37oC; c: intracellular localization of exosomes with actin; 
and d: the membrane does not bind to either exosomes or beads. e: Average diameter of exosome 




Figure 43 Characterization of System sensitivity of labeled exosome detection. A: Description of 
system setup (node and tissue phantoms), B: SNR in Tissue phantom at various depths, C: Dose 
response of exosomes (different concentrations at 2mm depth), D: Node phantom dose response 
to show limit of detection at node 
132 
 
Figure 44: Packet frequency at collecting vessels and draining lymph node. Packet frequencies 
were calculated based on number of packets detected per minute from the line diagram at A) the 
collecting vessels and B) the draining lymph node 
133 
 
Figure 45: Characterizing SV-LEC exosome transport in vivo a) Steady state fluorescence in the 
lymphatic collecting vessel b) Intensity profile of a specified region of interest of exosome 
transport in a representative vessel over a 10 minute period, c) Steady state fluorescence in the 
draining lymph node, d) Intensity profile of a specified region of interest of exosome transport in 
a representative lymph node over a 10 minute period, e) Arrival time of detectable levels of 
fluorescence for dominant and non-dominant collecting vessels and draining lymph nodes. F) 




A.2.2. Supplementary videos 
Supplemental Video 1: Example video of exosome arrival in the collecting vessels of a mouse 10 
cm downstream from the site of intradermal injection. The dominant vessel is seen below and the 
non-dominant vessel is seen above. Video is played at 10X speed 
 
Supplemental Video 2: Example video of exosome arrival in the draining (sciatic) lymph nodes of 
a mouse within minutes of intradermal exosome injection at the tip of the tail. The dominant node 
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